SEARCH:      Monitor Keywords |  Custom RSS

Drug, bio-affecting and body treating compositions August list RSS, inventions by patent category 08/07

20070203087 - Chondroitin sulfate synthesis promoter: The invention provides a chondroitin sulfate synthesis promoter useful for the treatment of diseases such as articular disease and discopathy. The chondroitin sulfate synthesis promoter contains, as an active ingredient, chondroitin sulfate glucuronyltransferase protein and/or chondroitin sulfate N-acetylgalactosaminyltransferase-1 protein, or a gene encoding the enzyme protein(s).... Agent: Factor & Lake, Ltd

20070203089 - Compositions and methods for the treatment of ophthalmic disease: Compositions and methods of treating ocular disorders comprising CXCR4 inhibitory compositions.... Agent: Allergan, Inc.

20070203056 - novel antiproliferative factor and methods of use: A novel antiproliferative factor comprising a glycopeptide is disclosed. In specific embodiments, the novel antiproliferative factor is associated with the bladder. Compositions, diagnostic kits and reagents, and methods of using the compounds for identifying and/or treating interstitial cystitis and cancer are disclosed.... Agent: Fulbright & Jaworski, LLP

20070203055 - Compounds and compositions for prevention of overdose of oxycodone: The invention relates to pharmaceutical compounds and compositions comprised of a chemical moiety attached to an opioid such as oxycodone in a manner that substantially decreases the potential of the opioid to cause overdose. When delivered at the proper dosage the pharmaceutical composition provides therapeutic activity similar to that of... Agent: Hunton & Williams LLP Intellectual Property Department

20070203054 - Fragments of nkp44 for targeting viral-infected and tumor cells: The present invention relates generally to peptides derived from the natural cytotoxicity receptors on natural killer (NK) cells and to antibodies against peptide epitopes on these receptors. In particular, the present invention identifies an essential epitope in the proximal domain of NKp46 and NKp44 receptors present on NK cells, as... Agent: Heslin Rothenberg Farley & Mesiti PC

20070203057 - Compounds and methods for modulating adhesion molecule function: Modulating agents and methods for enhancing or inhibiting cadherin-mediated functions are provided. The modulating agents comprise at least an HAV binding motif, an analogue or peptidomimetic thereof, or an antibody or fragment thereof that specifically binds to such a motif. Modulating agents may additionally comprise one or more cell adhesion... Agent: Seed Intellectual Property Law Group PLLC

20070203070 - 28 human secreted proteins: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20070203061 - Adiponectin expression-inducing agents and uses thereof: The present invention provides adiponectin expression-inducing agents, and therapeutic agents using the same for obesity and obesity-related diseases such as cardiovascular diseases or metabolic diseases, as well as methods of searching for adiponectin expression-inducing agents. KLF9, which can bind to the 32-bp fragment of position −188 to position −157 from... Agent: Hunton & Williams LLP Intellectual Property Department

20070203060 - Casein derived peptides and therapeutic uses thereof: Biologically active peptides that are derived from or are similar to sequences of the alphaS1-, alphaS2-, beta- or kapa-casein fractions of milk casein. These peptides are capable of immune modulation and other therapeutic activities, including but not limited to stimulating and enhancing immune response, protecting against viral infection, normalizing serum... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070203066 - Compositions and methods for inhibiting cellular proliferation: Compositions and methods effective in inhibiting abnormal or undesirable cell proliferation, particularly endothelial cell proliferation and angiogenesis related to neovascularization and tumor growth are provided. The compositions comprise peptide molecules, optionally containing one or more individual peptide chains covalently linked, and optionally modified with polyethylene glycol (PEG). The methods involve... Agent: King & Spalding LLP

20070203062 - Compositions and methods for promoting hemostasis and other physiological activities: Compositions that include nanoscale structured materials or precursors thereof (e.g., self-assembling peptides) are described. The compositions can include other substances (e.g., a vasoconstrictor). Also described are methods for using the compositions to promote hemostasis, to protect the skin or wounds from contamination, to decontaminate a site upon removal of previously... Agent: Fish & Richardson PC

20070203069 - Grf-containing lyophilized pharmaceutical compositions: Human growth hormone factor (GFR) containing pharmaceutical compositions are described, and more precisely, lyophilized compositions of hGRF stabilized by means of saccharose.... Agent: Dickstein Shapiro LLP

20070203065 - Insulin-independent, bone morphogenetic protein (bmp)-mediated uptake of blood glucose by peripheral cells and tissues: Methods and compositions comprising a bone morphogenetic protein (BMP) are described for stimulating uptake of serum glucose by peripheral cells and tissues, for treating type 1 or type 2 diabetes, for controlling exocrine pancreatic function, and for treating pancreatitis by an insulin-independent pathway.... Agent: Leon R Yankwich Yankwich & Associates

20070203058 - Novel glp-1 derivatives: Novel polypeptide derivatives having protracted profile of action. The present invention relates to a compound which comprises a therapeutic polypeptide linked to an albumin binding residue via a hydrophilic spacer. The present invention also relates to a compound which comprises a therapeutic polypeptide linked to an albumin binding residue via... Agent: Novo Nordisk, Inc. Patent Department

20070203063 - Pharmaceutical compositions including variants of vascular endothelial cell growth factor having altererd pharmacological properties: Described herein are pharmaceutical compositions including vascular endothelial cell growth factor (VEGF) variants having modifications in the C-terminal heparin binding domain. The variants exhibit reduced clearance rates for systemic administration generally at lower doses compared with native VEGF thus providing variants having longer availability for therapeutic effect.... Agent: Merchant & Gould PC

20070203068 - Stimulation of beta cell proliferation: The present invention relates to a method for increasing the number and/or the size of beta cells, for stimulating beta cell proliferation and for preventing diabetes. The invention is based on the recognition that GLP-1 acts as a beta cell growth factor. The invention also relates to a method for... Agent: Novo Nordisk, Inc. Patent Department

20070203059 - Targeted drug-formaldehyde conjugates and methods of making and using the same: A method and compositions for detecting autoimmunity to islet glucose-6 phosphatase related protein (IGRP). Detection of IGRP autoantibodies alone, and in combination with other molecules such as the 65-kDa form of glutamate decarboxylase (GAD65), insulin and insulin granule membrane proteins ICA512 (IA-2) and phogrin (IA-2) auto-antigens, provides an effective and... Agent: Sheridan Ross PC

20070203067 - Therapeutic, prophylactic, and diagnostic agent for cancer, useful for characterizing cancer cells with individual properties: A therapeutic or prophylactic agent for cancer is disclosed which damages the membrane and kills cancer cells, in particular of the blood-forming system, having membrane protein aggregates which contain several core histones or largely core-like histones and/or their parts. The therapeutic or prophylactic agent contains at least one pure histone... Agent: Bacon & Thomas, PLLC

20070203064 - Tlr3 glycosylation site muteins and methods of use: TLR3 glycosylation site muteins, nucleic acids encoding the muteins, and methods of modulating TLR3 activity in a cell are disclosed.... Agent: Philip S. Johnson Johnson & Johnson

20070203071 - Conformationally constrained parthyroid hormone (pth) analogs: The invention provides novel P1R polypeptide antagonists. These antagonists contain amino acid substitutions at selected positions in truncated PTH and PRHrP polypeptides and function by binding selectively to the juxtamembrane (“J”) domain of the receptor. The J domain is the region of the receptor that spans the seven transmembrane domain... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070203072 - Hcv ns-3 serine protease inhibitors: Peptidomimetic compounds are described which inhibit the NS3 protease of the hepatitis C virus (HCV). The compounds have the formula where the variable definitions are as provided in the specification. The compounds comprise a carbocyclic P2 unit in conjunction with a novel linkage to those portions of the inhibitor more... Agent: Scully, Scott, Murphy & Presser, P.C.

20070203073 - Sars and ebola inhibitors and use thereof, and methods for their discovery: The instant invention is drawn to methods useful for the treatment or the prevention of a viral infection. The methods include administering at least one compound that is an inhibitor of cathepsin L to an individual. The methods are particularly useful in individuals infected with, or at risk of infection... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20070203074 - Composition and method for the efficacious and safe administration of halopyruvate for the treatment of cancer: e

20070203076 - Creatine ester pronutrient compounds and formulations: The present invention describes a method for providing creatine to an animal, which includes receiving a creatine ester by the animal. The creatine ester is suitable for being modified by the animal to form creatine.... Agent: Dann, Dorfman, Herrell & Skillman

20070203075 - Novel lactam ring-opening enzyme and use thereof: An enzyme capable of reducing the antibiotic activity (i.e., toxicity) of streptothricin with respect to eukaryotic cells without sacrificing antibiotic activity with respect to prokaryotic cells is provided along with a streptothricin derivative having reduced toxicity with respect to eukaryotic cells while retaining antibiotic activity with respect to prokaryotic cells,... Agent: Hogan & Hartson LLPIPGroup, Columbia Square

20070203077 - Treatment and prophylaxis of sepsis and septic shock: A method and composition for the prophylaxis or treatment of humans or animals for septic shock and sepsis using a mixture of sophorolipids.... Agent: Powell Goldstein LLP

20070203078 - Method for the treatment and diagnosis of certain psychiatric disorders related to the menstrual cycle: A method for treating psychiatric disorders associated with the menstrual cycle, such as PMS/PMDD and catamenial epilepsy. Reduced activity of specific subtypes of GABA-A receptors is treated by administering compounds that promote activity of these receptors to restore normal function.... Agent: John P. O'banion O'banion & Ritchey LLP

20070203079 - Methods of using small molecule compounds for neuroprotection: Methods are provided for preventing neurodegeneration and neuronal loss by administering compositions comprising small molecule compounds with the effect of preventing neurodegeneration and neuronal loss. In one aspect of the invention, the methods and compositions are also useful for treating neurodegenerative diseases. Small molecule compounds provide an important treatment option... Agent: King & Spalding LLP

20070203080 - New drug delivery system for crossing the blood brain barrier: New ubiquinol analogs are disclosed, as well as methods of using these compounds to deliver drug moieties to the body.... Agent: Morgan, Lewis & Bockius LLP (sf)

20070203081 - Aminoglycosides as antibiotics: The present invention provides aminoglycosides and pharmaceutical compositions that include the aminoglycosides. The aminoglycosides are useful to treat or prevent infectious diseases (e.g., bacterial infections) in a mammal (e.g., human).... Agent: Schwegman, Lundberg, Woessner & Kluth, P.A.

20070203086 - Adenosine therapy via interfering rna: System, including methods and compositions, for treating medical conditions via adenosine therapy with interfering RNA that selectively inhibits adenosine metabolism.... Agent: Kolisch Hartwell, P.C.

20070203088 - Detection and modulation of iaps and naip for the diagnosis and treatment of proliferative disease: Disclosed are diagnostic and prognostic kits for the detection and treatment of proliferative diseases such as ovarian cancer, breast cancer, and lymphoma. Also disclosed are cancer therapeutics utilizing IAP antisense nucleic acids, IAP fragments, and antibodies which specifically bind IAP polypeptides.... Agent: Philip Swain, Phd C/o Gowling Lafleur Henderson

20070203084 - Interfering rna duplex having blunt-ends and 3'-modifications: The present invention relates to double-stranded RNA compounds with at least one blunt end comprising at least one 3′-end of Formula (I): wherein X is O or S R1 and R2 are independently OH, NH2, SH, alkyl, aryl, alkyl-aryl, aryl-alkyl, where alkyl, aryl, alkyl-aryl, aryl-alkyl can be substituted by additional... Agent: Novartis Corporate Intellectual Property

20070203085 - Methods for interfering with fibrosis: Modulation of the of glucocorticoid inducible kinases to restore Connective tissue growth factor activity. Also disclosed are methods and compounds useful for the detection and treatment of fibroproliferative disorders.... Agent: Millen, White, Zelano & Branigan, P.C.

20070203083 - Methods of regulating metabolism and mitochondrial function: The invention relates to novel methods of regulating metabolism and mitochondrial biogenesis. Some aspects of the invention relate to methods of treating or preventing diseases in a patient associated with reduced mitochondrial function, to methods of identifying agents to treat such diseases, and to methods of diagnosing such diseases. Other... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070203082 - Rnai agents for anti-sars coronavirus therapy: The present invention provides compositions and methods that are useful for the treatment of severe acute respiratory syndrome (SARS). More specifically, nucleic acid agents such as siRNA molecules and their analogues that target respiratory infections including SARS coronavirus and their methods of use are described, for clinical treatments of SARS,... Agent: Proskauer Rose LLP

20070203090 - N-pyrazole a2a receptor agonists: e

20070203091 - Methods and therapeutic compositions for improving liver, blood flow and skeletal muscle functions in advanced diseases and aging: Administration of adenosine 5′-triphosphate (ATP) and/or other adenine nucleotides such as adenosine 5′-monophosphate (AMP) and/or adenosine 5′-diphosphate (ADP) and/or adenosine provides significant benefits to liver, blood flow and skeletal muscle functions in humans suffering from advanced diseases or in aging individuals. In a preferred mode, 8 hours of continuous intravenous... Agent: Connolly Bove Lodge & Hutz LLP

20070203093 - Antistress agent: The present invention relates to an antistress agent comprising as an active ingredient a saccharide containing 3-O-α-D-glucopyranosyl-D-glucose as a structural unit. It is an object of the present invention to provide said antistress agent which is free from side effects as a medicine, and can be taken habitually and also... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070203094 - Esters of hyaluronic acid with rhein, process for their preparation and compositions comprising the same: The present invention relates to esters of hyaluronic acid with rhein, more particularly to a compound based on hyaluronic acid, wherein alcohol groups of hyaluronic acid are esterified with rhein, to a process for preparing said ester and to a pharmaceutical composition comprising said ester.... Agent: Clifford W Browning Krieg Devault

20070203095 - Treatment of arthritis and other musculoskeletal disorders with crosslinked hyaluronic acid: A method of treating a subject having a musculoskeletal disorder includes administering to a subject's articular site in need thereof an effective amount of a hyaluronic acid (HA) composition. In one embodiment, the HA composition includes an HA derivative, wherein carboxyl functionalities of the hyaluronic acid derivative are each independently... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070203096 - 9-chloro-15-deoxyprostaglandin derivatives, process for their preparation and their use as medicaments: The present invention relates to 9-chloroprostaglandin derivatives of the general formula I which may be advantageous for the treatment of fertility problems.... Agent: Millen, White, Zelano And Branigan, P.C. C/o Berlex Biosciences

20070203097 - Fluoroquinolone carboxylic acid salt compositions: The invention relates to pharmaceutical compositions that are a solution of a salt formed between a fluoroquinolone and a carboxylic acid, a cyclodextrin, and a pharmaceutically acceptable organic solvent and to methods of treating a condition in an animal by administering to an animal in need thereof the pharmaceutical composition... Agent: Kenyon & Kenyon LLP

20070203098 - Pten inhibitors: The therapeutic use of inhibitors of PTEN activity in the treatment of PTEN-mediated diseases, conditions, and injuries is disclosed.... Agent: Polsinelli Shalton Flanigan Suelthaus PC

20070203099 - Anionically substituted 7-nitroindoline derivatives and their uses: Anionically substituted 7-nitroindoline derivatives are disclosed and their uses as caged compounds from which effector species such as neurotransmitters and amino acids are releasable on irradiation with light.... Agent: Dann, Dorfman, Herrell & Skillman

20070203100 - Immunosuppressant compounds and compositions: The present invention relates to immunosuppressant, process for their production, their uses and pharmaceutical compositions containing them. The invention provides a novel class of compounds useful in the treatment or prevention of diseases or disorders mediated by lymphocyte interactions, particularly diseases associated with EDG receptor mediated signal transduction.... Agent: Genomics Institute Of The Novartis Research Foundation

20070203101 - Pyrazolyl-substituted heterocycles and their use as phytosanitary products: e

20070203102 - Estrogen receptor modulators: The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone... Agent: Merck And Co., Inc

20070203103 - Preparation of pharmaceutical salts of 3-o-(3',3'-dimethylsuccinyl)betulinic acid: This invention relates to a novel process for making 3-O-(3′,3′-dimethylsuccinyl)betulinic acid (“DSB”). This invention also relates to methods of treating HIV and related diseases using pharmaceutical compositions comprising salt forms of DSB prepared according to the process of the present invention. The invention further relates to dosage forms of pharmaceutical... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070203104 - Pharmaceutical formulations: An aspect of the present invention provides for a medicament including a solution containing pleconaril or a pharmaceutically acceptable salt thereof, wherein at least one solvent including the solution is a pleconaril-dissolving hydrofluorocarbon.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070203105 - Progesterone receptor modulators:

20070203106 - Method for producing 5alpha-pregnane derivative:

20070203107 - Pharmaceutical compositions: The invention relates to the use of compounds to ameliorate or treat an condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3β-hydroxy-17β-aminoandrost-5-ene, 3β-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3α-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3β-hydroxy-16β-fluoro-17β-aminoandrost-5-ene, 1α,3β-dihydroxy-4α-fluoroandrost-5-ene-17-one, 1α,3β,17β-trihydroxy-4α-fluoroandrost-5-ene, 1β,3β-dihydroxy-6α-bromoandrost-5-ene, 1α-fluoro-3β,12α-dihydroxyandrost-5-ene-17-one, 1α-fluoro-3β,4α-dihydroxyandrost-5-ene and 4α-fluoro-3β,6α,17β-trihydroxyandrostane.... Agent: Hollis-eden Pharmaceuticals, Inc.

20070203110 - 17-allylamino-17-demethoxygeldanamycin polymorphs and formulations: Polymorphs and pharmaceutical formulations of 17-allylamino-17-demethoxygeldanamycin (17-AAG).... Agent: Kosan Biosciences, Inc

20070203112 - Bladder cancer treatment and methods: Disclosed herein are various bladder cancer treatments and methods. The present disclosure can take advantage of propylene glycol concentrations and/or NAD(P)H:quinone oxidoreductase-1 (NQO1), Cytochrome P450 Oxidoreductase (P450R) and Glucose transporter 1 (Glut-1) protein expression in human transitional cell carcinoma of the bladder to offer individually targeted bladder cancer treatments.... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP

20070203109 - Compounds and compositions for treatment of cancer: The present invention relates to the use of a therapeutically effective amount of 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone (RH1), in the manufacture of a medicament for the treatment of a cancerous condition.... Agent: Swanson & Bratschun, L.L.C.

20070203108 - Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds: Disclosed are compounds which inhibit β-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits β-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical... Agent: Eli Lilly & Company

20070203111 - Cycloalkylamines as monoamine reuptake inhibitors: The invention relates to novel cyclohexylamine derivatives and their use in the treatment and/or prevention of central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as... Agent: Morgan, Lewis & Bockius LLP (sf)

20070203113 - Use of manzamine compounds in anti-cancer therapeutic regimens: Manzamine compounds have been discovered to decrease cell dissociation and cell migration associated with the metastatic potential of cancer cells and a restoration of cancer cell susceptibility to agents, such as TRAIL, which can induce apoptosis. Specifically, Manzamine A has a formerly unrecognized utility in both blocking tumor cell invasion... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070203114 - 7,8,9,10-tetrahydro-imidazo [2,1-a] isochinolines: n

20070203115 - Novel quaternary ammonium compounds: A method for inhibiting ileal bile acid transporter activity in a subject, comprising administering to said subject an effective amount of a compound represented by formula (1):... Agent: Young & Thompson

20070203116 - Dihydrospiro[dibenzo[a,d][7]annulene-5,4'-imidazol] compounds for the inhibition of beta-secretase: m

20070203117 - Novel azabicyclic aryl derivatives: This invention relates to novel azabicyclic aryl derivatives which are found to be cholinergic ligands at the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of... Agent: Birch Stewart Kolasch & Birch

20070203118 - Substituted tetrahydroisoquinolines used in the form of mmp inhibitors, method for the production and use thereof in the form of drugs: i

20070203119 - Combination therapy for the treatment of schizophrenia: The present invention relates to a combination of a NK3 receptor antagonist with a 5HT2A receptor antagonist and/or a D2 receptor antagonist, and the use of the combination in treating schizophrenia and associated conditions.... Agent: Merck And Co., Inc

20070203120 - Sulfonyl substituted 1h-indoles as ligands for the 5-hydroxytryptamine receptors: e

20070203121 - Substituted indole compounds, their preparation and use in medicaments: The present invention relates to substituted indole compounds of general formula (I), a process for their preparation, medicaments comprising substituted indole compounds as well as the use of substituted indole compounds for the preparation medicaments, which are suitable e.g., for the prophylaxis and/or treatment of disorders or diseases that are... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070203122 - Derivatives for modulation of ion channels: Sulfonamide derivatives act as ion channel antagonists. The compositions are useful for treating or relieving pain-related conditions.... Agent: Vertex Pharmaceuticals Inc.

20070203123 - Use of acetylamino benzoic acid compounds for nonsense suppression and the treatment of disease: Novel acetylamino benzoic acid compounds, methods of using and pharmaceutical compositions comprising an acetylamino benzoic acid derivative are disclosed. The methods include methods of treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay, or ameliorating one or more symptoms associated therewith.... Agent: Jones Day

20070203124 - Therapeutic piperazines: wherein R1, X, Z, n, and m have any of the values described herein, as well as salts of such compounds, compositions comprising such compounds, and therapeutic methods that comprise the administration of such compounds. The compounds are inhibitors of PDE4 function and are useful for improving cognitive function in... Agent: Heller Ehrman LLP

20070203125 - Medicament combinations for the treatment of respiratory diseases: e

20070203126 - Synergistic mixtures of o-phenylphenol and dazomet: Ortho phenylphenol acts synergistically with various other antimicrobial compounds commonly used in industrial applications.... Agent: Beck & Thomas, P.C. Suite 100

20070203127 - Antibacterial agents: Naphthalene, quinoline, quinoxaline and naphthyridine derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070203128 - Modulation of pathogenicity: In particular the invention refers to a family of compounds that block the quorum sensing system of Gram-negative bacteria, a process for their manufacture, pharmaceutical compositions containing them and to their use for the treatment and prevention of microbial damages and diseases, in particular for diseases where there is an... Agent: Womble Carlyle Sandridge & Rice, PLLC Attn: Patent Docketing 32nd Floor

20070203129 - 2-pyridone derivatives as neutrophil elastase inhibitors and their use: There are provided novel compounds of formula (I), wherein R1, R2, R4, R5, G1, G2, L, Y and n are as defined in the Specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in... Agent: Morgan Lewis & Bockius LLP

20070203130 - Bicyclic derivatives as modulators of voltage gated ion channels: Bicyclic derivatives useful as ion channel antagonists are disclosed herein. The compositions thereof are useful for treating or relieving pain-related conditions.... Agent: Vertex Pharmaceuticals Inc.

20070203131 - Bis-aryl sulfonamides: Compounds are provided that act as potent antagonists of chemokine receptors. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of chemokine receptor-mediated diseases, and as controls in assays for the identification of chemokine antagonists.... Agent: Brinks Hofer Gilson & Lione

20070203132 - Triazole derivatives which inhibit vasopressin antagonistic activity: R3 represents H, methyl, methoxy or chloro; are useful for treating anxiety, cardiovascular disease (including angina, atherosclerosis, hypertension, heart failure, edema, hypernatremia), dysmenorrhoea (primary and secondary), endometriosis, emesis (motion sickness), intrauterine growth retardation, inflammation (including rheumatoid arthritis), mittlesmerchz, preclampsia, premature ejaculation, premature (preterm) labor and Raynaud's disease.... Agent: Pfizer Inc

20070203133 - Substituted 5,12-diaza-benzoanthracene analogues: Substituted 5,12-diaza-benzoanthracene analogues are provided, of the Formula (I) wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated... Agent: Edwards Angell Palmer & Dodge LLP

20070203134 - Benzimidazole acetonitriles: The present invention is related to benzimidazole acetonitriles as well as to pharmaceutical formulations containing such benzimidazole acetonitriles of formula (I). Said benzimidazole acetonitriles are useful in the treatment of metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type II, inadequate glucose tolerance, insulin resistance, obesity, polycystic ovary... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070203135 - Novel fused pyrrolocarbazoles: The present invention relates generally to selected fused pyrrolocarbazoles, including pharmaceutical compositions thereof and methods of treating diseases therewith. The present invention is also directed to intermediates and processes for making these fused pyrrolocarbazoles.... Agent: Woodcock Washburn LLP

20070203136 - Triazolopyridazines as kinase modulators: where R1, R5, R6, R7, R8, and A are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of c-Met, and the use of such compounds to reduce or inhibit kinase activity of c-Met in a cell or a subject, and modulate c-Met expression... Agent: Philip S. Johnson Johnson & Johnson

20070203137 - new salt: The present invention relates to a new pharmaceutically acceptable salt, the 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]1H-indole-5-carbonitrile citrate, a process for its preparation, pharmaceutical formulations containing said salt and to the use of said active salt in therapy, and particularly to GSK3 related conditions and disorders.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20070203138 - Novel compounds and compositions as cathepsin s inhibitors: The present invention relates to novel selective cathepsin S inhibitors, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making.... Agent: Synnestvedt & Lechner LLP

20070203139 - Aryl glycinamide derivatives and their use as nk1 antagonists and serotonin reuptake inhibitors: Compounds of the following Formula (I) wherein R1 and R2 are independently selected from alkyl or alkenyl or from a heterocyclic ring together with the N to which they are bound, n is 0-2, Ar1 is (substituted) phenyl and Ar1 is (substituted) phenyl, naphthyl or tetralin, further as defined in... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20070203141 - Method for administering birb 796 bs: Disclosed are methods of administering BIRB 796 BS, a p38 MAPK inhibitor, at particular dosages.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070203140 - N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase: The present invention is directed to modulators of indoleamine 2,3-dioxygenase (IDO), as well as pharmaceutical compositions containing the same and methods for the treatment of IDO-associated diseases.... Agent: Fish & Richardson PC

20070203142 - Azaindoles useful as inhibitors of janus kinases: The present invention relates to compounds useful as inhibitors of protein kinases, particularly of JAK family kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.... Agent: Vertex Pharmaceuticals Inc.

20070203143 - Protein kinase inhibitors: Compounds that inhibit protein kinases, compositions containing the compounds and methods of treating diseases using the compounds are disclosed.... Agent: Robert Deberardine Abbott Laboratories

20070203144 - Use of memantine and brimonidine to attenuate vitreoretinal vascular endothelial growth factor (vegf) protein levels in animals: Reducing the VEGF level in a patient suffering from an ocular disease or condition which is characterized by elevated VEGF and/or blood retina barrier (BRB) breakdown which comprises treating said patient with an effective amount of a compound selected from the group consisting of memantine, brimonidine and mixtures thereof.... Agent: Allergan, Inc.

20070203145 - Zopiclone resolution: Zopiclone can be effectively resolved, and the S-zopiclone isolated, by the use of L-tartaric acid, D-tartaric acid, (+)-ditoluoyltartaric acid, or (−)-ditoluoyltartaric acid.... Agent: SynthonIPInc

20070203146 - Specific salt, anhydrous and crystalline form of a dihydropteridione derivative: The present invention relates to a specific salt of a dihydropteridione derivative, namely the trihydrochloride salt of the compound N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide, to its crystallisation in the form of an hydrate with water, to a process for the manufacture thereof, and to the use thereof in a pharmaceutical composition.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070203147 - 2-aminothiazole compounds useful as aspartyl protease inhibitors: The present invention is directed to 2-aminothiazole compounds which are aspartyl protease inhibitors, and are inhibitors of both the beta-secretase enzyme and HIV protease, and that are useful in the treatment of diseases in which the beta-secretase enzyme and HIV are involved, such as Alzheimer's disease, HIV Infection and AIDS.... Agent: Merck And Co., Inc

20070203148 - Haloalkyl carboxamides: e

20070203149 - Ccr5 antagonists useful for treating hiv: as inhibitors of the CCR5 receptors, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with CCR5 using such compounds or... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070203150 - Low hygroscopic aripiprazole drug substance and processes for the preparation thereof: The present invention provides low hygroscopic forms of aripiprazole and processes for the preparation thereof which will not convert to a hydrate or lose their original solubility even when a medicinal preparation containing the aripiprazole anhydride crystals is stored for an extended period.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070203151 - Low hygroscopic aripiprazole drug substance and processes for the preparation thereof: The present invention provides low hygroscopic forms of aripiprazole and processes for the preparation thereof which will not convert to a hydrate or lose their original solubility even when a medicinal preparation containing the aripiprazole anhydride crystals is stored for an extended period.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070203152 - Low hygroscopic aripiprazole drug substance and processes for the preparation thereof: The present invention provides low hygroscopic forms of aripiprazole and processes for the preparation thereof which will not convert to a hydrate or lose their original solubility even when a medicinal preparation containing the aripiprazole anhydride crystals is stored for an extended period.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070203153 - Compositions and methods for treating thrombocytopenia: The present invention in certain embodiments is directed to a pharmaceutical dosage form comprising a therapeutically effective amount of a first agent that agonizes a human TPO receptor by binding to the rhTPO binding site of the human TPO receptor; and a therapeutically effective amount of a second agent that... Agent: Davidson, Davidson & Kappel, LLC

20070203154 - Therapeutic compounds: wherein R1-R6, X, Y, and B have any of the values described herein, as well as salts of such compounds, compositions comprising such compounds, and therapeutic methods that comprise the administration of such compounds. The compounds are inhibitors of MAO-B enzyme function and are useful for improving cognitive function and... Agent: Heller Ehrman LLP

20070203155 - Compounds and compositions as ppar modulators: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of the Peroxisome Proliferator-Activated Receptor (PPAR) families, particularly the activity of PPAR.... Agent: Genomics Institute Of The Novartis Research Foundation

20070203156 - Oxazole ketones as modulators of fatty acid amide hydrolase: Certain oxazole ketone compounds are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat anxiety, pain, inflammation, sleep disorders, eating... Agent: The Scripps Research Institute

20070203157 - Heterocyclic dihydropyrimidine compounds: r

20070203158 - Fungicidal mixtures:

20070203159 - Purine compounds: The invention provides an antimycobacterial 6-aryl-9-(m- or p-substituted-benzyl) purine and purine analog compounds.... Agent: Bacon & Thomas, PLLC

20070203160 - P38 map kinase inhibitors and methods for using the same: Compounds effective as p38 MAP kinase inhibitors, methods of making the compounds, and methods of using the compounds for treatment of p38 MAP kinase-mediated diseases.... Agent: Roche Palo Alto LLC Patent Law Dept. M/s A2-250

20070203161 - Compositions and methods for inhibition of the jak pathway: The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful.... Agent: Foley & Lardner LLP

20070203162 - Compositions and methods for inhibition of the jak pathway: The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful.... Agent: Foley & Lardner LLP

20070203163 - Novel treatment of irritable bowel syndrome 1: The present invention relates to the use of metabotropic glutamate receptor 5 (mGluR5) antagonists for the treatment of irritable bowel syndrome (IBS).... Agent: Birch, Stewart, Kolasch & Birch, LLP

20070203165 - Compounds and methods for lowering the abuse potential and extending the duration of action of a drug: The abuse potential of a bioavailable drug such as an opiate analgesic agent is reduced and its duration of action is extended by converting it to a poorly absorbed ester prodrug or other prodrug derivative prior to formulation. Unlike many existing sustained release formulations of active pharmaceutical agents wherein an... Agent: Nastech Pharmaceutical Company Inc

20070203164 - Methods and compositions for bactericide, bacteriostatic and anti-inflammation: The present invention relates to a method for providing bactericide or bacteriostatic, especially for treating disease due to bacterial infection. The method comprising administering a patient in need of such treatment a therapeutically effective amount of a compound of dextromethorphan or naloxone or a pharmaceutically acceptable salt or an analog... Agent: Cohen, Pontani, Lieberman & Pavane

20070203166 - Pharmaceutical and diagnostic compositions containing nanoparticles useful for treating targeted tissues and cells: Nanoparticles made from a select group of lipids and optionally containing a therapeutically active agent are employed in pharmaceutical compositions for delivery to targeted tissues and/or cells for the treatment or diagnosis of such diseases as cancer.... Agent: Allen R. Kipnes, Esq. Watov & Kipnes, P.C.

20070203167 - 2-(hetero)-aryl substituted tetrahydrochinoline: Compounds of the formula I, in which W, R, R1, R2, R3, R4, R5, R6 and R7 have the meanings indicated in Claim 1, can be employed, inter alia, for the treatment of tumours... Agent: Heller Ehrman LLP

20070203171 - Combination of rapamycin and its tetrazole isomers and epimers, methods of making and using the same: Epimers and isomers of tetrazole-containing rapamycin analogs are immunomodulatory agents and are useful in the treatment of restenosis and immune and autoimmune diseases. Also disclosed are cancer-, fungal growth-, restenosis-, post-transplant tissue rejection- and immune- and autoimmune disease-inhibiting compositions and a method of inhibiting cancer, fungal growth, restenosis, post-transplant tissue... Agent: Philip S. Johnson Johnson & Johnson

20070203172 - Isomers and 42-epimers of rapamycin alkyl ether analogs, methods of making and using the same: Isomers and 42-epimers of rapamycin alkyl ether analogs and pharmaceutically acceptable salts or prodrugs thereof, are immunomodulatory agents and are useful in the treatment of restenosis and immune and autoimmune diseases. Also disclosed are cancer-, fungal growth-, restenosis-, post-transplant tissue rejection- and immune- and autoimmune disease-inhibiting compositions and a method... Agent: Philip S. Johnson Johnson & Johnson

20070203169 - Isomers and 42-epimers of rapamycin ester analogs, methods of making and using the same: Isomers and 42-epimers of rapamycin ester analogs and pharmaceutically acceptable salts or prodrugs thereof, are immunomodulatory agents and are useful in the treatment of restenosis and immune and autoimmune diseases. Also disclosed are cancer-, fungal growth-, restenosis-, post-transplant tissue rejection- and immune- and autoimmune disease-inhibiting compositions and a method of... Agent: Philip S. Johnson Johnson & Johnson

20070203168 - Isomers of rapamycin and 42-epi-rapamycin, methods of making and using the same: 15-C isomers of rapamycin and of 42-C Epi rapamycin, and pharmaceutically acceptable salts or prodrugs thereof are disclosed. These compounds are potential immunomodulatory and anti-inflammatory agents, and may be useful in the treatment of restenosis and immune and autoimmune diseases. Also disclosed are cancer-, fungal growth-, restenosis-, post-transplant tissue rejection-... Agent: Philip S. Johnson Johnson & Johnson

20070203170 - Rapamycin analogs containing an antioxidant moiety: A rapamycin analog with an antioxidant moiety or a pharmaceutically acceptable salt or prodrug thereof, is an immunomodulatory agent and is useful in the treatment of restenosis and immune and autoimmune diseases. Also disclosed Are cancer-, fungal growth-, restenosis-, post-transplant tissue rejection- and immune- and autoimmune disease-inhibiting compositions and a... Agent: Philip S. Johnson Johnson & Johnson

20070203173 - Stable formulations, and methods of their preparation and use: Described herein are formulations comprising therapeutic agents, including but not limited to formulations comprising rapamycin, pharmaceutical formulations, unit dose forms, kits, methods of preparing formulations, and methods of using formulations. Such formulations and methods have increased stability.... Agent: Morrison & Foerster LLP

20070203174 - Method of treating glaucoma: Described are methods for the treatment of ocular hypertension or glaucoma comprising administering a pharmaceutically effective amount of one or more compounds that inhibit the enzyme EgLN-3. Certain embodiments of the invention combine the use of EgLN-3 with other glaucoma treatment agents. The compounds of the invention may be formulated... Agent: Alcon

20070203175 - Productioin of dolasetron: The present invention provides an improved process for the preparation of Dolasetron salts, in particularly Dolasetron mesylate. Also provided are intermediates for the process and methods of preparing the intermediates. Intermediates for preparing Dolasetron according to the invention include 7-alkoxycarbonyl-9-(alkoxycarbonylmethyl)-3-trialkylsilyloxy-9-azabicyclo[3.3.1]nonane compounds (SAN compounds) and endo-9-alkoxycarbonyl-5-trialkylsilyloxy-8-azatricyclo[5.3.1.03,8]undecan-10-one compounds (SQO compounds).... Agent: Kenyon & Kenyon LLP

20070203176 - Crystalline forms of dolasetron base and processes for preparation thereof: The present invention provides crystalline polymorphic forms of Dolasetron base. Also provided are methods of preparing the crystalline polymorphic forms of Dolasetron base.... Agent: Kenyon & Kenyon LLP

20070203177 - Forms of dolasetron mesylate and processes for their preparation: The present invention provides crystalline polymorphic forms of Dolasetron mesylate. Also provided are methods of preparing the crystalline polymorphic forms of Dolasetron mesylate. Further, the crystalline Dolasetron mesylate forms may be used in pharmaceutical compositions.... Agent: Kenyon & Kenyon LLP

20070203178 - Crystalline solvates of apixaban: The present invention generally relates to crystalline dimethyl formamide and formamide solvates of apixaban, designated as Forms DMF-5 and FA-2, which are useful for preparing crystalline apixaban hydrate and neat forms.... Agent: Louis J. Wille Bristol-myers Squibb Company

20070203179 - Azadecalin glucocorticoid receptor modulators: The present invention provides a novel class of azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators.... Agent: Townsend And Townsend And Crew, LLP

20070203180 - Substituted quinoline compounds for use as selective estrogen receptor modulator: The present invention relates to novel compounds of formula (I) with a variety of therapeutic uses, more particularly novel substituted quinoline compounds particularly useful for selective estrogen receptor modulation.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070203181 - Quinoline derivatives and insecticide comprising thereof as active ingredient: Disclosed are compounds that have excellent insecticidal activity and are usable as agricultural and horticultural insecticides. Compounds represented by formula (I) or agriculturally and horticulturally acceptable acid addition salts thereof have excellent insecticidal activity and are usable as agricultural and horticultural insecticides.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070203182 - Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders: The invention relates to the use of certain alpha-aminoamide derivatives in the treatment of RLS and addictive disorders. The compounds of this invention are able to reduce or even stop the symptoms of RLS and addictive disorders substantially without side effects.... Agent: Young & Thompson

20070203183 - Diaryl piperidines as cb1 modulators: e

20070203184 - Novel indolin-2-one derivatives, their preparation and the pharmaceutical compositions comprising them:

20070203185 - Therapeutical composition containing dentritic cells and use thereof: The present invention relates to a method for the preparation of a therapeutical composition, in particular, the present invention relates to a method for treating dendritic cells with a combination of at least one interferon gamma receptor agonist and at least one toll like receptor 2 and/or TLR 6 agonist... Agent: Whitham, Curtis & Christofferson & Cook, P.C.

20070203189 - 2-amino-4,5-trisubstituted thiazolyl derivatives: L is optionally substituted phenyl or an optionally substituted monocyclic 5 or 6-membered partially saturated or aromatic heterocycle or a bicyclic partially saturated or aromatic heterocycle; aryl is optionally substituted phenyl; for the manufacture of a medicament for the prevention or the treatment of inflammatory and/or auto-immune diseases mediated through... Agent: Philip S. Johnson Johnson & Johnson

20070203187 - Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof: i

20070203188 - Low molecular weight myc-max inhibitors: Compounds and compositions for interfering with the association of Myc and Max are described herein. These compounds and compositions are useful in methods inhibiting growth or proliferation of a cell. Methods of inhibiting growth or proliferation of a cell are provided, comprising contacting the cell with an amount of a... Agent: Jesse A. Hirshman, Esq.

20070203186 - Pyrazole amide derivatives, compositions containing such compounds and methods of use: Pyrazole amides are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.... Agent: Merck And Co., Inc

20070203190 - Hydroxylamines and derivatives for the inhibition of complement activation: Methods for the inhibition of complement activation, for the treatment of complement-mediated pathologies, and for the treatment of drusen-mediated pathologies are disclosed. The methods utilize hydroxylamine compounds and ester derivatives thereof, administered to subjects in effective amounts.... Agent: Woodcock Washburn LLP

20070203191 - Insecticidal n-substituted (6-haloalkylpyridin-3-yl)alkyl sulfoximines: N-Substituted (6-haloalkylpyridin-3-yl)alkyl sulfoximines are effective at controlling insects.... Agent: Dow Agrosciences LLC

20070203193 - Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist: S

20070203192 - Saturated and unsaturated 3-pyridyl-benzocycloalkylmethyl-amines for use in treating pain, depression and/or anxiety:

20070203194 - Ion channel modulators: The invention relates to compounds, compositions comprising the compounds, and methods of using the compounds and compound compositions. The compounds, compositions, and methods described herein cab be used for the therapeutic modulation of ion channel function, and treatment of disease and disease symptoms, particularly those mediated by certain calcium channel... Agent: Edwards Angell Palmer & Dodge LLP

20070203196 - Methods of preparing indazole compounds: e

20070203195 - Transition metal mediated oxidation of hetero atoms in organic molecules coordinated to transition metals: The present invention is directed to a process for the catalytic oxidation of the thioether 5-methoxy-2-((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)methylthio)-1H-benzimidazole to its sulfoxide: 5-methoxy-2-((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)methylsulfinyl)-1H-benzimidazole comprising: reacting the thioether with: 1) a transition metal catalyst; and, 2) an oxygen source; wherein the thioether is oxidized to a sulfoxide and wherein one of either the R... Agent: Kenneth S. Wheelock

20070203197 - Phosphodiesterase 4 inhibitors: Selective PDE4 inhibition is achieved by aryl and heteroaryl pyrazole compounds. The compounds exhibit improved PDE4 inhibition as compared to compounds such as rolipram and show selectivity with regard to inhibition of other classes of PDEs.... Agent: Millen, White, Zelano & Branigan, P.C.

20070203200 - 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt, hydrate as pharmaceutical: (iv) provides a Raman spectrum containing peaks at 3106, 3069, 3002, 2961, 1750, 1718, 1684, 1385, 1335, 1229, 1078, 917, 428 and 349 cm−1 and/or (iv) provides a solid-state nuclear magnetic resonance spectrum containing chemical shifts substantially as set out in Table I; a process for the preparation of such... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20070203198 - Pharmaceutical composition: Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.... Agent: Foley And Lardner LLP Suite 500

20070203199 - Pioglitazone salts, such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same: Water-soluble salts of pioglitazone especially pioglitazone sulfate are useful in pharmaceutical applications.... Agent: SynthonIPInc

20070203201 - Substituted anthranilamides for controlling invertebrate pests: t

20070203203 - Composition and method for treating fibrotic diseases: The present invention discloses 5-methyl-1-(substituted phenyl)-2(1H)-pyridones have enhanced anti-fibrotic activities than 5-methyl-1-(non-substituted phenyl)-2(1H)-pyridones. An representative example of 5-methyl-(1-substituted phenyl)-2(1H)-pyridones is 1-(3′-fluorophenyl)-5-methyl-2(1H)-pyridone. Accordingly, there are provided compositions comprising one or more compounds selected from the group consisting of 5-methyl-1-(substituted phenyl)-2(1H)-pyridones and methods of using the same to treat or prevent fibrosis... Agent: Law Offices Of Albert Wai-kit Chan, LLC

20070203202 - Methods of reducing adverse events associated with pirfenidone therapy: The invention relates to methods for reducing adverse events in patients receiving pirfenidone (5-methyl-1-phenyl-2-(1H)-pyridone) therapy.... Agent: Knobbe Martens Olson & Bear LLP

20070203204 - 2-pyridinylcycloalkylbenzamide derivatives and their use as fungicides: e

20070203205 - Diarylsulfones as 5-ht2a antagonists:

20070203206 - 2-pyrrolidone derivatives and use thereof as factor xa inhibitors:

20070203208 - Agents for combating plant pests:

20070203207 - Heteroaromatic glucokinase activators: 2,3-Di-substituted N-heteroaromatic propionamides with said substitution at the 3-position being a substituted phenyl group and at the 2-position being a methyl cycloalkyl ring, said propionamides being glucokinase activators which increase insulin secretion in the treatment of type II diabetes.... Agent: Hoffmann-la Roche Inc. Patent Law Department

20070203209 - Useful indole compounds: Indoles having various activities, including indoles that are CRTH2 are described. The compounds are useful for treating asthma, neuropathic pain, allegic rhinitis and other disorders.... Agent: Fish & Richardson PC

20070203210 - Thiazolyl-benzimidazoles: d

20070203211 - Drug for preventing or treating angiogenic eye diseases: A method for the prevention or treatment of intraocular angiogenic diseases such as proliferative retinopathy, retinal vein occlusion, retinal artery occlusion or age-related macular degeneration, which comprises administering to a mammal (such as a human) in need thereof a pharmaceutically effective amount of an angiotensin II receptor antagonist such as... Agent: Frishauf, Holtz, Goodman & Chick, PC

20070203212 - Method of treating osteoarthritis: This invention relates to combinations, compositions, and methods using or having a substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compound, or a pharmaceutically acceptable salt thereof, as an active component for preventing or treating osteoarthritis, preventing or inhibiting cartilage damage, preventing or treating... Agent: Warner-lambert Company

20070203213 - Novel ppar ligands that do not cause fluid retention, edema or congestive heart failure: Methods are provided for treating or prophylactically preventing metabolic disorders in humans without causing, promoting, or aggravating fluid retention, peripheral edema, pulmonary edema, or congestive heart failure, by administration of a therapeutically effective amount of a compound sufficient to partially or fully activate peroxisome proliferator activated receptors (PPARs) and partially... Agent: Morrison & Foerster LLP

20070203214 - Synthesis of chromanones: Processes for the preparation of biologically active chromanones are disclosed, including processes for the preparation of intermediates useful in the preparation of the biologically active chromanones. The chromanones and the intermediates disclosed herein may be useful for a variety of therapies, including the treatment of various cancers and the treatment... Agent: Senniger Powers

20070203216 - Method of treating inflammatory diseases: The present invention relates to the use of gaboxadol, or a combination of gaboxadol and one or more anti-inflammatory compounds, for the treatment of an inflammatory disease. The present invention further relates to a pharmaceutical composition comprising gaboxadol and one or more anti-inflammatory compounds. The present invention further relates to... Agent: Darby & Darby P.C.

20070203215 - Methods & compositions for enhancing pharmaceutical treatments: Improved methods are provided for therapeutic and/or preventative treatment to a mammal in which the mammal is protected against the toxicity of active pharmaceutical agents that (i) bind to or are substrates for P-gp, (ii) are taxane analogues, and/or (iii) are inhibitors of tubulin disassembly. Additionally provided are compositions and... Agent: Wilson Sonsini Goodrich & Rosati

20070203217 - Substituted stilbenes and their reactions: The present invention relates to stilbene and quinine compounds related to combretastatin A-4 and their use as anticancer compounds and prodrugs. The compounds include those with an alkyl group on the double bond of cis or trans-stilbenes, compounds with one or more (and preferably 2 or 3) alkyl group substituents... Agent: Dann, Dorfman, Herrell & Skillman

20070203218 - Compounds which potentiate glutamate receptor and uses thereof in medicine: This case discloses compounds of formula (I) wherein R1 is C1-6alkyl, haloC1-6alkyl, C2-6alkenyl, amino, monoC1-4alkylamino or diC1-4alkylamino; R2 and R3, which may be the same or different, are hydrogen, halogen, C1-6alkyl, haloC1-6alkyl, C1-4alkoxy, haloC1-4alkoxy, cyano or amino; each R4, which may be the same or different, is C1-6alkyl, halogen, haloC1-6alkyl,... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070203219 - Production of dolasetron: The present invention provides an improved process for the preparation of Dolasetron salts, in particularly Dolasetron mesylate. Also provided are intermediates for the process and methods of preparing the intermediates.... Agent: Kenyon & Kenyon LLP

20070203220 - Inhibitors of pai-1 for treatment of muscular conditions: This invention describes novel methods of treating muscle damage, muscle wasting, muscle degeneration, muscle atrophy or reduced rates of muscle repair associated with various conditions such as muscular dystrophy, through the use of small-molecule PAI-1 inhibitors.... Agent: Woodcock Washburn LLP/wyeth

20070203222 - Substituted gamma lactams as therapeutic agents: Therapeutic compounds, compositions, medicaments, and methods are disclosed herein.... Agent: Allergan, Inc.

20070203221 - Processes for preparing darifenacin hydrobromide: The invention encompasses processes for the preparation of darifenacin hydrobromide.... Agent: Kenyon & Kenyon LLP

20070203223 - Synthesis of udp-glucose: n-acylsphingosine glucosyltransferase inhibitors: Disclosed is a novel enantiomeric synthesis ceramide-like inhibitors of UDP-glucose: N-acylsphingosine glucosyltransferase. Also disclosed are novel intermediates formed during the synthesis.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070203224 - Small-molecules for treating cancer and abnormal cell proliferation disorders: Novel compounds and compositions that can be used to bind tubulin, prevent tubulin polymerization, inhibit cell growth, arrest cell cycle, cause cell death, or treat cancer or abnormal cell proliferation disorders. Also disclosed are methods for identifying, synthesizing, and using such compounds.... Agent: Hogan & Hartson L.L.P.

20070203225 - Method of increasing endogenous adiponectin production and leptin production: A formulation for and method of enhancing adiponectin and leptin secretion is disclosed. The method comprises contacting living cells with an inhibitor of the enzyme pyruvate dehydrogenase kinase (PDHK). The PDHK inhibitor causes the cells it contacts to increase adiponectin secretion as well as increasing the production of leptin. The... Agent: Bozicevic, Field & Francis LLP

20070203226 - Calcilytic compounds: Novel calcilytic compounds and methods of using them are provided.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070203227 - Isoflavan and isoflavene compounds and their use as angiogenesis inhibitors: wherein R1 and R2 independently have the meaning of a hydroxy group, or a group that decreases the metabolism or increases the bioavailability of the compound, and the dotted line means an optional double bond, for the treatment of pathological conditions associated with or dependent on enhanced or abnormal angiogenesis... Agent: Birch Stewart Kolasch & Birch

20070203228 - Method for treating chronic obstructive pulmonary disease: e

20070203229 - Novel tricyclic spiroderivatives as modulators of chemokine receptor activity:

20070203230 - Novel tricyclic spiroderivatives as modulators of chemokine receptor activity:

20070203231 - Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion: The present invention relates to a method of treating a central nervous system disorder, such as a mood disorder (e.g., major depressive disorder) or an anxiety disorder (e.g., general anxiety disorder, social anxiety disorder, post traumatic stress disorder, and panic disorder) with a low dose combination of escitalopram and bupropion.... Agent: Darby & Darby P.C.

20070203232 - Propargylated aminoindans, processes for preparation, and uses thereof: e

20070203233 - Novel 2-(alpha-n-pentanonyl)benzoates, their preparation and use: The present invention relates to novel compounds 2-(α-n-pentanonyl)benzoates, their preparation method, the pharmaceutical composition containing the same, and their use in preparing the medicament for preventing and treating cardio-cerebral ischemic disease, inhibiting thrombosis and alleviating the disturbance of cardio-cerebral circulation.... Agent: Townsend And Townsend And Crew, LLP

20070203234 - Cell repair and regeneration by suramin and related polysulfonated napthylureas: Disclosed herein are compositions and methods for promoting the repair and regeneration of injured tissues, such as injuries resulting from ischemic damage.... Agent: Needle & Rosenberg, P.C.

20070203238 - Method for preventing or reducing elevated triglyceride levels: The present invention is directed to a novel method for reducing triglyceride levels in an infant. The method comprises administration of a therapeutically effective amount of DHA and ARA, alone or in combination with one another, to the subject.... Agent: Richard D. Schmidt Bristol-myers Squibb Company

20070203235 - Method for preventing or treating anemia: The present invention is directed to a novel method for preventing or treating anemia in a subject. The method comprises administration of a therapeutically effective amount of DHA and ARA to the subject.... Agent: Bristol-myers Squibb Company - Mead Johnson

20070203237 - Method for preventing or treating obesity: The present invention is directed to a novel method for preventing or treating obesity in a subject. The method comprises administration of a therapeutically effective amount of DHA and ARA, alone or in combination with one another, to the subject.... Agent: Richard D. Schmidt Bristol-myers Squibb Company

20070203236 - Novel antagonists of the human fatty acid synthase thioesterase: The present invention provides for compounds of formula (I)-(XIII), as well as pharmaceutically acceptable salts thereof, metabolites thereof, pro-drugs thereof, and pharmaceutical kits that include such compounds. The present invention also provides for the compounds of formula (I)-(XIII) for use in medical therapy or diagnosis. The present invention also provides... Agent: Schwegman, Lundberg, Woessner & Kluth, P.A.

20070203240 - Personal care compositions and methods for regulating mammalian hair growth: Personal care composition, comprising a first ingredient selected from the group consisting of α-phenyl butyl nitrone (PBN), PBN doxylcyclohexane radicals, 5,5-dimethyl pyrroline N-oxide (DMPO), α-(4-pyridyl 1-oxide)-N-tert-butylnitrone (POBN), 2,2,6,6-tetramethylpiperidine 1-oxide, 4-hydroxytetramethylpiperidine 1-oxide, and the salts of N-(1-oxido-2,2,6,6-tetramethyl-4-piperidyl)-N,N-dimethyl-N-hydroxyethylammonium, 3,5-dibromo-4-nitrosobenzenesulfonic acid, 2-methyl-2-nitrosopropane, nitrosodisulfonic acid, α-(4-pyridyl-1-oxide)-N-t-butylnitrone, 3,3,5,5-tetramethylpyrroline N-oxide, and 2,4,6-tri-t-butylnitrosobenzene, spin-trapping derivatives thereof, and... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070203239 - Compounds for the treatment of an acute injury to the central nervous system: KATP channel closers (KCCs) are useful for the prophylactic and/or therapeutic treatment of a CNS acute damage in a mammal, including a human, because their administration, particularly in the case of glibenclamide, potientates the neuroprotector microglial effect. Therefore, they may be useful in treating the acute phase of CNS diseases... Agent: Trask Britt

20070203241 - Antiviral treatments: The invention provides unit dosage forms, kits, and methods useful for treating viral infections.... Agent: Viksnins Harris & Padys Pllp

20070203242 - Method for treating gastric reflux: Methods and compositions for treating gastric reflux or the pain associated therewith comprising orally administering therapeutically effective amounts of a compound or composition capable of releasing nitric oxide in a pharmaceutically acceptable composition are described herein.... Agent: Gary Calton

20070203243 - Resolution of alpha-(phenoxy) phenylacetic acid derivatives: t

20070203244 - Inhibitors of membrane type-1 matrix metalloproteinase for the treatment of insulin-dependent diabetes mellitus: Provided herein are compositions and methods for inhibiting the transmigration of T cells through pancreatic capillary endothelium and treating insulin-dependent diabetes mellitus (IDDM; type I diabetes) using inhibitors of MT1-MMP.... Agent: Needle & Rosenberg, P.C.

20070203245 - Abca1 elevating compounds: The present invention provides compounds useful for increasing cellular ATP binding cassette transporter ABCA1 production in mammals, and to methods of using such compounds in the treatment of coronary artery diseases, dyslipidiemias and metabolic syndrome. The invention also relates to methods for the preparation of such compounds, and to pharmaceutical... Agent: Cv Therapeutics, Inc.

20070203246 - Combinations of cholesterol ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications: The present invention provides combinations of cardiovascular therapeutic compounds for the prophylaxis or treatment of cardiovascular disease including hypercholesterolemia, atherosclerosis, or hyperlipidemia. Combinations disclosed include an HMG CoA reductase inhibitor combined with a cholesteryl ester transfer protein (CETP) inhibitor.... Agent: Pfizer Inc.

20070203248 - Cardioprotective agents: The invention relates to pharmaceutical compositions comprising 5-Methoxytryptamine or a salt thereof for the prevention and/or treatment of mammalian cardiac tissue damage. 5-Methoxytryptamine and the salts thereof act as free radical scavengers in the prevention and/or treatment of mammalian cardiac tissue damage mediated by free oxygen radicals.... Agent: Ladas & Parry

20070203247 - Epinephrine dosing regimens: The present invention relates to methods for administering a first dose of epinephrine solution and an optional second dose of epinephrine solution. Also provided herein are kits useful in these methods.... Agent: Wilson Sonsini Goodrich & Rosati

20070203249 - Method for treating cancer: This invention relates to a process of treating/affecting cancers that are particularly susceptible to radiation therapy by administering to a host in need of such treatment an amino acid and radiation therapy.... Agent: Schwegman, Lundberg, Woessner & Kluth, P.A.

20070197429 - Conotoxin analogues and methods for synthesis of intramolecular dicarba bridge-containing peptides: According to the present invention, there is provided a range of new conotoxin derivatives and methods for synthesizing these analogues and other intramolecular dicarba bridge-containing peptides, including dicarba-disulfide bridge-containing peptides.... Agent: Fish & Richardson PC

20070197442 - Methods for the treatment of macular degeneration and related eye conditions: The invention provides a peptide-lipid complex for treating age-related macular degeneration and related conditions. The compositions and methods of the instant invention encompass a novel approach to the treatment of age-related macular degeneration and related conditions. Pharmaceutical compositions for this use are also provided.... Agent: Pharmacia & Upjohn

20070197440 - Therapeutic preparation of very high purity fviia and method for obtaining same: The therapeutic preparation of FVIIa having a purity of at least 1000 IU/mg of protein is characterized in that said preparation is free of proteins of non-human origin. In the method for obtaining FVII, purification starts from FrII+III, FrIII or equivalent of Cohn fractioning and comprises precipitation with PEG, chromatography... Agent: Darby & Darby P.C.

20070197444 - Phage displayed cell binding peptides: e

20070197446 - Mhc binding peptides and their uses: The present invention is concerned with MHC binding peptides derived from the avian influenza virus H5N1 and in particular MHC class I restricted binding peptides from the Haemagglutinin 5 (H5) protein from this virus and their uses.... Agent: Ked & Associates, LLP

20070197452 - Treatment of amyloid-related diseases: e

20070197455 - Processes for the convergent synthesis of calicheamicin derivatives: This invention describes processes for the convergent synthesis of calicheamicin derivatives, and similar analogs using bifunctional and trifunctional linker intermediates.... Agent: Wyeth Patent Law Group

20070197478 - Novel pharmaceuticals: The present invention relates to immune response modifiers of formula (I), which act selectively through agonism, of Toll-Like Receptors (TLRs), uses thereof, processes for the preparation thereof, intermediates used in the preparation thereof and compositions containing said inhibitors. These inhibitors have utility in a variety of therapeutic areas including the... Agent: Pfizer Inc

20070197424 - Glatiramer acetate for use as an immuno-modulatory agent: A method for the treatment of hepatic fibrotic injuries caused by various diseases, viral infections or toxic agents which involves the use of glatiramer acetate as an immuno-modulatory agent. The diseases to be treated are hepatic fibrosis and hepatic cellular carcinomas. Also disclose is the use of glatiramer acetate in... Agent: Fleit Kain Gibbons Gutman Bongini & Bianco

20070197425 - Combinations of chromium with antidiabetics for glucose metabolism disorders: Compositions and methods of using the same for the treatment of diabetes and other disorders of glucose metabolism are provided. Compositions may include an anti-diabetic agent and one or more of a bioavailable source of chromium and vanadium.... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20070197426 - Lactoferrin polypeptide, process for producing the same and inflammation inducing substance: To provide lactoferrin polypeptides which have inducing activity for production of various inflammatory cytokines and various chemokines. Lactoferrin polypeptides characterized by comprising the amino acid sequence of phenylalanine (F), lysine (K) and aspartic acid (D). They are obtained by digestion with proteases. Molecular weights of them are less than 25... Agent: Young & Thompson

20070197427 - O,o'-amidomalonate and n,o-amidomalonate platinum complexes: The present invention relates to amidomalonate O,O′—Pt and N,O—Pt chelates and methods of preparing them in essentially pure form.... Agent: Foley & Lardner LLP

20070197428 - Novel indications of mannan-binding lectin (mbl) in the treatment of immuno-compromised individuals: The present invention relates to the use of a composition comprising at least one mannan-binding lectin (MBL) subunit, or at least one mannan-binding lectin (MBL) oligomer comprising the at least one mannan-binding lectin (MBL) subunit, in the manufacture of a medicament for prophylaxis and/or treatment of infection. In particular the... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070197430 - Conjugates and therapeutic uses thereof: Conformationally constrained peptides that mimic BH3-only proteins and their conjugation to antibodies and other cell targeting compounds, compositions containing the conjugates and their use in the regulation of cell death are disclosed. The conformationally constrained peptides are capable of binding to and neutralising pro-survival Bcl-2 proteins. Processes for preparing the... Agent: Proskauer Rose LLP

20070197437 - Compositions for enhanced epithelial permeation of y2 receptor-binding peptides: Pharmaceutical compositions comprising a PYY peptide, a cyclodextrin, and a compound selected from phosphatidylcholine or diglyceride, wherein the cyclodextrin and the compound selected from phosphatidylcholine or diglyceride are present in an amount sufficient to enhance epithelial permeation.... Agent: Nastech Pharmaceutical Company Inc

20070197433 - Differentiation- or regeneration-inducing agent for alveoli: The present invention provides an agent comprising HGF for inducing differentiation of bone marrow cells into alveolar cells. The present invention also provides an HGF-containing agent for alveolar formation in pulmonary emphysema and the like in which alveoli are destroyed.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070197438 - Dynamin mediated diseases and associated methods and products: This invention relates generally to the treatment of cathepsin or dynamin mediated diseases, such as proteinuria, cancer, and cognitive disease and related products. Diagnostic and other assays are also provided, as well as methods for podocyte cell gene transfer.... Agent: Wolf Greenfield & Sacks, P.C.

20070197443 - Methods and compositions for modulating immunity: Methods and compositions for inducing immune suppression are disclosed. The methods involve administering an effective amount of a CD200 protein or a nucleic acid encoding a CD200 protein. The methods are useful in preventing graft rejection, fetal loss, autoimmune disease, and allergies. Methods and compositions for preventing immune suppression are... Agent: Bereskin And Parr

20070197431 - Novel protein for inhibiting tumor progression and increasing nerve regeneration: The present invention provides compositions and methods useful for inhibiting the activity of ErbB3 and ErbB4, inhibiting neoplastic growth, or increasing nerve growth. The present invention also provides a dominant negative form of Nrdp1 and methods of use thereof. Methods screening for agents capable of regulating the interaction of Nrdp1... Agent: Morgan, Lewis & Bockius LLP (sf)

20070197432 - Peptides for preventing, diagnosing and treating animal and/or human leptospirosis: Compounds (I) that are the peptide of sequence (1), its homologs with at least 60% homology, or their salts, functional fragments, chemical analogs and chemical derivatives, are new. Compounds (I) that are the peptide of sequence (1), its homologs with at least 60% homology, and their salts, functional fragments, chemical... Agent: Alston & Bird LLP

20070197436 - Peptidyl diacylglycerides: Peptide and peptides that may be covalently linked to a lipid and methods of using such peptides and lipopeptides to prevent or treat disease are disclosed herein.... Agent: Pepper Hamilton LLP

20070197435 - Process for the synchronization of ovulation for timed breeding without heat detection: A method for synchronizing ovulation in sows and gilts by a single injection of hormones is disclosed. A hormone, gonadotropin releasing hormone (GnRH), luteinizing hormone (LH), follicle stimulating hormone (FSH), human chorionic gonadotropin (hCG), analogues, derivatives, agonists or combinations thereof is administered to an open sow post weaning at a... Agent: Barnes & Thornburg LLP

20070197439 - Stabilized compositions of proteins having a free thiol moiety: Compositions of proteins having free thiols, and methods of making and using such compositions, are described.... Agent: Fish & Richardson PC

20070197434 - Theurapeutic or prophyiactic agent for arthritis: This invention provides a new therapeutic or prophylactic agent for arthritis such as osteoarthritis. Specifically, it provides a therapeutic or prophylactic agent for arthritis such as osteoarthritis, or an agent for promoting the growth of articular chondrocyte, comprising a guanyl cyclase B (GC-B) activator as an active ingredient; or a... Agent: Birch Stewart Kolasch & Birch

20070197441 - Truncated il-17ra soluble receptor and methods of using in inflammation: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A alone, or both IL-17A and IL-17F polypeptide molecules. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. IL-17RA is a receptor for IL-17A and does also bind IL-17F. The present... Agent: Zymogenetics, Inc. Intellectual Property Department

20070197445 - Compounds for control of appetite: This invention relates generally to neuropeptide Y (“NPY”) Y4 receptor agonists including pancreatic polypeptide (PP), analogs thereof, and peptide fragments of PP, e.g. PP(32-36), and analogs thereof, to pharmaceutical compositions containing such Y4 receptor agonists, and to methods for treatment of mammals using the same. The NPY Y4 receptor agonists... Agent: Wood, Herron & Evans, LLP

20070197447 - Oligopeptide acetate and formulations thereof: The invention relates to acetates of the tetrapeptides AQGV (SEQ ID NO:2) and LQGV (SEQ ID NO:3), pharmaceutical compositions comprising the acetates of the tetrapeptides, and methods of treating using the acetates of the tetrapeptides or pharmaceutical compositions to treat acute inflammatory conditions including sepsis.... Agent: Trask Britt

20070197448 - Sulfur compounds as inhibitors of hepatitis c virus ns3 serine protease: The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070197451 - Carbohydrate conjugates to prevent abuse of controlled substances: The invention provides a “street-safe” version of a controlled substance that permits the therapeutically beneficial effects of the substance while reducing or eliminating the euphoric effects that lead to substance abuse. The invention provides pharmaceutical compositions comprising a controlled substance and a carbohydrate covalently bound to said controlled substance in... Agent: Hunton & Williams LLP Intellectual Property Department

20070197453 - Compositions and methods for treatment of disorders of protein aggregation: The invention relates to compositions, methods and uses comprising an epi-inositol compound that provides beneficial effects in the treatment of a disorder and/or disease including a disorder in protein folding and/or aggregation, and/or amyloid formation, deposition, accumulation, or persistence. In aspects of the invention, the epi-inositol compounds provide beneficial effects... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070197449 - Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof: The present invention provides nitrogen-containing fused cyclic derivatives represented by the following general formula or pharmaceutically acceptable salts thereof, or prodrugs thereof, which exhibit an excellent inhibitory activity in human SGLT and are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes,... Agent: Sughrue Mion, PLLC

20070197450 - Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof: The present invention provides fused heterocyclic derivatives represented by the following general formula (I) or pharmaceutically acceptable salts thereof, or prodrugs thereof, which exhibit an inhibitory activity in human SGLT and are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, postprandial... Agent: Sughrue Mion, PLLC

20070197454 - P1-(2'-deoxycytidine 5'-)p4-(uridine 5'-)tetraphosphate, tetra-(alkali metal) salt, for treating disorders: The present invention provides a method of treating edematous retinal disorders. The method comprises administration of a pharmaceutical formulation comprising a hydrolysis-resistant P2Y receptor agonist to stimulate the removal of pathological extraneous fluid from the subretinal and retinal spaces and thereby reduce the accumulation of said fluid associated with retinal... Agent: Howery LLP

20070197456 - Preparation and diabetic use of gibberellins: The present invention relates to application of compounds of formula (1) (Gibberellins) and their derivatives for the preparation of a pharmaceutical composition or medicaments for the treatment of diabetes, its complications and associated conditions, including obesity, micro and macro vascular diseases, nephropathy, neuropathy, eye diseases, diabetic ulcerations and the like.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070197459 - Induction of apoptosis by inhibition of sirtuin sirta expression: The invention relates to the induction of apoptosis by inhibition of the sirtuin SIRT1 expression, in particular the induction of apoptosis in tumour cells. Materials and methods for inhibiting SIRT1 expression are provided, including RNA interference methods. In particular, the invention provides a method of treating a proliferative disease comprising... Agent: Nixon & Vanderhye, PC

20070197458 - Nucleic acid useful for triggering tumor cell lethality: The invention relates to double-stranded nucleic acid fragments comprising a chemically modified backbone and at least 4-1000 bp, preferably 8-500 bp, and most preferably 16-200 bp. The disclosed molecules (DRIL molecules) may interfere with DNA damage signalling and repair pathways, in particular the non homologous NHEJ pathway of double-stranded break... Agent: Nixon & Vanderhye, PC

20070197460 - Rnai inhibition of influenza virus replication: The invention relates to compositions and methods for modulating the expression of influenza viral genes, and more particularly to the downregulation of influenza viral genes by chemically modified oligonucleotides.... Agent: Fish & Richardson PC

20070197457 - Tak1-mediated inhibition of osteogenesis: This invention is directed to methods, nucleic acids and compositions in TAK1-mediated regulation of SMAD activity. Promotion of TAK1 interaction with MH2 domains in SMADs negatively regulates SMAD biological activity. BMP-mediated SMAD activity is subject to TAK1 effects.... Agent: Martin Moynihan Prtsi Inc

20070197461 - Methods of optimizing drug therapeutic efficacy for treatment of immune-mediated gastrointestinal disorders: The present invention provides a method of optimizing therapeutic efficacy and reducing toxicity associated with 6-mercaptopurine drug treatment of an immune-mediated gastrointestinal disorder such as inflammatory bowel disease. The method of the invention includes the step of determining the level of one or more 6-mercaptopurine metabolites in the patient having... Agent: Townsend And Townsend And Crew, LLP

20070197463 - Antiviral nucleosides: Compounds having the formula I wherein R1 is as herein defined are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for inhibiting hepatitis replication, and processes for making the compounds of formula I... Agent: Roche Palo Alto LLC Patent Law Dept. M/s A2-250

20070197462 - Treatment of ebv and khsv infection and associated abnormal cellular proliferation: A method and composition for the treatment, prevention and/or prophylaxis of a host, and in particular, a human, infected with Epstein-Barr virus (EBV), is provided that includes administering an effective amount of a 5-substituted uracil nucleoside or its pharmaceutically acceptable salt or prodrug, optionally in a pharmaceutically acceptable diluent or... Agent: Merchant & Gould PC

20070197464 - Surfactant composition: A surfactant composition containing at least one branched non-ionic surfactant and at least one surfactant capable of forming liquid crystals in water. The surfactant composition is particularly suitable for forming emulsions, especially for use as a sprayable personal care or cosmetic product.... Agent: Mayer, Brown, Rowe & Maw LLP

20070197465 - Hyaluronic acid-methotrexate conjugate: An object of the present invention is to provide a hyaluronic acid-methotrexate conjugate useful as a therapeutic drug for joint diseases. There is provided a hyaluronic acid-methotrexate conjugate useful as a therapeutic drug for joint diseases, wherein methotrexate is conjugated with a carboxyl group of hyaluronic acid through a linker... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070197466 - Synthetic membrane anchors: The invention relates to synthetic molecules that spontaneously and stably incorporate into lipid by-layers, including cell membranes. Particularly, although not exclusively, the invention relates to the use of these molecules as synthetic membrane anchors or synthetic molecule constructs to effect qualitative and quantitative changes in the expression of cell surface... Agent: Nixon & Vanderhye, PC

20070197467 - Zafirlukast compositions: Intimate dispersions comprising zafirlukast and hydroxypropyl cellulose.... Agent: Dr. Reddy's Laboratories, Inc.

20070197469 - Fluoroquinolone carboxylic acid salt compositions: The invention relates to pharmaceutical compositions that are a solution of a salt formed between a fluoroquinolone and a carboxylic acid, a cyclodextrin, and a pharmaceutically acceptable organic solvent and to methods of treating a condition in an animal by administering to an animal in need thereof the pharmaceutical composition... Agent: Kenyon & Kenyon LLP

20070197468 - Oral formulations of cladribine: Provided are compositions of cladribine and cyclodextrin which are especially suited for the oral administration of cladribine.... Agent: Buchanan, Ingersoll & Rooney PC

20070197471 - Treatment of degenerative cartilage conditions in a mammal with glycosidasc inhibitors: This invention relates to treating, preventing, and lessening the severity of conditions selected from the group consisting of osteoarthritis, rheumatoid arthritis, synovitis, subchondral bone edema, and cartilage degradation with administration of glycosidase inhibitors.... Agent: Catalyst Law Group, Apc

20070197470 - Use of n-acetyl-d-aminogylcosamine in preparation of drugs for modulating microorganisms on mucous membrane: The present invention has disclosed a use of N-acetyl-D-glucosamine in the preparation of a medicament for regulating microecological balance of mucocutaneous membrane. N-acetyl-D-glucosamine has functions of promoting bacteria and cellular redistribution and against allochthonous flora colonization. Preparations comprising N-acetyl-D-glucosamine as main active substance are able to be used for regulating... Agent: Price Heneveld Cooper Dewitt & Litton, LLP

20070197472 - N-alkynyl-2-heteroaryloxyalkylamides for use as fungicides: Compounds of the general formula (I) are useful as fungicides wherein Het is a 5- or 6-linked group of the formula (a) or (b), and the variables are as defined in the claims.... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20070197473 - Methods of using saha and bortezomib for treating cancer: The present invention relates to a method of treating cancer in a subject in need thereof, by administering to a subject in need thereof a first amount of a histone deacetylase (HDAC) inhibitor such as suberoylanilide hydroxamic acid (SAHA), or a pharmaceutically acceptable salt or hydrate thereof, and a second... Agent: Mintz Levin Cohn Ferris Glovsky & Popeo

20070197474 - Methods for controlling plants pathogens using n-phosphonomethylglycine: The present invention relates to compositions and methods for disease control in plants. The compositions for use in the methods of the invention include glyphosate as the active compound. In addition, methods and compositions are disclosed to prevent and treat pest infection in glyphosate tolerant plants.... Agent: Arnold & Porter, LLP

20070197475 - Medical emulsion of perfluororganic compounds and method for the production thereof: Medicine, in particular medications for treating blood losses, hypoxic and ishemic states, for improving a blood oxygen supply and for preserving isolated perfused organs and tissues. The inventive medical emulsion of perfluororganic compounds includes rapidly excretable perfluororganic compounds such as perfluordecalin, perfluoractilbromide, a perfluoroganic additive embodied in the form of... Agent: Pauley Petersen & Erickson

20070197477 - Phosphonium salts derivatives: d

20070197476 - Triptolide derivatives and their uses: wherein, C5 and C6 connect with each other by a C—C single bond or double bond; when C5 and C6 are connected with C—C single bond, X and Y represents independently hydrogen, oxygen, hydroxyl, halogen, lower alkyl-oxy, lower alkyl-amino, mercapto, lower alkyl-thio, the group of formula —OCOR, —OSO2R or —OPO(OH)2,... Agent: Butzel Long

20070197479 - Derivatives of 4- or 5-aminosalicylic acid: The present invention provides new derivatives of 4- or 5-aminosalicylic acid, and a pharmaceutical composition containing these derivatives of 4- or 5-aminosalicylic acid as active ingredients, useful for the treatment of intestinal diseases such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) and for the prevention/treatment of colon... Agent: Bennett Jones C/o Ms Roseann Caldwell

20070197480 - (s)-2-n-propylamino-5-hydroxytetralin as a d3-agonist: The invention relates to a medicament containing (S)-2-N-propylamino-5-hydroxytetralin, the salts or prodrugs thereof. As a D3 agonist, (S)-2-N-propylamino-5-hydroxytetralin is suitable particularly for the treatment of dopa-sensitive movement disorders.... Agent: Harness, Dickey, & Pierce, P.l.c

20070197481 - Certain chemical entities, compositions, and methods: Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of one or more mitotic kinesins are disclosed.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070197482 - Regulation of guanine nucleotide exchange factor for a protein belonging to the rap family of small gtpases: The invention relates generally to the methods of treating brain diseases and compounds for treating brain diseases, and more specifically relates to using compounds that are able to modulate guanine nucleotide exchange factors for proteins belonging to the Rap family of small GTPases to treat diseases of the brain, such... Agent: Edwards Angell Palmer & Dodge LLP

20070197483 - External preparation for treating painful skin wound: External preparations for treatment of painful skin wound having an analgesic activity which comprises acetylsalicylic acid or its pharmacologically acceptable salt as an active ingredient.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070197484 - Method of treating disorder related to high cholesterol concentration: t

20070197486 - Methods and systems for the delivery of corticosteroids: The present invention relates to methods and systems for the delivery of a corticosteroid comprising (1) an inhalable aqueous mixture comprising a corticosteroid and a solubility enhancer and (2) an inhalable nebulizer, wherein the delivery of the aqueous mixture comprising the corticosteroid by the nebulizer results in an enhanced pharmacokinetic... Agent: Wilson Sonsini Goodrich & Rosati

20070197487 - Systems and methods for the delivery of corticosteroids having an increased lung deposition: The present invention relates to methods and systems for the delivery of a corticosteroid comprising (1) an inhalable aqueous mixture comprising a corticosteroid and a solubility enhancer and (2) an inhalable nebulizer, wherein the delivery of the aqueous mixture comprising the corticosteroid by the nebulizer results in an enhanced pharmacokinetic... Agent: Wilson Sonsini Goodrich & Rosati

20070197485 - Therapy and use of compounds in therapy: A method for treating cachecia, liver disease, and other wasting syndromes is provided. The treatment method comprises administering a therapeutically effective amount of a compound that is able to reduce the production, absorption and/or the effect of an endotoxin. Examples of such compounds include, but are not limited to, bile... Agent: Norris, Mclaughlin & Marcus, P.A.

20070197488 - Prodrugs of erbeta-selective substances, process for their production, and pharmaceutical compositions that contain these compounds: m

20070197489 - Composition of matter: The invention provides a process for the sterilization of a powdered form of a glucocorticosteroid, sterile glucocorticosteroids, sterile formulations containing glucocorticosteroids and use thereof in the treatment of an allergic and/or inflammatory condition of the nose or lungs.... Agent: Fish & Richardson P.C.

20070197490 - Method for producing 5alpha-pregnane derivative: e

20070197491 - Method for treating primary and secondary forms of glaucoma: Methods and compositions for controlling ocular hypertension associated with (i) primary open angle glaucoma (POAG), (ii) other forms of glaucoma, or (iii) glucocorticoid therapy are disclosed. The methods involve administration of angiostatic agents and other IOP-lowering agents via local injections in the anterior segment of the eye. The most preferred... Agent: Alcon

20070197492 - Modulation of pathogenicity: In particular the invention refers to a family of compounds that block the quorum sensing system of Gram-negative bacteria, a process for their manufacture, pharmaceutical compositions containing them and to their use for the treatment and prevention of microbial damages and diseases, in particular for diseases where there is an... Agent: Womble Carlyle Sandridge & Rice, PLLC Attn: Patent Docketing 32nd Floor

20070197494 - Photosensitisers and their uses:

20070197493 - Selenophene anti-tumor agents:

20070197495 - Anti-parasitic compounds and methods of their use: The present invention provides a novel class of compounds that disrupt the parasitic infectious life cycle and serve as promising agents for anti-parasitic therapy.... Agent: Townsend And Townsend And Crew, LLP

20070197496 - Substituted porphyrins: The present invention relates, in general, to a method of modulating physiological and pathological processes and, in particular, to a method of modulating cellular levels of oxidants and thereby processes in which such oxidants are a participant. The invention also relates to compounds and compositions suitable for use in such... Agent: Paul, Hastings, Janofsky & Walker LLP

20070197498 - Novel diphenylazetidinone with improved physiological properties, process for its preparation, medicaments comprising this compound, and its use: e

20070197499 - Pharmaceutical compounds: Compounds or their salts of general formula (I): A-B—N(O)s wherein: s is an integer equal to 1 or 2; A=R-T1-, wherein R is the drug radical and T1=(CO)t or (X)t′, wherein X═O, S, NR1c, R1c is H or a linear or branched alkyl or a free valence, t and t′... Agent: Arent Fox PLLC

20070197497 - Compounds, compositions and methods: Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070197500 - Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as orl1-receptor antagonists: This invention provides the compounds of formula (I): or a pharmaceutically acceptable ester of such compound, or a pharmaceutically acceptable salt thereof, wherein R1 and R2 independently represent a hydrogen atom or the like; R3 represents a hydrogen atom, or the like; R4 represents a hydrogen atom or the like;... Agent: Warner-lambert Company

20070197501 - Use of chemotherapeutic agents: The use of chemotherapeutic agents for the preparation of a medicament for the topical and/or local treatment of diseases caused by bacteria and/or for prophylaxis in humans or animals.... Agent: Perman & Green

20070197502 - Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders: Disclosed herein are analogs of clozapine and pharmaceutically acceptable salts, esters, amides, or prodrugs thereof, methods of synthesizing the analogs; and methods of using the analogs for treating neuropsychiatric disorders. In some embodiments, the analogs are amino substituted diaryl[a,d]cycloheptenes.... Agent: Knobbe Martens Olson & Bear LLP

20070197503 - Solutions containing epinastin: Topically administered aqueous solutions containing epinastin, optionally in the form of its racemate or its enantiomers and optionally in the form of the pharmacologically acceptable acid addition salts thereof.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070197504 - Certain chemical entities, compositions and methods: Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070197505 - Certain chemical entities, compositions and methods: Certain substituted urea derivatives modulate diskeletal myosin, skeletal actin, skeletal tropomyosin, skeletal troponin C, skeletal troponin I, skeletal troponin T, and skeletal muscle, including fragments and isoforms thereof, as well as the skeletal sarcomere, and are useful in the treatment of obesity, sarcopenia, wasting syndrome, frailty, muscle spasm, cachexia, neuromuscular... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070197506 - Modulators of 11-beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same: The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1 and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 such as obesity and diabetes.... Agent: Fish & Richardson PC

20070197507 - Certain chemical entities, compositions and methods: Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070197508 - Novel processes for the preparation of piperazinyl and diazapanyl benzamide derivatives: The present invention is directed to novel processes for the preparation of substituted piperazinyl and diazepanyl benzamides, useful for the treatment of disorders and conditions mediated by the histamine receptor.... Agent: Philip S. Johnson Johnson & Johnson

20070197509 - Compositions and methods for modulating gated ion channels: The present invention relates to compositions and methods to modulate the activity of gated ion channels.... Agent: Lahive & Cockfield, LLP

20070197510 - Nitriles and medicinal compositions containing the same as the active ingredient: wherein Y and Z each is independently N or C; ring A is a carbocyclic group or a heterocyclic group; ring B is a heterocyclic group containing at least one nitrogen atom; R is a hydrogen atom, a substitutent, etc.; n is 0, or an integer of from 1 to... Agent: Sughrue Mion, PLLC

20070197512 - Carboxylic acid compounds and use thereof: e

20070197511 - Neuroprotective bicyclic compouds and methods for their use: Embodiments of this invention provide novel cyclic compounds structurally related to diketopiperazines and methods for their therapeutic use. Such compounds are neuroprotective and have utility as therapeutic agents for treatment of diseases, injuries and other conditions characterised by neuronal degeneration and/or death. Compounds are also useful for manufacture of medicaments... Agent: Borson Law Group, PC

20070197513 - Ion channel modulators: The invention relates to compounds, compositions comprising the compounds, and methods of using the compounds and compound compositions. The compounds, compositions, and methods described herein can be used for the therapeutic modulation of ion channel function, and treatment of disease and disease symptoms, particularly those mediated by certain calcium channel... Agent: Edwards Angell Palmer & Dodge LLP

20070197514 - Conjugated psychotropic drugs and uses thereof: Novel chemical conjugates of psychotropic drugs and organic acids, uses thereof in the treatment of psychotic and/or proliferative disorders and diseases and as chemosensitizing agents, and their syntheses are disclosed. The organic acids are selected to reduce side effects induced by the psychotropic drugs and/or to exert an anti-proliferative activity.... Agent: Martin D. Moynihan Prtsi, Inc.

20070197516 - Lactams of alkylated acyclic diamine derivatives as modulators of chemokine receptor activity: v

20070197515 - Lanthionine-related compounds for the treatment of inflammatory diseases: The present invention provides compositions comprising lanthionine ketimine derivatives and thiomorpholine dicarboxylic acid derivatives, as well as processes for the preparation of such compounds. The invention also concerns the use of lanthionine, lanthionine ketimine (LK), LK derivatives, thiomorpholine dicarboxylic acid (TMDCA), and TMDCA derivatives. It concerns the use of these... Agent: Fulbright & Jaworski L.L.P.

20070197518 - Antibacterial agents: Described herein are antibacterial compounds, methods for making the compounds, pharmaceutical compositions containing the compounds and methods of treating bacterial infections utilizing the compounds and pharmaceutical composition.... Agent: Warner-lambert Company

20070197517 - Combination therapy for hyperproliferative disease: This invention relates a method of treating hyperproliferative diseases. More particularly, the present invention relates to a method of treating hyperproliferative diseases, such as cancer, comprising the step of administering to a mammal in need of such treatment, either simultaneously or sequentially, (i) a therapeutically effective amount of a taxane... Agent: Pfizer Inc

20070197520 - Mineralocorticoid receptor modulator compounds, processes for their preparation, and their uses: This invention relates to compounds that bind to mineralocorticoid receptors and/or modulate activity of mineralocorticoid receptors, and to methods for making and using such compounds.... Agent: Knobbe Martens Olson & Bear LLP

20070197519 - New process for the preparation of oxabispidines: There is provided a process for the preparation of a compound of formula (I): which process comprises reaction of a compound of formula (TI): with either a compound of formula (ITT): or acrylamide, followed, in the latter case, by reaction of the resulting intermediate of formula (IV): with an alcohol... Agent: Pepper Hamilton LLP

20070197521 - Novel bicyclic heterocycles useful as selective androgen receptor modulators: The present invention is directed to novel bicyclic heterocycles, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor.... Agent: Philip S. Johnson Johnson & Johnson

20070197523 - Calcium channel antagonists: The present invention provides novel calcium channel antagonists, and methods of treating disease sates using the novel antagonists.... Agent: Townsend And Townsend And Crew, LLP

20070197522 - Dpp-iv inhibitors: e

20070197524 - Fluorenes and carbazoles as ligands of the ep2 receptor: The present invention relates to carbazoles/fluorenes, to processes for their preparation and to their use for preparing pharmaceutical agents for the treatment of disorders connected to the EP2 receptor.... Agent: Millen, White, Zelano & Branigan, P.C.

20070197525 - Novel tetracyclic tetrahydrofuran derivatives: This invention concerns novel substituted tetracyclic tetrahydrofuran derivatives of Formula (I), an N-oxide form, a pharmaceutically acceptable addition salt or a stereochemically isomeric form thereof wherein the variables are declared as in claim 1. These compound have binding affinities towards serotonin receptors, in particular 5-HT2A and 5-HT2C receptors, and towards... Agent: Philip S. Johnson Johnson & Johnson

20070197526 - Pyrazoles for the treatment of obesity and other cns disorders: This invention relates to compounds having pharmacological activity, to compositions containing these compounds, and to a method of treatment employing the compounds and compositions. More particularly, this invention concerns certain pyrazole derivatives, their salts and solvates. These compounds have H3 histamine receptor binding activity. This invention also relates to pharmaceutical... Agent: Wood, Phillips, Katz, Clark & Mortimer

20070197527 - Bicyclic heteroaromatic compounds: wherein R1 is (3-8C)cycloalkyl, (2-7C)heterocycloalkyl, (6-14C)aryl or (4-13C)heteroaryl; all optionally substituted with one or more substituents; R2 is (1-4C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, (6-14C)aryl or (4-13C)heteroaryl; R3 is (1-8C)alkyl, (3-8C)cycloalkyl, (2-7C)heterocycloalkyl, (6-14C)aryl or (4-13C)heteroaryl; Y is CH or N; Z is NH2 or OH; A is S, N(H), N(R), O or a... Agent: Akzo Nobel Inc.

20070197528 - Analogs of nitrobenzylthioinosine: Analogs or derivatives of nitrobenzylthioinosine, pharmaceutical compositions comprising such analogs or derivatives, and the use of such analogs or derivatives of nitrobenzylthioinosine for the treatment of pain and various other diseases.... Agent: Crowell & Moring LLP Intellectual Property Group

20070197530 - Amido compounds and their use as pharmaceuticals: The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1 and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1.... Agent: Fish & Richardson PC

20070197531 - Benzoyl-piperidine derivatives as dual modulators of the 5-ht2a and d3 receptors: e

20070197529 - Isolated desfluoro-linezolid, preparation thereof and its use as a reference marker and standard: The present invention provides an isolated linezolid impurity, desfluoro linezolid, the preparation thereof and its use as a reference standard.... Agent: Kenyon & Kenyon LLP

20070197532 - Glucokinase activators: e

20070197533 - Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds: The invention relates to antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds and pharmaceutical compositions thereof. This invention also relates to a method of using such compounds in the treatment of bacterial infections in mammals, especially humans.... Agent: Connolly Bove Lodge & Hutz LLP

20070197534 - Novel 1,2,4-benzotriazine-1,4-dioxides: The present invention provides a simplified set of characteristics that can be used to select 1,2,4 benzotriazine 1,4 dioxide compounds (TPZ analogues) with therapeutic activity against hypoxic cells in human tumour xenografts, and to further provide a novel class of 1,2,4-benzotriazine-1,4-dioxides (TPZ analogues) with predicted in vivo activity against tumours,... Agent: Nixon & Vanderhye, PC

20070197535 - Polymorphic forms of vardenafil: Crystalline polymorphic forms of vardenafil and vardenafil hydrochloride, and processes for preparing them.... Agent: Dr. Reddy's Laboratories, Inc.

20070197536 - Pyridazin-3(2)-one derivatives and their use as pde4 inhibitors: New pyridazin-e-(2H)-one derivatives having the chemical structure of general formula (I) are disclosed; as well as processes for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of phosphodiesterase 4.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070197537 - Heterobicyclic thiophene compounds and methods of use: Compounds of Formula I and pharmaceutically acceptable salts thereof, are useful for inhibiting receptor tyrosine kinases and for treating disorders mediated thereby. Methods of using compounds of Formula I and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in... Agent: Viksnins Harris & Padys Pllp

20070197538 - Anti-vascular and anti-proliferation methods, therapies, and combinations employing specific tyrosine kinase inhibitors: This invention is directed to potent inhibitors of protein tyrosine kinase alone or in synergistic combination with antiangiogenic or chemotherapeutic agents for the abrogation of mature vasculature within chemotherapeutic refractory tumors, pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or... Agent: Wiley Rein LLP

20070197539 - Hexahydro-pyrazino[1,2-a]pyrimidine-4,7-dione derivatives substituted with amino acids: The invention relates to substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives substituted with amino acids, and to the physiologically tolerated salts thereof, processes for their preparation and their use as medicaments... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070197540 - Pyrazolopyrimidines: e

20070197541 - Biaryl heterocyclic amines,amides, and sulfur-containing compounds and methods of making and using the same: The present invention relates generally to the field of anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents. More particularly, the invention relates to a family of biaryl heterocyclic amines, amides, and sulfur-countering compounds that are useful as such agents agents.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070197542 - N-{'4-substituted piperazine-1-sulfonylmethyl!alkyl}-n-hydroxyfomamide compounds as metalloproteinase inhibitors: The invention provides compounds of formula (I): or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein ring B represents a monocyclic aryl ring having six ring atoms or a monocyclic heteroaryl ring having up to six ring atoms and containing one or more ring heteroatoms wherein each said heteroatom... Agent: Fish & Richardson P.C.

20070197544 - Iloprost in combination therapies for the treatment of pulmonary arterial hypertension: Preferred embodiments of the present invention are related to novel therapeutic drug combinations and methods for treating pulmonary arterial hypertension. More particularly, aspects of the present invention are related to using a combination of iloprost and at least one additional agent, selected from the group consisting of an endothelin receptor... Agent: Knobbe Martens Olson & Bear LLP

20070197543 - Use of derivatives of 2, 5-dihydroxyb enzene-sulphonic acids in the elaboration of a medicinal product to enhance the effect of other drugs used for the treatment of erectile dysfunction: The present invention refers to the use of derivatives of 2,5-dihidroxybenzenosulphonic acids of general formula (I), to develop medicinal products of therapeutic value to enhance the effects of phosphodiesterase-5 including sildenaphyl, vardenaphyl and IC-351, of apomorphine, of nitric oxide donors including amyl nitrate, nitroglycerine, nitroprussiate, nitrosothioles and nicorandyl, of the... Agent: Ostrolenk Faber Gerb & Soffen

20070197545 - Crystalline polymorphs of methanesulfonic acid addition salts of imatinib: This invention relates to the methanesulfonic acid addition salts of Imatinib and to the synthesis thereof. In particular, this invention relates to the synthesis of crystalline α-form of Imatinib methanesulfonate. Furthermore, the invention is directed to a novel acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-[(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]benzamide with two molecules of methanesulfonic acid and... Agent: Matthias Scholl

20070197546 - Quinoline-4-carboxamide as nk-2 and nk-3 receptor antagonists: i

20070197547 - Inhibitors of macrophage migration inhibitory factor and methods for identifying the same:

20070197548 - Fluoroquinolone compositions: The invention relates to pharmaceutical compositions comprising (i) a fluoroquinolone, (ii) a salt formed between a carboxylate anion and a divalent metal cation, (iii) a liquid comprising an organic solvent selected from the group consisting of glycerol, propylene glycol, glycerol formal, and (iv) optionally water. The invention further relates to... Agent: Kenyon & Kenyon LLP

20070197549 - Tetrazole compounds and their use as metabotropic glutamate receptor antagonists: The present invention relates to new compounds of formula I, wherein P, Q, X1, X2, X3, X4, R1, R2, m and p, are as defined as in formula I, or salts, solvates or solvated salts thereof, processes for their preparation and new intermediates used in the preparation thereof, pharmaceutical compositions... Agent: Birch, Stewart, Kolasch & Birch, LLP

20070197550 - Histone deacetylase inhibitors for enhancing activity of antifungal agents: The present invention relates to compositions and methods to selectively treat fungal infection. More particularly, this invention relates to compositions and methods for selectively enhancing fungal sensitivity to antifungal compounds.... Agent: Keown & Zucchero, LLP

20070197552 - Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states: The present invention is related to a method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states comprising administering inhibitors of the enzymes NEP and DPP-IV to individuals suffering from one or more of those conditions. Inhibition of the activity of the two enzymes will... Agent: Novo Nordisk, Inc. Patent Department

20070197551 - Pyrimidine derivatives: The invention furthermore provides a therapeutic method of IBS, characterized by having 5-HT1A agonistic activity and 5-HT3 antagonistic activity work simultaneously and cooperatively in vivo, which comprises either administering 5-HT3 antagonistic agent which concurrently exhibits 5-HT1A agonistic activity, or administering 5-HT1A agonistic agent and 5-HT3 antagonistic agent simultaneously, in sequence... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070197553 - 4-aryl-pyridine-2-carboxyamide derivatives: e

20070197554 - Methods of optimizing drug therapeutic efficacy for treatment of immune-mediated gastrointestinal disorders: The present invention provides a method of optimizing therapeutic efficacy and reducing toxicity associated with 6-mercaptopurine drug treatment of an immune-mediated gastrointestinal disorder such as inflammatory bowel disease. The method of the invention includes the step of determining the level of one or more 6-mercaptopurine metabolites in the patient having... Agent: Townsend And Townsend And Crew, LLP

20070197555 - Pyrimidinone compounds as calcilytics: The pyrimidinone compounds are disclosed. Methods of preparing the pyrimidinone compounds are also disclosed.... Agent: Kevin B Laurence Stoel Rives

20070197556 - Fungicidal mixtures: Ra, Rb are halogen, cyano, alkyl, haloalkyl, alkoxycarbonyl, alkoxy, haloalkoxy, alkylthio, alkylcarbonyl, formyl, alkylene or alkenylene which links two adjacent carbon atoms; m is 0, 1, 2, 3, 4 or 5; n is 0, 1 or 2; in a synergistically effective amount, methods for controlling harmful fungi using mixtures of... Agent: Birch Stewart Kolasch & Birch

20070197557 - Fungicidal mixtures: ,

20070197558 - Anti-viral compounds: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using... Agent: Robert Deberardine Abbott Laboratories

20070197559 - Aryl substituted purine analogues: Aryl-substituted purine analogues are provided, of the formula: (I) wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated... Agent: Edwards Angell Palmer & Dodge LLP

20070197560 - Cgmp pde 5 inhibitors for inhalation in the treatment of sexual dysfunction: Treatment of sexual dysfunction by inhalation of a cGMP PDE 5 inhibitor, especially 5-[2-ethoxy-5-(4-methylpiperazinylsulfonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one, 4-phenylmethylamino-6-chloro-2-(1-imidazolyl)quinazoline, 4-phenylmethylamino-6-chloro-2-(3-pyridyl)quinazoline, 1,3-dimethyl-6-(2-propoxy-5-methanesulfonylamidophenyl)-1,5-dihydropyrazolo[3,4-d]pyrimidin-4-one or 1-cyclopentyl-3-ethyl-6-(3-ethoxy-4-pyridyl)-pyrazolo[3,4-d]pyrimidin-4-one.... Agent: Novartis Corporate Intellectual Property

20070197561 - Inhibitors of nucleoside metabolism: e

20070197562 - Remedies for prostatic hypertrophy: A treatment and/or preventive agent for prostatic hypertrophy includes a compound having an antagonistic effect to an angiotensin II receptor, or a pharmaceutically acceptable salt or a prodrug thereof, as an active ingredient, wherein said compound having an antagonistic effect to an angiotensin II receptor is one or more compounds... Agent: Osha Liang L.L.P.

20070197564 - Compounds for the treatment of inflammatory disorders: t

20070197563 - Substituted, bicyclic 8-pyrrolidinoxanthines, and methods for their use as inhibitors of dipeptidyl peptidase: wherein the various R groups are defined herein. The present invention also comprises pharmaceutical compositions comprising them as well as processes for the preparation of these compounds and methods for the treatment of metabolic disorders such as type-2 diabetes, insulin resistance, hyperglycemia, arteriosclerosis diseases and the like through the administration... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070197565 - Bicycloheteroaryl compounds as p2x7 modulators and uses thereof: e

20070197566 - Novel pyrazolylquinazolinones as potassium channel openers: The present invention is directed to novel pyrazolylquinazolinone derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders related to potassium channel.... Agent: Philip S. Johnson Johnson & Johnson

20070197567 - Compositions and methods to treat diseases characterized by cellular proliferation and angiogenesis: Described herein are compositions and methods for preventing and/or treating diseases involving aberrant angiogenesis employing one or more benzo[c]chromen-6-one derivatives.... Agent: Burns & Levinson, LLP

20070197568 - Methods of using saha and erlotinib for treating cancer: The present invention relates to a method of treating cancer in a subject in need thereof, by administering to a subject in need thereof a first amount of a histone deacetylase (HDAC) inhibitor such as suberoylanilide hydroxamic acid (SAHA), or a pharmaceutically acceptable salt or hydrate thereof, and a second... Agent: Mintz Levin Cohn Ferris Glovsky & Popeo

20070197569 - Method for treating central nervous system disorders with substituted 2-imidazoline derivatives: e

20070197570 - Indanol derivative:

20070197571 - Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzheimer' s disease: which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of... Agent: Merck And Co., Inc

20070197573 - Compositions and methods in the treatment of bone metabolic disorders: Bone metabolic disorders are treated by administering to an individual a therapeutically effective amount of a peripheral opioid antagonist at one or more of the opioid receptors, including the various naloxone and naltrexone analogs or a pharmaceutically acceptable salt thereof. The invention is further embodied in the use of peripheral... Agent: Mueller And Smith, Lpa Mueller-smith Building

20070197572 - Oxycodone polymorphs: Oxycodone.HCl polymorph forms are disclosed which are useful as analgesic agents either in combination with or as replacements for oxycodone.... Agent: Philip S. Johnson Johnson & Johnson

20070197574 - Methods and compositions for predicting irinotecan toxicity: The present invention concerns the methods and compositions for evaluating the risk of ironotecan toxicity in a cancer patient based on the genotype of the patient at position −3156 of the UGT1A1 gene or at any position in linkage disequilibrium with the −3156 variant.... Agent: Fulbright & Jaworski L.L.P.

20070197575 - Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers: e

20070197576 - Production of cabergoline and novel polymorphic form thereof: The present application relates to a novel polymorphic form of cabergoline comprising cabergoline and t-amyl methyl ether, designated Form TAME cabergoline, together with a novel method of producing cabergoline.... Agent: Rakoczy Molino Mazzochi Siwik LLP

20070197581 - Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors: R2 and R3, or R2 and R4, or R3 and R4, together with the atoms to which they are bound, can form a fused cycloalkyl or fused heterocycloalkyl ring. The cycloalkyl ring or the heterocycloalkyl ring can be optionally substituted with one or more substitutents. One or more compounds of... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070197578 - Control agent containing n-substituted indole derivative for acarian parasitic on animal: Conventional control agents against acarians parasitic on animals do not have sufficient selective toxicity and are hence not safe for the animals to which the control agents are applied. The control agents are not always satisfactory also in control effect and quick-acting properties. Intensive studies were made on the insecticidal... Agent: Nields & Lemack

20070197579 - Heteroaryl-substituted diazatricycloalkanes and methods of use thereof: The present invention relates to amide and urea derivatives of heteroaryl-substituted diazatricycloalkanes, pharmaceutical compositions including the compounds, methods of preparing the compounds, and methods of treatment using the compounds. More specifically, the methods of treatment involve modulating the activity of the α7 nAChR subtype by administering one or more of... Agent: Womble Carlyle Sandridge & Rice, PLLC

20070197577 - Inhibitors of anthrax lethal factor: Methods, compounds and compositions for preventing and treating anthrax infections by inhibiting Anthrax Lethal Factor (LF) activity.... Agent: Buchanan, Ingersoll & Rooney LLP

20070197580 - Novel 5-ht3 receptor antagonists and methods of use: The subject invention provides useful and novel 5-HT3 antagonists. The subject invention also provides methods for synthesizing the compounds of invention. The invention also provides methods for the treatment of irritable bowel syndrome and other such conditions.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070197582 - Imidazo[[1, 5-a] pyridine derivatives and methods for treating aldosterone mediated diseases: provide pharmacological agents which are inhibitors of the P450 enzyme, aldosterone synthase, and thus may be employed for the treatment of aldosterone mediated conditions. Accordingly, the compounds of formula (I) may be employed for prevention, delay of progression, or treatment of hypokalemia, hypertension, congestive heart failure, renal failure, in particular,... Agent: Novartis Corporate Intellectual Property

20070197584 - Aryl-substituted polycyclic amines, method for the production thereof, and use thereof as a medicament: o

20070197583 - Novel compositions and methods for modulation of the acid-sensing ion channel (asic) for the treatment of anxiety and drug addiction: This invention provides novel compositions and methods for modulating acid-sensing ion channels (ASIC) function comprising ASIC and derivatives thereof; methods for modulating ASIC function and methods for treating anxiety or anxiety disorders and drug addiction using the novel compositions of the invention; and a method for increasing synaptic plasticity are... Agent: Mckee, Voorhees & Sease, P.L.C

20070197585 - Use of cysteinyl leukotriene 2 receptor antagonists: The instant invention provides a method for treating and/or reducing the risk for atherosclerosis, pulmonary fibrosis and stroke, comprising administering an effective amount of a cysteinyl leukotriene 2 receptor antagonist, including a selective cysteinyl leuoktriene 2 receptor antagonist and a dual cysteinyl leukotriene 1 receptor and cysteinyl leukotriene 2 receptor... Agent: Merck And Co., Inc

20070197586 - 8-hydroxy-5-[(-hydroxy-2-[[ (1r)-2-(4-methoxyphenyl)-1-methylethyl] amino][ethyl]-2(1h)-quinolinone monohydrochloride in crystalline form and the process for its preparation: The invention relates to 8-hydroxy-5-[(1R)-1-hydroxy-2[[(1R)-2-(4-methoxyphenyl)-1-methyl ethyl]amino]ethyl]-2 (1 H)-quinolinone monohydrochloride of formula (I) in crystalline form, provided with suitable characteristics in order to be used for the preparation of pharmaceutical compositions for inhalation in combination with suitable carriers or vehicles and the process for its preparation.... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070197587 - Quinoline derivatives as crth2 antagonists: e

20070197588 - Tetralone-based monoamine reuptake inhibitors: The invention relates to novel tetralone based amines and their use in the treatment of central nervous system (CNS) disorders, such as depression, attention deficit hyperactivity disorder (ADHD) and Parkinson's disease. The invention further relates to pharmaceutical compositions containing the compounds and compositions of the invention as well as methods... Agent: Morgan, Lewis & Bockius LLP (sf)

20070197589 - Cyclic quaternary amino derivatives as modulators of chemokine receptors: Compounds of formula (1) wherein, m, n, R1, R2, Ra, ALK3, E and Y are as defined in the claims, being potent and selective inhibitors of chemokine binding to the CXCR3 receptor, are accordingly of use in the treatment and/or prevention of conditions involving inappropriate T-cell trafficking, including inflammatory, autoimmune... Agent: Woodcock Washburn LLP

20070197590 - Substituted dipiperidine ccr2 antagonists: m

20070197593 - Hydroxylamines and derivatives for treatment of inflammatory conditions of the liver: Methods for the treatment and inhibition of hepatitis are disclosed. The methods utilize hydroxylamine compounds or ester derivatives thereof, administered to patients in an amount effective to treat or inhibit hepatitis.... Agent: Woodcock Washburn LLP

20070197591 - Use of paliperidone for the treatment of a mental disorder in a psychiatric patient with reduced hepatic function: The present invention provides a method for the treatment of psychiatric patients having or at risk of hepatic impairment comprising administering a therapeutically effective amount of paliperidone, its pharmaceutically acceptable acid addition salts, enantiomeric forms and esters thereof to psychiatric patients in need thereof.... Agent: Philip S. Johnson Johnson & Johnson

20070197592 - Use of paliperidone for the treatment of substance abuse: The present invention relates to the use of paliperidone, its pharmaceutically acceptable acid addition salts, enantiomeric forms, or esters thereof, for the treatment of substance abuse in a patient in need thereof. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of paliperidone, its pharmaceutically acceptable acid addition... Agent: Philip S. Johnson Johnson & Johnson

20070197594 - Cyclic amine derivative or salt thereof: Provided are compounds which are an NMDA antagonist having a broad safety margin and are useful as a treating agent or a preventing agent for Alzheimer's disease, cerebrovascular dementia, Parkinson's disease, ischemic apoplexy, pain, etc. Concretely provided are an amine derivative or its salt characterized in that the amine-containing structure... Agent: Sughrue Mion, PLLC

20070197595 - Benzisoxazoles: The present invention relates to novel fatty acid esters of the reversible Iloperidone metabolite P-88-8991, their preparation, their use as pharmaceuticals and pharmaceutical compositions containing them.... Agent: Hoffman Warnick & D'alessandro, LLC

20070197596 - Piperidine derivatives: Compounds of the formula (I), in which R1, R2, Q, X, Y, m and n have the meanings indicated in Claim (1), are potent 5-HT2A antagonists and are suitable for the treatment of psychoses, schizophrenia, depression, neurological disorders, memory disorders, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease, Huntington's disease, eating... Agent: Millen, White, Zelano & Branigan, P.C.

20070197598 - Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1: The present invention relates to thiazolinones and also to pharmaceutical compositions comprising the compounds, as well as methods of use of the compounds for treatment of disorders associated with human 11-β-hydroxysteroid dehydrogenase type 1 enzyme and for the preparation of a medicament which acts on the human 11-β-hydroxysteroid dehydrogenase type... Agent: Foley And Lardner LLP Suite 500

20070197597 - Process for the preparation of tryptase inhibitors: e

20070197599 - Hydroxylamines and derivatives as anti-angiogenic agents: The present disclosure provides compounds that include hydroxylamines and ester derivatives thereof and methods for using the same for the treatment of angiogenesis and related diseases.... Agent: Woodcock Washburn LLP

20070197600 - Heterocyclic substituted 4-(aminomethyl)-piperidine benzamides as 5ht4-antagonists: The present invention is concerned with novel compounds of formula (I) having 5HT4-antagonistic properties. The invention further relates to methods for preparing such novel compounds, pharmaceutical compositions comprising said novel compounds as well as the use as a medicine of said compounds.... Agent: Philip S. Johnson Johnson & Johnson

20070197601 - Use of n-[phenyl(piperidin-2-yl)methyl]benzamide derivatives in therapy: e

20070197602 - Combined pharmaceutical composition: At least one hyperlipidemic agent selected from the group consisting of a fibrate compound (e.g., fenofibrate, bezafibrate, or a salt thereof) and an HMG-CoA reductase inhibitor (e.g., a statin compound, for example, pravastatin, atorvastatin, or salts thereof) is, as active ingredients, combined with an α-glucosidase inhibitor (e.g., voglibose, and acarbose)... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070197603 - Substituted indole ligands for the orl-1 receptor:

20070197605 - Arylcycloakyl-substituted alkanoic acid derivatives useful as peroxisome proliferator-activated receptor (ppar) ligands for the treatment of hyperlipidemia and diabetes:

20070197604 - Oxazole derivatives as histamine h3 receptor agents,preparation and therapeutic uses: The present invention discloses novel aryl oxazole compounds of Formula I (I), or pharmaceutically acceptable salts thereof, which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing and using such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as... Agent: Eli Lilly & Company

20070197606 - Use of ppar agonists as anti-oxidants: As described herein, L-FABP is an antioxidant and as such PPAR agonists such as the fibrate and statin class of pharmacological agents (e.g., clofibrate) can be used to induce FABP which in turn induces antioxidant activity. This anti-oxidant activity may be used to treat or prevent diseases characterized by free... Agent: Ade & Company Inc.

20070197607 - Continuous dosing regimen: The invention relates to pharmaceutical compositions comprising combinations of ABT-751 and anti-cancer drugs. These combinations have additive antitumorigenesis activity. This invention also relates to methods of treatment using the combinations.... Agent: Robert Deberardine D-377/ap6a-1

20070197608 - Piperazines as oxytocin agonists: Disclosed are novel compounds according to general formula (I), which have shown OT agonist activity.... Agent: Foley And Lardner LLP Suite 500

20070197609 - Salts of inducible nitric oxide synthase dimerization inhibitors: The present invention relates to novel salts and methods useful as inhibitors of the nitric oxide synthase.... Agent: Global Patent Group Attn: Ms Lavern Hall

20070197610 - Benzisoxazoles: The present invention concerns the compounds of formula (I), the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein m represents an integer from 1 to 3; X represents amino, hydroxy, -oxo or -Z-R1; Y is absent when X represents -Z-R1 and —(C═O)—R6 when X... Agent: Woodcock Washburn LLP

20070197611 - Fermentative preparation process for and crystal forms of cytostatics: The invention relates to a new process for concentrating epothilones in culture media, a new process for the production of epothilones, a new process for separating epothilones A and B and a new strain obtained by mutagenesis for the production of epothilones, as well as aspects related thereto, New crystal... Agent: Novartis Corporate Intellectual Property

20070197615 - Process for the preparation of the ppar alpha agonist ns-220: e

20070197613 - 2-{-3,'2-(phenyl)-oxazol-4-ylmethoxyl-cyclohexyl methoxy}-propionic acid derivatives used as peroxisome proliferator-activated receptor (ppar) ligands for the treatment of hyperlipidemia and diabetes:

20070197612 - 2-{-3-'2-(phenyl)-oxazol-4-ylmethoxymethyl-cyclohexylmethoxy}-propionic acid derivatives useful as peroxisome proliferator-activated receptor (ppar) ligands for the treatment of hyperlipidemia and diabetes:

20070197614 - Method for the production of diarylcycloalkyl derivatives: wherein the respective R-group substituents are defined herein. These compounds of formula (I) are activators for peroxisome proliferator-activated receptors (PPAR activators) which are useful in the therapeutic treatment of a number of diseases and disorders of the central nervous system such as multiple sclerosis, Parkinson's Disease, psychiatric disorders and the... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070197616 - Novel imidazolopyrazole derivatives useful as selective androgen receptor modulators: The present invention is directed to novel imidazolopyrazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor.... Agent: Philip S. Johnson Johnson & Johnson

20070197617 - Substituted hydantoins: e

20070197618 - Novel 2-amino benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels: This invention relates to novel 2-amino benzimidazole derivatives useful as modulators of small-conductance calcium-activated potassium channels (SK channels). In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.... Agent: Birch Stewart Kolasch & Birch

20070197619 - Ion channel modulators: The invention relates to compounds, compositions comprising the compounds, and methods of using the compounds and compound compositions. The compounds, compositions, and methods described herein can be used for the therapeutic modulation of ion channel function, and treatment of disease and disease symptoms, particularly those mediated by certain calcium channel... Agent: Edwards Angell Palmer & Dodge LLP

20070197620 - Methods for treating cns disorders with bicyclo-substituted 2-imidazoline and 2-imidazoles: e

20070197621 - Method for the treatment of cns disorders with substituted 2-imidazoles or imidazole derivatives:

20070197622 - Methods for treating cns disorders with 4-imidazole derivatives:

20070197623 - Novel fluoroglycoside derivatives of pyrazoles, medicaments containing these compounds, and the use thereof: The invention relates to substituted fluoroglycoside derivatives of pyrazoles of formula (I) as further defined in the specification, to the physiologically compatible salts thereof, to a method for their production, and to their use as antidiabetics.... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070197624 - Acylated amino acid amidyl pyrazoles and related compounds: This invention is directed to acylated amino acid amidyl pyrazoles and related compounds of Formula I. The invention is also directed to a pharmaceutical formation comprising such compound or in a pharmaceutically acceptable salt form thereof. The invention is further directed to a method for inhibiting β-amyloid peptide release and/or... Agent: Howrey LLP

20070197625 - Azabicyclic compounds, a process for their preparation and pharmaceutical compositions containing them.: wherein m and n, which may be identical or different, each represent an integer from 0 to 2 inclusive, with the sum of the two integers being from 2 to 3 inclusive, p and q, which may be identical or different, each represent an integer from 0 to 2 inclusive,... Agent: The Firm Of Hueschen And Sage

20070197627 - Indoline compound and process for producting the same: The present invention provides an industrial method production of silodosin, which is useful for a therapeutic agent for dysuria associated with benign prostatic hyperplasia. The production of silodosine is characterized by mixing 3-{7-cyano-5-[(2R)-2-({(2-[2-(2,2,2-trifluoroethoxy)-phenoxy]ethyl}amino]propyl]-2,3-dihydro-1H-indol-1-yl}-propyl benzoate and oxalic acid to yield the oxalate, subsequently hydrolyzing the oxalate salt to yield 1-(3-hydroxypropyl)-5-[(2R)-2-({2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl}amino]propyl]-2,3-dihydro-1H-indole-7-carbonitrile and... Agent: Stuart D. Frenkel Frenkel & Associates, P.C.

20070197626 - Indoline derivatives: The present invention relates to novel indoline derivatives, to processes for their preparation and to their use in medicaments, in particular as potent PPAR-delta-activating compounds for the prophylaxis and/or treatment of cardiovascular disorders, in particular of dyslipidaemias, arteriosclerosis and coronary heart diseases.... Agent: Jeffrey M. Greenman

20070197628 - Cannabinoid receptor modulators: e

20070197629 - Indole derivative and application thereof: wherein X represents a halogen atom; R1 represents a hydrogen atom, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, a substituted or unsubstituted aromatic group, substituted or unsubstituted aralkyl, substituted or unsubstituted acyl, substituted or unsubstituted arylsulfonyl, substituted or unsubstituted C1-6 alkylsulfonyl, or... Agent: Birch Stewart Kolasch & Birch

20070197631 - Processes for preparing darifenacin hydrobromide: The invention encompasses processes for the preparation of darifenacin hydrobromide.... Agent: Kenyon & Kenyon LLP

20070197630 - Pure darifenacin hydrobromide substantially free of oxidized darifenacin and salts thereof and processes for the preparation thereof: Provided are darifenacin hydrobromide free of oxidized darifenacin, and processes for the preparation thereof.... Agent: Kenyon & Kenyon LLP

20070197632 - Aminocyclohexyl ether compounds and uses thereof: Aminocyclohexyl ether compounds are disclosed. The compounds of the present invention may be incorporated in compositions and kits. The present invention also discloses uses for the compounds and compositions, including the treatment of arrhythmia.... Agent: Seed Intellectual Property Law Group PLLC

20070197633 - Novel forms of pravastatin sodium: New polymorphic forms of pravastatin sodium are provided. Each of the new forms is selectively obtained by crystallization from different solvent systems, each solvent system having a protic component, and by controlling the rate of crystallization through temperature. The new polymorphic forms are suitable for use as active substances of... Agent: Kenyon & Kenyon LLP

20070197634 - Tetracyclic steroid derivatives useful as progesterone receptor modulators: The present invention is directed to tetracyclic steroid derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by a progesterone or glucocorticoid receptor.... Agent: Philip S. Johnson Johnson & Johnson

20070197635 - Oxa-steroids derivatives as selective progesterone receptor modulators: The present invention is directed to novel 7-oxa-estra-4,9-diene-3,17-dione derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by at least one progesterone or glucocorticoid receptor.... Agent: Philip S. Johnson Johnson & Johnson

20070197636 - Coumarin derivative and use thereof: The present invention relates to an alkaline earth metal salt or an organic amine salt of a compound represented by the formula : wherein R1 and R2 are each a hydrogen atom, a halogen atom, or an optionally substituted linear hydrocarbon group; ring A is an optionally further substituted benzene... Agent: Edwards Angell Palmer & Dodge LLP

20070197637 - Use of oligosaccharide for preventing blood clotting in extracorporeal blood circuits: A method for preventing clotting in an extracorporeal blood circuit by administering a synthetic oligosaccharide that is a selective inhibitor of factor Xa, acting via antithrobmin III.... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070197638 - Weight loss induced by reduction in neuropeptide level: This invention provides a method for inducing weight loss in an animal by administering to the animal a compound which reduces the expression and/or secretion of neuropeptide Y (NPY). The effect may be accomplished directly, indirectly, or humorally. Preferably, administration of this compound has the effect of increasing malonyl CoA... Agent: Hunton & Williams LLP Intellectual Property Department

20070197639 - Hepoxilins and modulators of ichthyin for treatment skin disorders: The present application relates to compositions and methods for treating skin disorders, dry skin, and protection of skin in inflammatory events. The present application more particularly discloses the identification of new genes and metabolic pathways involved in skin disorders, which provide novel targets and approaches for treating said disorders and... Agent: Nixon & Vanderhye, PC

20070197640 - Certain chemical entities, compositions, and methods: Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of one or more mitotic kinesins are disclosed.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070197641 - Androgen modulators: The present invention is directed to a new class of 4-cyano-phenoxy-alkyl carboxyl derivatives and to their use as androgen receptor modulators. Other aspects of the invention are directed to the use of these compounds to decrease excess sebum secretions and to stimulate hair growth.... Agent: Warner-lambert Company

20070197642 - Androgen modulators: The present invention is directed to a class of 4-cyano-phenoxy derivatives of formula I and to their use as androgen receptor modulators. Other aspects of the invention are directed to the use of these compounds to decrease excess sebum secretions and to stimulate hair growth.... Agent: Warner-lambert Company

20070197643 - Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating inflammatory bowel disease: The invention relates to the use of compound of Formula I in treating patients for the symptoms of inflammatory bowel disease including Crohn's disease and ulcerative colitis.... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070197644 - Use of 13-hode as a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia: This invention relates to the regulation of vascular endothelium biocompatibility and to the inhibition of vessel wall cell and other types of cell hyperplasia following vessel wall dysfunction and/or injury. More particularly, the invention relates to the dietetic and pharmaceutical preparations of 13-hydroxyoctadeca-9Z, 11E-dienoic acid (13-HODE) and its use in... Agent: Jacobson Holman PLLC

20070197645 - Treatment of adhd: A method is provided for treating a subject in need of therapy for attention deficit hyperactivity disorder (ADHD) and related CNS disorder symptoms of impaired learning, impaired planning impaired problem solving, impulsiveness, attention deficit and aggression comprising administering to said subject an amount of a ketogenic material sufficient to produce... Agent: Nixon & Vanderhye, PC

20070197646 - Substituted taraxastanes useful for treating viral infections: and the pharmaceutically acceptable salts thereof, wherein the variables R1, R2, and X are defined herein. The compounds described herein are thought to act by inhibiting retroviral maturation, including maturation of encapsulated retroviruses viruses, such as the HIV viruses, HIV-1 and HIV-2. Pharmaceutical compositions comprising such compounds of Formula I... Agent: Cantor Colburn, LLP

20070197647 - Inhibitor for the onset and progress of liver cancer to be used in hepatitis c virus-positive human liver cirrhosis patients: The present invention provides, as a pharmaceutical agent having an effect to inhibit the development and/or progression of liver cancer in hepatitis C virus-positive human cirrhosis patients, an agent for inhibiting the development and/or progression of liver cancer in hepatitis C virus-positive human cirrhosis patients, which contains three kinds of... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070197648 - Pharmaceutical product containing tranilast: The invention provides a pharmaceutical product in which a tranilast-containing pharmaceutical preparation is contained in a packaging container through which the content can be visually observed and which can inhibit photodegradation of tranilast. The invention provides a pharmaceutical product in which a pharmaceutical preparation containing tranilast and/or a salt thereof... Agent: Fitch, Even, Tabin & Flannery

20070197649 - Use of deferiprone and methods to treat and/or prevent friedreich ataxia resulting from intracellular mishandling of iron: A therapeutically effective amount of deferiprone or deferasirox or physiologically acceptable salts thereof for the prevention, stabilization, treatment, or reversal of iron-induced FRDA disease in patients resulting from mitochondrial iron-induced damage to preferentially reduce the iron stores in the mitochondria. Also for the treatment of other conditions affecting the brain... Agent: Ivor M. Hughes, Barrister & Solicitor, Patent & Trademark Agents

20070197650 - Ethers of 3-hydroxyphenylacetic acid as selective gamma-hydroxybutyric acid receptor ligands: t

20070197651 - Treatment of stereotypic, self-injurious and compulsive behaviors in man and animals using antagonists of nmda receptors: NMDA receptor antagonists can be used in methods of treatment, for reducing the frequency of stereotypic behaviors in animals and for reducing the frequency of analogous compulsive behaviors in humans, for example, those that have been said to be a manifestation of, or related to, obsessive-compulsive disorder. Of particular interest... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070197652 - Solid pharmaceutical composition for the treatment of the benign prostatic hyperplasia its preparation procedure and its therapeutical method: We are hereby dealing with a solid pharmaceutical composition for the treatment of hyperplasia benign of prostate, also of a manufacturing procedure and the treatment method, where the pharmaceutical composition at least includes between 0.5 and 5 mg of a polysaccharide extract from a Gram negative bacteria wall and also... Agent: Sanchelima And Associates, P. A. Jesus Sanchelima, Esq.

20070197653 - Amide or thioamide derivatives and their use in the treatment of pain: The present invention relates to novel compounds, pharmaceutical compositions comprising the same, use of said compounds for the manufacture of a medicament for treatment of pain and disorders related thereto as well as a method for treatment of pain and disorders related thereto, wherein said compounds are administered. The compounds... Agent: Pillsbury Winthrop Shaw Pittman LLP

20070197654 - Combination of a cb1 receptor antagonist and of a product which activates dopaminergic neurotransmission in the brain, the pharmaceutical compositions comprising them and their use in the treatment of parkinson's disease: The present invention relates to the combination of one or more CB1 antagonist azetidine derivatives and of one or more products which activate dopaminergic neurotransmission in the brain, to the pharmaceutical compositions comprising them and to their use in the treatment of Parkinson's disease.... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070197656 - Compositions and methods for preventing or treating an inflammatory response: The present invention relates to methods for modulating the inflammatory response of respiratory tract cells using an agent that increases ceramide levels in the cells of the respiratory tract.... Agent: Licata & Tyrrell P.C.

20070197655 - Galenic formulations of organic compounds: The present invention relates to a solid oral dosage form comprising a therapeutically effective amount of aliskiren or a pharmaceutically acceptable salt thereof, and wherein the active ingredient is present in an amount of more than 46% by weight based on the total weight of the oral dosage form.... Agent: Novartis Corporate Intellectual Property

20070197657 - Method for treating non-inflammatory musculoskeletal pain: A method for treating non-inflammatory musculoskeletal pain in a subject comprises administering to the subject a compound as defined herein, illustratively lacosamide, or a pharmaceutically acceptable salt thereof.... Agent: Harness, Dickey, & Pierce, P.l.c

20070197658 - Polyamines and their use as antibacterial and sensitizing agents: Polyamines with varying chain-lengths were evaluated for antimicrobial activity in order to test the hypothesis that these bis-cationic amphipathic compounds may also bind to and permeabilize intact Gram negative bacterial membranes. The compounds were found to possess significant antimicrobial activity and mediated via permeabilization of bacterial membranes. Homologated spermine, bis-acylated... Agent: Stinson Morrison Hecker LLP Attn: Patent Group

20070197659 - Antagonist of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states: This invention provides a class of therapeutic compounds and methods for the treatment of mammals with physiological disorders, such as for example a frequently occurring type of essential hypertension, which are critically associated with the decreased binding of magnesium to the plasma membranes of their cells. These methods consist of... Agent: Stinson Morrison Hecker LLP Attn: Patent Group

20070197661 - Phenylephrine liquid formulations: An oral, aqueous-based, liquid pharmaceutical composition is provided. The composition comprises up to about 45% w/v glycerin and up to about 10% w/v sorbitol wherein the glycerin to sorbitol ratio is about 2:1 to 10:1.... Agent: Wyeth Patent Law Group

20070197660 - Compounds for modulating cell proliferation: Compounds having the Formula (I) or (III) wherein R1, R2 and R3 are each independently selected from H, OH, C1-6alkyl, C1-6alkoxy, NH2, NH—(C1-6alkyl), N(C1-6alkyl)(C1-6alkyl), SH, S—C1-6alkyl, NO2, CF3, OCF3, and halo; R4 is unsubstituted Ar or Ar substituted with 1-4 substituents independently selected from C1-6alkyl, C1-6alkoxy and halo; X is... Agent: Gowling Lafleur Henderson LLP

20070197662 - Amine compounds and inhibiting neurotransmitter reuptake: The invention relates to amine compounds as well as methods and materials involved in modulating neurotransmitter reuptake. Specifically, the invention provides amine compounds, methods for synthesizing amine compounds, and methods for inhibiting neurotransmitter reuptake.... Agent: Fish & Richardson P.C.

20070197663 - Methods of treating memory and cognitive impairments in humans following stroke and traumatic brain injury: Cognitive impairments are treated and cognition is improved with an amphetamine compound. In one embodiment, the method includes administering an l-amphetamine compound. In another embodiment, the method includes administering an l-methamphetamine compound.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070197664 - Prevention and treatment of androgen-deprivation induced osteoporosis: This invention provides a method of treatment, prevention, suppression, inhibition, or reduction of risk of developing androgen-deprivation induced skeletal-related events (SRE), such as pathologic fractures, surgery to bone, radiation to bone, spinal cord compression, change in antineoplastic therapy, including changes in hormonal therapy, new bone metastases, bone loss, or a... Agent: Pearl Cohen Zedek Latzer, LLP

20070197665 - Oligomeric ketone compounds: A novel ketogenic compound is provided having general: Formula R(OCH(CH3)CH2C(O))n—O—A wherein n is an integer of 3 to 10, A is the residue of a 3-keto alkan-1-ol and R is selected from the group consisting of H, C1-C6 alkyl and acetoacetyl-Preferred compounds are those wherein A is a residue is... Agent: Nixon & Vanderhye, PC

20070197666 - Pharmaceutical combination for the treatment of benign prostatic hyperplasia or for the long-term prevention of acute urinary retention: The present invention relates to a new pharmaceutical combination for treating benign prostatic hyperplasia (BPH) or for the long-term prevention of acute urinary retention (AUR).... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070191266 - Methods of treating blepharospasm using cyclosporine components: Methods of treating humans or animals afflicted with primary blepharospasm, for example, benign essential blepharospasm, or secondary blepharospasm not caused by an ocular surface disease or condition, are component to a human or animal so afflicted.... Agent: Allergan, Inc.

20070191273 - Modulation of angiogenesis: This invention relates to compounds, compositions, and methods for the treatment of traits, diseases and conditions that respond to the modulation of angiogenic growth factor bioavailability or biological activity.... Agent: Buchanan, Ingersoll & Rooney LLP

20070191303 - Polysaccharide compositions and methods of producing, screening, and formulating polysaccharide compositions: Provided herein are polysaccharide compositions and methods of culturing microalgae to produce polysaccharides. Also provided are methods of using polysaccharides for applications such as reducing cholesterol in mammals, inactivating viruses, stabilizing foods, and other uses. Also provided are transgenic algae capable of utilizing fixed carbon sources for energy.... Agent: Solazyme, Inc.

20070191313 - Indole-3-carboxylic acid amide, ester, thioamide and thiol ester compounds bearing aryl or heteroaryl groups having sphingosine-1-phosphate (s1p) receptor antagonist biological activity: o

20070191262 - Cancer therapy and prevention based on modulation of complement activity: The present invention encompasses methods for inhibiting cancer, but in particular for inhibiting metastasis, by administering to a cancer patient an inhibitor of the complement cascade.... Agent: Fulbright & Jaworski L.L.P.

20070191261 - Hairscents with anti-dandruff formula: A product for eliminating odors that can accumulate in a person's hair and to address itching and flaking associated with dandruff.... Agent: Fulwider Patton LLP

20070191259 - Inhibition of s6 kinaze activity for the treatment of insulin resistance: This invention provides screening methods for agents effective in treating insulin resistance through specific inhibition of S6 kinase 1 activity. Also provided are methods of treating insulin resistance by administering an effective amount of an inhibitor specific for S6 kinase 1.... Agent: Novartis Corporate Intellectual Property

20070191260 - Novel indole derivative for alkylating specific base sequence of dna and alkylating agent and drug containing the derivative: i

20070191263 - Valency platform molecules comprising aminooxy groups: Molecules comprising aminooxy groups are provided, wherein the aminooxy groups provide attachment sites for the covalent attachment of other molecules. In one embodiment, polyoxyethylene molecules comprising aminooxy groups are provided that can be conjugated to wide variety of biologically active molecules including poly(amino acids). In another embodiment, valency platform molecules... Agent: Morrison & Foerster LLP

20070191264 - Methods for inhibiting the growth of bacteria: The present invention is directed to a novel method for inhibiting the growth of bacterial pathogens expressing a type III secretory system as well as enteroaggregative E. coli and/or preventing or treating an infection caused by the same. The method comprises administering to the subject an effective amount of bovine... Agent: Bristol-myers Squibb Company - Mead Johnson

20070191265 - Anti-hiv agent: Disclosed are anti-HIV agents which comprise a mannose binding protein (MBP) as an active component and are useful for effectively inhibiting progress of diseases state in and useful in therapy for individuals infected with human immunodeficiency virus (HIV). Also disclosed are a method for evaluating an anti-HIV activity of MBP... Agent: Marshall, Gerstein & Borun LLP

20070191274 - Active hedgehog protein conjugate: A hedgehog conjugate which is characterized in that it contains: a) a polypeptide composed of 10 to 30 hydrophobic amino acids and/or amino acids which form transmembrane helices and are positively charged, b) 1 to 4 aliphatic, saturated or unsaturated hydrocarbon residues with a chain length of 10 to 24... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070191278 - Cd8 as an inhibitor of the cellular immune system: This invention is directed to a method for inhibiting cytotoxic T lymphocyte (CTL) activity in which soluble CD8 is used as the inhibitor. The invention is further directed to soluble forms of the CD8 molecule which can be administered to a patient. The method of this invention is particularly useful... Agent: Banner & Witcoff, Ltd.

20070191276 - Compositions and therapeutic methods using morphogenic proteins, hormones and hormone receptors: This invention features devices and methods for inducing tissue formation in a mammal, involving the use of a morphogenic protein, a hormone and a soluble receptor of the hormone. The hormone and receptor thereof are used to enhance the tissue inductive activity of the morphogenic protein.... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070191280 - High purity lipopeptides: The invention discloses highly purified daptomycin and to pharmaceutical compositions comprising this compound. The invention discloses a method of purifying daptomycin comprising the sequential steps of anion exchange chromatography, hydrophobic interaction chromatography and anion exchange chromatography. The invention also discloses a method of purifying daptomycin by modified buffer enhanced anion... Agent: Cubist Pharmaceuticals, Inc.

20070191269 - Medicament comprising ptx3, alone or in combination with tsg-6, for treating degenerative diseases of cartilage and bone and treating female infertility: The use of pentraxin PTX3 and of its combination with TSG-6 for the preparation of a medicament for the treatment of bone or cartilage diseases and for the treatment of female infertility is described.... Agent: Nixon & Vanderhye, PC

20070191271 - Method for stabilizing polypeptides lacking methionine: Methionine is an effective antioxidant for polypeptides having an amino acid sequence lacking methionine. Compositions containing polypeptides having an amino acid sequence that is free of methionine residues are stabilized from oxidative degradation by combining methionine in the composition in an amount effective to inhibit oxidation of the polypeptide.... Agent: Howard Eisenberg, Esq.

20070191275 - Method of treating, preventing, inhibiting or reducing damage to cardiac tissue with thymosin beta 4 fragments: A method of treatment for promoting regeneration or repair a damaged cardiovascular tissue, or for preventing damage to cardiovascular tissue, includes administering to the tissue a damage-treating or -preventing fragment of thymosin beta 4 (Tβ4), such as AcSDKP, or a stimulating agent that forms such a fragment of (Tβ4).... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070191279 - Methods and compositions for treating disorders associated with increased bone turnover and osteopenia: The invention provides methods and compositions for modulating osteoclastogenesis and for treating bone diseases characterized by bone loss or a decrease in bone mass or density, by administering a compound or agent that modulates the adenosine A1 receptor, in particular, an inhibitor or antagonist of the A1 receptor.... Agent: Klauber & Jackson

20070191277 - Methods for modulating angiogenesis: Recombinant plasminogen activator inhibitor-1 (PAI-1) isoforms which lack the reactive center loop and contain the complete heparin-binding domain or lack at least a portion of the heparin-binding domain are described. The rPAI-1 isoforms disclosed herein may be used to modulate angiogenesis through blocking release of VEGF from a VEGF-heparin complex.... Agent: Licata & Tyrrell P.C.

20070191272 - Proteinaceous pharmaceuticals and uses thereof: The present invention provides cysteine-containing scaffolds and/or proteins, expression vectors, host cell and display systems harboring and/or expressing such cysteine-containing products. The present invention also provides methods of designing libraries of such products, methods of screening such libraries to yield entities exhibiting binding specificities towards a target molecule. Further provided... Agent: Wilson Sonsini Goodrich & Rosati

20070191268 - Recombiant lubricin molecules and uses thereof: Recombinant lubricin molecules and uses thereof Novel recombinant lubricin molecules and their uses as lubricants anti-adhesive agents and/or intra-articular supplements for, e.g., synvial joints, meniscus, tendon, peritoneum, pericardium and pleura are provided.... Agent: Fish & Richardson P.C.

20070191270 - Secreted and transmembrane polypeptides and nucleic acids encoding the same: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides... Agent: Heller Ehrman LLP

20070191267 - Use of tyrosine kinase inhibitors for treating cerebral ischemia: The present invention relates to a method for treating cerebral ischemia, comprising administering a compound capable of depleting mast cells or a compound inhibiting mast cells degranulation to a human in need of such treatment. Such compounds can be chosen from tyrosine kinase inhibitors and more particularly non-toxic, selective and... Agent: Foley And Lardner LLP Suite 500

20070191282 - Composition for suppressing re-elevation of cholesterol, and usage thereof: The present invention provides a composition (composition for suppressing re-elevation of cholesterol) that has the effects of suppressing re-elevation of cholesterol in patients with high cholesterol or pre-high cholesterol, and that can therefore be used to suppress re-elevation of cholesterol in those patients. The present invention also provides a composition... Agent: Armstrong, Kratz, Quintos, Hanson & Brooks, LLP

20070191281 - Compound containing a labile disulfide bond: A labile disulfide-containing compound under physiological conditions containing a labile disulfide bond and a transduction signal.... Agent: Mirus Corporation

20070191284 - Compounds for enzyme inhibition: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds.... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070191283 - Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues: The present invention relates to a method of stimulating the motility of the gastrointestinal system in a subject in need thereof, wherein the subject suffers from maladies (i.e., disorders or diseases) of the gastrointestinal system. The method comprises administering to a subject in need thereof a therapeutically effective amount of... Agent: Palmer & Dodge, LLP Kathleen M. Williams

20070191287 - D-ribose for improving depression-like symptoms: An agent for improving depression-like symptoms comprising D-ribose, which may improve an alleviate various symptoms such as hypobulia, general fatigue, sluggishness, enervation, deterioration in concentration, memory impairment, abnormal sensation/obtundation such as impaired sight, decline in thinking power, indefinite complaint, drop in operation efficiency, or feeling of malaise, etc.... Agent: Birch Stewart Kolasch & Birch

20070191286 - Injectable composition: An injectable composition comprising a combination of 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole (lansoprazole), its optically active compound or a salt thereof, and a chelating agent, which is used at pH 9 to 12. The injectable composition is excellent in stability and solubility, and has such a high-quality that particulate insolubles are not formed when... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070191285 - Pesticide of environmental preservation type: The present invention relates to a pesticide with surfactant of alkyl glucoside-derivatives blended into hydrogenated starch hydrolysate. Pesticide of the present invention, therefore, causes no concern about occurrence of pesticide-resistance, giving no adverse effect to agricultural and horticultural products, while working better to control harmful organisms at lower concentrations than... Agent: Rader Fishman & Grauer PLLC

20070191288 - Treatments for benign tumors, cancers, neoplasias, and/or other inflammatory disorders or diseases: The subject invention provides methods and compositions for the treatment of benign tumors, cancers, neoplasias, and/or other inflammatory disorders or diseases. In the practice of the subject invention, an anti-convulsant agent, such as topiramate, is administered to an individual.... Agent: Frank C. Eisenschenk, Ph.d. Saliwanchik, Lloyd & Saliwanchik

20070191289 - Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs: The present invention provides nitrogen-containing fused-ring derivatives represented by the following general formula, or pharmaceutically acceptable salts thereof, or prodrugs thereof, which exhibit an excellent inhibitory activity in human SGLT and are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, postprandial... Agent: Sughrue Mion, PLLC

20070191290 - Smilagenin and its use: The invention discloses the use of a smilagenin in the treatment of cognitive dysfunction and similar conditions. Methods of treatment, and pharmaceuical compositions are also disclosed.... Agent: Fulwider Patton LLP

20070191292 - Antimycotic rhamnolipid compositions and related methods of use: Antimycotic compositions comprising a rhamnolipid component and related methods of use.... Agent: Reinhart Boerner Van Deuren S.c. Attn: Linda Kasulke, Docket Coordinator

20070191291 - Compound antibacterial drugs comprising n-acetyl-d-glucosamine: The use of the combination of N-acetyl-D-glucosamine and antibiotics for the preparation of antibacterial drugs is disclosed. In the therapies of infections with antibiotics, the pathogens may be changed into slender shaped forms called cryptic growth cells (CGCs), CGCs can colonize and thereby physiological drug resistance arises. In the meantime,... Agent: Christie, Parker & Hale, LLP

20070191293 - Inhibitors of e1 activating enzymes: This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.... Agent: Millennium Pharmaceuticals, Inc.

20070191298 - Beta secretase genes: Disclosed are novel genes encoding beta secretase polypeptides. Also disclosed are methods of making and using the polypeptides.... Agent: Amgen Inc.

20070191296 - Diagnostics and therapeutics for diseases associated with kallikrein 13 (klk13): The invention provides a human KLK13 which is associated with the hematological diseases, neurological diseases, metabolic diseases, endocrinological diseases, dermatological diseases, gastroenterological diseases, urological diseases, cancer disorders and inflammation. The invention also provides assays for the identification of compounds useful in the treatment or prevention of hematological diseases, neurological diseases,... Agent: Banner & Witcoff, Ltd.

20070191299 - Extension of the expression of transgenic proteins by immunomodulation: Prolongation of the expression of transgenic proteins by immunomodulating treatment The invention relates to the use of one or more immunosuppressants for the production of a pharmaceutical for increasing the tolerance of a mammal to transgenic cells, and to a process for identifying immunosuppressants suitable for this. By the use... Agent: Synnestvedt & Lechner LLP

20070191295 - Gene silencing by systemic rna interference: Nucleic acid and protein sequences relating to a gene required for systemic RNAi are disclosed. The SID-1 and 2 proteins are shown to be required for systemic RNAi. Nucleic acids, vectors, transformed cells, transgenic animals, polypeptides, and antibodies relating to the <i>sid-1</i><i>and</i>2 genes and proteins are disclosed. Also provided are... Agent: Burns & Levinson, LLP

20070191300 - Methods for modulating ikkalpha activity: A method for modulating NF-κB dependent gene transcription in a cell comprised of modulating IKKα protein activity in the cell. The present invention also provides siRNA compositions and methods thereof for modulating NF-κB dependent gene transcription.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070191297 - Methods of treating and monitoring systemic lupus erythematosus in individuals: The invention provides methods for treating SLE including renal SLE and methods of reducing risk of renal flare in individuals with SLE, and methods of monitoring such treatment. One method of treating SLE including renal SLE and reducing risk of renal flare in an individual with SLE involves the administration... Agent: Morrison & Foerster LLP

20070191294 - Short interfering rna (sirna) analogues: The present invention is directed to novel double-stranded short interfering (siRNA) analogues comprising locked nucleic acid (LNA) monomers. Such compounds induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). The compounds disclosed herein has improved properties compared to non-modified siRNAs and may, accordingly,... Agent: Edwards Angell Palmer & Dodge LLP

20070191301 - Purine derivatives and methods of use thereof: The present invention relates to Purine Derivatives; compositions comprising an effective amount of a Purine Derivative; and methods for reducing an animal's core body temperature, protecting an animal's heart against myocardial damage during cardioplegia; or for treating or preventing a cardiovascular disease, a neurological disorder, an ophthalmic condition, an ischemic... Agent: Wilmer Cutler Pickering Hale And Dorr LLP

20070191302 - Amino acid diamides in non alpha position which are useful as adjuvants for administration of biological active agents: Amino acid diamides in non α position of formula (1), wherein R1 is selected from amongst the group consisting of the functional groups alkyl, halogen, NO2, OH, OCH3 alone or associated and R2 is selected from the group consisting of functional groups H, alkyl, halogen, NO2, OH, OCH3, which are... Agent: Innovar, LLC

20070191304 - Methods for performing percutaneous coronary intervention: Methods for performing percutaneous coronary intervention in a patient in need thereof comprising administering intravenously a bolus comprising an effective amount of enoxaparin sodium to the patient after sheath insertion and prior to the percutaneous coronary intervention are described. Also described are methods for preventing or treating thrombosis, such as... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070191305 - Chromone complexes: The invention relates to complexes of certain chromone derivatives, to compositions which comprise such derivatives, to corresponding processes for the preparation of the chromone derivatives or of compositions comprising same, and to the use thereof, in particular for the care, maintenance or improvement of the general state of the skin... Agent: Millen, White, Zelano & Branigan, P.C.

20070191306 - Factor xa inhibitor formulation and method: An injectable Factor Xa inhibitor formulation is provided which includes the Factor Xa inhibitor razaxaban or apixaban, a solubilizing agent which is a substituted β-cyclodextrin, preferably, sulfobutyl ether β-cyclodextrin (SBE-CD) or hydroxypropyl-β-cyclodextrin (HPB-CD), and water. A method for preventing or treating venous thrombosis, deep venous thrombosis and acute coronary syndrome... Agent: Louis J. Wille Bristol-myers Squibb Company

20070191307 - Nanosized carotenoid cyclodextrin complexes: Methods for the preparation of nanosized nutrient formulations for enhanced absorption of nutritional agents. The methods include the complexation of cyclodextrin with carotenoids and incorporation of the complexes into the nutritional supplements without intermediate collection, isolation, and drying steps.... Agent: Thorpe North & Western, LLP.

20070191308 - Intranasal formulation of rotigotine: This invention pertains to a liquid intranasal pharmaceutical formulation comprising a pharmaceutically acceptable acid addition salt of rotigotine and α-cyclodextrin, preferably in the form of a buffered aqueous solution having a viscosity of 0.5-1.5 mm2/s... Agent: Scully Scott Murphy & Presser, PC

20070191309 - Pyrrolobenzodiazepines as key intermediates in the synthesis of dimeric cytotoxic pyrrolobenzodiazepines: Compounds and a method of synthesis of compounds of formula (Ia) or (Ib): and salts, solvates, and chemically protected forms thereof, wherein the dotted lines indicate the optional presence of a double bond between C1 and C2 or C2 and C3; R2 and R3 are independently selected from —H, ═O,... Agent: Michael Best & Friedrich, LLP

20070191310 - Phospholipid derivatives of non-steroidal anti- inflammatory drugs: Disclosed are compounds having non-steroidal anti-inflammatory drugs (NSAIDS) covalently linked to a phospholipid moiety via a bridging group. Also disclosed are a process for the synthesis of the compounds, pharmaceutical compositions comprising the compounds and the use thereof for the treatment of diseases and disorders related to inflammatory conditions, such... Agent: Davidson, Davidson & Kappel, LLC

20070191312 - Novel heterocyclic compounds, preparation process and intermediates, and use as medicaments, in particular as beta-lactamase inhibitors and antibacterials: s

20070191311 - P2x receptor inhibitor: Since the “P2X2/3 and/or P2X3 receptor inhibitor” of the invention inhibits the function of P2X2/3,3 receptor known as a molecule which is concerned in various pains consisting of nociceptive pain, inflammatory pain and neurogenic pain, it is useful for the prevention or treatment of various pains in which the P2X2/3,3... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070191315 - Method for administering ibandronate: Disclosed is an improved method for treating pain associated with metastatic bone disease comprising the quick administration of an IV loading dose of ibandronate followed by an oral or intravenous (IV) maintenance dosing regimen. This method provides desirable therapeutic effects, including fast onset of pain relief, with a tolerable level... Agent: Hoffmann-la Roche Inc. Patent Law Department

20070191314 - Thermoreversible oil-in-water emulsion: The invention relates to a thermoreversible oil-in-water emulsion comprising: a TLR4 agonist, the chemical structure of which does not comprise a sugar ring, squalene, a nonionic surfactant belonging to the polyoxyethylene alkyl ether chemical group, a hydrophilic surfactant, an aqueous solvent, and which shows immunostimulating properties.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070191316 - Vitamin d analog - nel, methods and uses thereof: Compounds of formula IA or IB are provided where X1, X2 and X3 are independently selected from H or hydroxy protecting groups and R1 is selected from straight or branched chain alkyl groups having from 1 to 8 carbon atoms; straight or branched chain alkenyl groups having from 2 to... Agent: Godfrey & Kahn, S.c.

20070191317 - Vitamin d analog - rak, methods and uses thereof: Compounds of formula IA or IB are provided where X1, X2 and X3 are independently selected from H or hydroxy protecting groups and R1 is selected from straight or branched chain alkyl groups having from 1 to 8 carbon atoms; straight or branched chain alkenyl groups having from 2 to... Agent: Godfrey & Kahn, S.c.

20070191318 - Process for the preparation of amorphous rosuvastatin calcium: The invention relates to processes for the preparation of amorphous rosuvastatin calcium. More particularly, it relates to the preparation of pure amorphous rosuvastain calcium and pharmaceutical compositions that include the pure amorphous rosuvastatin calcium. The invention also relates to use of said compositions for treating hyperlipidemia, hypercholesterolemia, and atherosclerosis. Formula... Agent: Ranbaxy Inc.

20070191321 - Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof: The present invention is directed to monophasic pharmaceutical compositions comprising a conjugated estrogen and a hydrophilic or lipophilic excipient. The present invention is also directed to kits and applicators comprising the pharmaceutical compositions. The invention is also directed to methods for treating menopausal conditions in a female comprising administration of... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070191320 - Methods of treatment for female sexual arousal disorder: The invention provides methods of treatment for female sexual arousal disorder. In preferred embodiments, the invention provides methods of treatment with a semisolid composition suitable for topical application comprising: an effective amount of a vasoactive prostaglandin, a penetration enhancer, a polymer thickener, a lipophilic component, water and an acidic buffer... Agent: Mirick, O'connell, Demallie & Lougee, LLP

20070191319 - Treatment of conditions that present with low bone mass by continuous combination therapy with selective prostaglandin ep4 receptor agonists and an estrogen: This invention is directed to methods for treating conditions which present with low bone mass in a patient in need thereof using continuous combination therapy with a synergistically effective combination of an EP4 receptor selective agonist or a pharmaceutically acceptable salt thereof, such as 5-(3-{2S-[3R-hydroxy-4-(3-trifluoromethyl-phenyl)-butyl]-5-oxo-pyrrolidin-1-yl}-propyl)-thiophene-2-carboxylic acid or a pharmaceutically acceptable... Agent: Pfizer Inc.

20070191323 - Stable corticosteroid mixtures: A corticosteroid mixture, such as a budesonide solution, is prepared by the active and inactive ingredients of the mixture under oxygen-depleted conditions. The resulting mixture demonstrates superior stability of the active pharmaceutical ingredient corticosteroid. The invention provides novel methods of manufacturing corticosteroid mixtures, wherein the resulting mixtures possess superior stability... Agent: Wilson Sonsini Goodrich & Rosati

20070191322 - Cationic steroid microbial compositions and methods of use: The invention relates to methods for decreasing or inhibiting influenza virus infection or pathogenesis of a cell in vitro, ex vivo or in vivo, a symptom or pathology associated with influenza infection or pathogenesis in vitro, ex vivo or in vivo, or an adverse side effect of influenza infection or... Agent: Pillsbury Winthrop Shaw Pittman LLP

20070191324 - Methods for treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist: The present invention provides methods for the treatment or prophylaxis of one or more aldosterone-mediated pathogenic effects in a subject suffering from or susceptible to the pathogenic effect or effects wherein the subject has one or more conditions selected from the group consisting of a sub-normal endogenous aldosterone level, salt... Agent: Pharmacia Corporation Global Patent Department

20070191327 - Sterilization of corticosteroids with reduced mass loss: Novel methods of sterilizing corticosteroid solutions resulting in improved final yield of active corticosteroid ingredient.... Agent: Wilson Sonsini Goodrich & Rosati

20070191325 - Methods for altering insulin secretion: Modulation of the activity of glucocorticoid inducible kinase SGK1 in pancreatic islet cells restores insulin release. Also disclosed are methods and compounds useful for the treatment of glucocorticoid induced diabetes mellitus type-2.... Agent: Millen, White, Zelano & Branigan, P.C.

20070191326 - Methods for altering insulin secretion: Modulation of the activity of serum and glucocorticoid inducible kinases to restore glutamate receptor activity. Also disclosed are methods and compounds useful for the detection and treatment of neuropsychiatric disorders.... Agent: Millen, White, Zelano & Branigan, P.C.

20070191328 - Isoquinoline compounds: d

20070191329 - Ethylene glycol esters as photoactive agents:

20070191330 - Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases: Polyhydroxylated aromatic compounds, and compositions containing them, are useful for the treatment of amyloidosis, especially Alzheimer's disease, and for the treatment of diseases characterized by α-synuclein fibril formation, especially Lewy body disease and Parkinson's disease.... Agent: Jones Day

20070191331 - Crystalline forms of cefdinir potassium salt: The present invention encompasses the solid state chemistry of cefdinir potassium salt.... Agent: Kenyon & Kenyon LLP

20070191332 - Compounds for the treatment of inflammatory disorders: e

20070191333 - Antibacterial agents: Compounds of formula I and methods for their preparation are disclosed. Further disclosed are methods of making biologically active compounds of formula I as well as pharmaceutically acceptable compositions comprising compounds of formula I. Compounds of formula I as disclosed herein can be used in a variety of applications including... Agent: Pfizer Inc.

20070191335 - Heterocylic antiviral compounds: Chemokine receptor antagonists, in particular, 3,7-diazabicyclo[3.3.0]octane compounds according to formula (I) wherein R1-R3 R6c and X1 are as defined herein are antagonists of chemokine CCR5 receptors which are useful for treating or preventing an human immunodeficiency virus (HIV-1) infection, or treating AIDS or ARC. The invention further provides methods for... Agent: Roche Palo Alto LLC Patent Law Dept. M/s A2-250

20070191334 - Tricyclic imidazopyridines: e

20070191336 - Anti-inflammatory medicaments: Novel compounds and methods of using those compounds for the treatment of inflammatory conditions are provided. In a preferred embodiment, modulation of the activation state of p38 kinase protein comprises the step of contacting the kinase protein with the novel compounds.... Agent: Hovey Williams LLP

20070191337 - Annellated carbamyl-aza-heterocyclic compounds, a focused library, pharmaceutical compositions, and methods of preparing the same: R1, R2 and R3 are, independently of one another, a hydrogen atom, an inert substituent, an optionally substituted C1-C6 alkyl, an optionally substituted C3-C8 cycloalkyl, an optionally substituted phenyl, an optionally substituted aryl, or an optionally substituted heterocyclyl; and Q is a pyrrole, pyrazole, imidazole, thiazole, pyrrolidine, indole, benzofuran, 4,5,6,7-tetrahydrobenzothiophene,... Agent: David B Waller David B Waller & Associates

20070191338 - Combinations comprising staurosporines: The present invention relates to a method of treating myelodysplastic syndromes, lymphomas and leukemias, and also solid tumors with a pharmaceutical combination of a FLT-3 kinase inhibitor and a histone deacetylase inhibitor (HDAI). It also relates to the use of a pharmaceutical combination of a histone deacetylase inhibitor and a... Agent: Novartis Corporate Intellectual Property

20070191339 - Crystalline forms of a pharmaceutical compound: Described are crystalline forms of the pharmaceutical compound “[9S-(9α,10β,12α)]-5,16-Bis[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-9, 12-epoxy-1H-diindolo[1,2,3-fg:3′,2′,1′-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid methyl ester”, as well as methods for their use and preparation.... Agent: Darby & Darby P.C.

20070191340 - Compounds which modulate the cb2 receptor: s

20070191341 - N-substituted benzene sulfonamides:

20070191342 - Thiophenyl and pyrrolyl azepines as serotonin 5-ht2c receptor ligands and uses thereof: The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are thiophenyl and pyrrolyl azepine compounds. These compounds are serotonin receptor (5-HT2c) ligands and are useful... Agent: Wood, Phillips, Katz, Clark & Mortimer

20070191343 - 4-((4-(2-azaperhydroepinylethoxy)phenyl)methyl)-3-2(2,4-dichlorophenyl)-7-hydroxychromen-2-one, pharmaceutically acceptable salts thereof and methods of use therewith: e

20070191344 - Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases: The present invention relates to 4,6-disubstituted aminopyrimidine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, prion diseases, immunological diseases, autoimmune diseases, bipolar and clinical disorders, cardiovascular diseases, cell proliferative diseases, diabetes,... Agent: Brooks Kushman P.C.

20070191345 - 3-((hetero)arylsulfonyl)-8-'(aminoalkyl)oxyquinolines as 5-ht6 receptor antagonists for the treatment of cns disorders: e

20070191346 - 3-cyano-quinoline derivatives: The invention concerns quinoline derivatives of Formula (I) wherein each of Z1, m, R1, n, R3, Z2 and R14 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an... Agent: Morgan Lewis & Bockius LLP

20070191347 - Substituted sulfonamides and ureas useful for inhibiting kinase activity: Sulfonamide and urea compounds having an inhibitory effect on Src kinase including enantiomers, stereoisomers and tautomers thereof, as well as pharmaceutically acceptable salts or solvates of said compound, said compound having the general structure shown in Formula II are disclosed and claimed:... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070191349 - C8, c8' linked 5-oxo-1,2,3,11a-tetrahydro-5h-pyrrolo[2,1-c][1,4] benzodiazepine dimers with 1h-pyrrole-dicarboxylic acid amide linkers and oligomeric analogs therof as well as related compounds for the treatment of proliferative diseases: Compounds of formula (I): PBD-A-Y—X—(Het)na-L-(Het)nb-L-(Het)nc-T-(Het′)nd-L-(Het′)ne-L-(Het′)nf—X′—Y′- A′-PBD′ and salts, solvates and chemically protected forms thereof, are disclosed wherein the PBD units have the formulae (PBD) (PBD′) with the bonds at the 8 position on each molecule bond to the A and A′ groups respectively; A is selected from O, S, NH... Agent: Michael Best & Friedrich, LLP

20070191350 - Combinations comprising alpha-2-delta ligands: The instant invention relates to a combination, particularly a synergistic combination, of an alpha-2-delta ligand and an atypical antipsychotic, and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof and their use in the treatment of pain, particularly neuropathic pain.... Agent: Pfizer Inc

20070191348 - Isopropanol water solvate of olanzapine: The invention relates to a novel and well defined Oolvate form of olanzapine which contains 2 molecules of water and 1 molecule of isopropanol per 2 molecules of olanzapine, and which can be converted into other, forms of olanzapine, in particular form (I) of olanzapine, as well as processes for... Agent: Cohen, Pontani, Lieberman & Pavane

20070191351 - Salts of potassium atp channel openers and uses thereof: Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing... Agent: Foley & Lardner LLP

20070191352 - Inhibition of tau-tau-association: A composition and use thereof for the prophylaxis or treatment of Alzheimer's disease, motor neurone disease, Lewy body disease, Pick's disease or progressive supranuclear palsy. The composition includes an agent which modulates or inhibits tau-tau association and which does not inhibit tau-tubulin binding. In the method the agent is administered... Agent: Foley And Lardner LLP Suite 500

20070191353 - Use of thiadiazoleurea derivatives: Use of compounds of the formula (I), in which Ar1, Ar2 and Z have the meanings indicated in Patent Claim 1, for the prophylaxis and/or treatment of diseases in which the inhibition, regulation and/or modulation of signal transduction by kinases, in particular RAF kinases, plays a role.... Agent: Millen, White, Zelano & Branigan, P.C.

20070191355 - Process for preparing intermediates to 5-ht4 receptor agonist compounds: The invention provides 8-azabicyclo[3.2.1 ]octyl intermediates useful for the preparation of 5-HT4 receptor agonist compounds. The invention also provides processes for the preparation of such useful intermediates.... Agent: Theravance, Inc.

20070191354 - Antiparasitic artemisinin derivatives (endoperoxides): This invention relates to the use of certain C-10 substituted derivatives of artemisinin of general formula (I) in the treatment and/or prophylaxis of diseases caused by infection with a parasite, certain novel C-10 substitued derivatives of artemisinin, processes for their preparation and pharmaceutical compositions containing such C-10 substituted derivatives. The... Agent: Jeffrey M. Greenman

20070191357 - Methods of using potassium channel inhibiting compounds: Described herein are methods of treating, preventing or inhibiting a variety of medical conditions by administering to subjects in need thereof an effective amount of at least one potassium Kv1.3 channel inhibiting compound which can optionally also have either or both CBx modulating properties and/or potassium K(atp) channel opening properties.... Agent: Mayer, Brown, Rowe & Maw LLP

20070191356 - Pyridobenzoxazine derivative: [wherein, R1: hydrogen, alkyl, cycloalkyl, or substituted carbonyl derived from amino acid, peptide or tripeptide; R2: hydrogen, alkyl, or cycloalkyl; R3: hydrogen, amino, halogen, or alkyl; R4: hydrogen, phenyl, acetoxymethyl, pivaloyloxymethyl, ethoxycarbonyl, choline, dimethylaminoethyl, 5-indanyl, phthalidinyl, 5-alkyl-2-oxo-1,3-dioxol-4-ylmethyl, 3-acetoxy-2-oxobutyl, alkyl, alkoxymethyl, or phenylalkyl; X, X1, X2: hydrogen or halogen] or salt... Agent: Sughrue Mion, PLLC

20070191358 - Novel piperidine derivative for the treatment of depression: Compounds of formula: (chemical formula to be inserted here—please see paper copy) wherein Arl is as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the treatment of depression.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20070191359 - 3-spiroindolin-2-one derivatives, preparation and therapeutic use thereof: m

20070191361 - Aminotropane derivatives, preparation thereof and therapeutic use thereof: The present invention relates to compounds of formula (I) as defined herein that are melanocortin receptor agonists, to the preparation thereof and to the therapeutic use thereof in the treatment and in the prevention of obesity, diabetes and sexual dysfunctions that can affect both sexes, in the treatment of cardiovascular... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070191360 - Curcumol derivatives, the compositions containing the said derivatives, and the use of the same in the manufacture of medicaments:  —OH or —OR1;R1 is selected from H, R, RCO or HO3S; and R is selected from the group consisting of H; saturated or unsaturated linear C1-10 hydrocarbon group and the like; R2 is selected from the group consisting of F; Cl; Br; I; H; —OH; —OR; —HSO3 and the like;... Agent: Yuan Qing Jiang

20070191362 - Tetrahydro-cyclopentyl pyrazole cannabinoid modulators: x

20070191364 - Aminopiperidine derivatives, preparation thereof and therapeutic use thereof: The present invention relates to compounds of formula (I) as defined herein that are melanocortin receptor agonists, to the preparation thereof and to the therapeutic use thereof in the treatment and in the prevention of obesity, diabetes and sexual dysfunctions that can affect both sexes, in the treatment of cardiovascular... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070191363 - Heteroalkyl-substituted biphenyl-4-carboxylic acid arylamide analogues: Heteroalkyl-substituted biphenyl-4-carboxylic acid arylamide analogues are provided, of the formula: wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans,... Agent: Edwards Angell Palmer & Dodge LLP

20070191365 - 3,4,6-substituted pyridazines for treating neuropathic pain and associated syndromes: The present invention is directed to the use of 3,4,6-substituted pyridazines such as those characterized by structure I for treating conditions such as neuropathic pain among others.... Agent: Robins & Pasternak LLP

20070191366 - Use of effectors of glutaminyl and glutamate cyclases: The present invention provides novel physiological substrates of mammalian glutaminyl cyclase (QC, EC 2.3.2.5), new effectors of QC, methods for screening for such effectors, and the use of such effectors and pharmaceutical compositions comprising such effectors for the treatment of conditions that can be treated by modulation of QC-activity. Preferred... Agent: Sonnenschein Nath & Rosenthal LLP

20070191367 - 3-spiroindolin-2-one derivatives, preparation and therapeutic use thereof: e

20070191368 - Inhibition of tissue damage to skin from radiation treatment therapy: A method of and composition for inhibiting the deleterious effects on mammalian skin tissue by radiation treatment therapy comprising administering to a patient in need thereof, in conjunction with exposure of the skin tissue to radiation, a safe and effective amount of a chelating agent.... Agent: Miles & Stockbridge PC

20070191369 - Inhibitors of c-met and uses thereof: The present invention provides compounds useful as inhibitors of c-Met tyrosine kinase. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various proliferative disorders.... Agent: Vertex Pharmaceuticals Inc.

20070191370 - Multicyclic amino acid derivatives and methods of their use: Compounds of formulae I and II are disclosed, as well as compositions comprising them and methods of their use to treat, prevent and manage serotonin-mediated diseases and disorders:... Agent: Lexicon Pharmaceuticals, Inc.

20070191371 - Heterocyclic modulators of ppar: The present invention relates to compounds and methods useful as modulators of Peroxisome Proliferator-Activated Receptors (PPARs) for treatment or prevention of disease.... Agent: Global Patent Group Attn: Ms Lavern Hall

20070191375 - Crystalline forms of (3r,4r)-4-amino-1-[[4-[(3-methoxyphenyl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl]piperidin-3-ol: e

20070191372 - Dna-targeted benzotriazine 1,4-dioxides and their use in cancer therapy: The present invention relates to DNA-targeted 1,2,4-benzotriazine-1,4-dioxides and related analogues, to their preparation, and to their use as hypoxia-selective drugs and radiosensitizers for cancer therapy, both alone or in combination with radiation and/or other anticancer drugs.... Agent: Nixon & Vanderhye, PC

20070191373 - Heterocyclic compounds for use in the treatment of viral infections: 6-substituted-3-substituted-3H-furo[2,3-d]pyrimidin-2-one and 6-substituted-2-substituted-furo[2,3-d]pyrimidine novel compounds are useful in the treatment of viral infection, in particular cytomegalovirus viral infection. The substituents are independently selected from alkyl, aryl, alkenyl and alkynyl. The preferred substituent at the 6 position is alkyl.... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20070191374 - Substituted cinnolin-4-ylamines: Substituted cinnolin-4-ylamines are provided, of the Formula (I): wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion... Agent: Edwards Angell Palmer & Dodge LLP

20070191376 - Bicyclic heteroaryl compounds: b

20070191377 - Methods for treating blood disorders with nitric oxide donor compounds: The invention describes methods for treating blood disorders or for treating the symptoms and/or complications associated with blood disorders by administering a therapeutically effective amount of at least one nitric oxide donor compound and optionally at least one antioxidant, or a pharmaceutically acceptable salt thereof, and/or at least one therapeutic... Agent: Wilmer Cutler Pickering Hale And Dorr LLP

20070191379 - Abca1 elevating compounds: The present invention provides compounds useful for increasing cellular ATP binding cassette transporter ABCA1 production in mammals, and to methods of using such compounds in the treatment of coronary artery diseases, dyslipidiemias and metabolic syndrome. The invention also relates to methods for the preparation of such compounds, and to pharmaceutical... Agent: Cv Therapeutics, Inc.

20070191378 - Anthranilic acid derivatives and their use as activators of the hm74a receptor: Therapeutically active anthranilic acid derivatives of Formula (I), processes for the preparation of said derivatives, pharmaceutical formulations containing the compounds and the use of the compounds in therapy, particularly in the treatment of diseases in which under-activation of the HM74A receptor contributes to the disease or in which activation of... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070191380 - Kinase inhibitor scaffolds and methods for their preparation: General methods for the solution phase as well as solid phase synthesis of various substituted heteroaryls has been demonstrated. These substituted heteroaryls can be further elaborated by aromatic substitution with amines at elevated temperature or by anilines, boronic acids and phenols via palladium catalyzed cross-coupling reactions.... Agent: Towmsend & Townsed & Crew LLP

20070191381 - Novel pharmaceutical compounds: The present invention relates to derivatives of tadalafil, substituted with fluorine on the methylene carbon atom situated between the oxygens of the benzodioxol ring, and optionally further substituted with deuterium atoms in place of normally abundant hydrogen, and 13C in place of normally abundant 12C. These compounds are selective PDE5... Agent: Edwards Angell Palmer & Dodge LLP

20070191382 - Novel tricyclic dihydropyrazines as potassium channel openers: The present invention is directed to novel tricyclic dihydropyrazine derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders related to potassium channel.... Agent: Philip S. Johnson Johnson & Johnson

20070191384 - Use of substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives as therapeutic agents: wherein X, Y, R1, R2, R3, R4, R5, n, p and q are as described herein for treating a variety of disease states. More specifically, the invention relates to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070191385 - Substituted imidazole derivatives, compositions, and methods of use as ptpase inhibitors: The present invention provides imidazole derivatives of Formula (I-IV), methods of their preparation, pharmaceutical compositions comprising the compounds of Formula (I-IV), and their use in treating human or animal disorders. The compounds of the invention inhibit protein tyrosine phosphatase 1B and thus can be useful for the management, treatment, control,... Agent: Kilpatrick Stockton LLP - 41305 Charles Calkins

20070191386 - Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them: Bicyclo-pyrazole compounds of formula (I), as herein defined, are useful for treating diseases linked to disregulated protein kinases.... Agent: Scully Scott Murphy & Presser, PC

20070191383 - Mtp inhibiting aryl piperydines or piperazines substituted with 5-membered heterocycles: c

20070191387 - Substituted dihydroquinazolines: The invention relates to substituted dihydroquinazolines and to processes for their preparation and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular for use as antiviral agents, in particular against cytomegalo viruses.... Agent: Jeffrey M. Greenman

20070191388 - Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases: e

20070191389 - Biaryl derivatives: is a single bond or a double bond; A is a group selected from the group consisting of the substitutent group α; and R5 is hydrogen atom, a lower alkyl group, cyano group, an alkoxy group or a trialkylsilyl group; having an mGluR1 inhibiting action and being useful as treatment... Agent: Merck And Co., Inc

20070191390 - Substituted heterocyclic compounds:

20070191391 - Urotensin ii receptor antagonists: The invention is directed to Urotensin II antagonists. More specifically, the present invention relates to certain novel compounds, methods for preparing compounds, compositions, intermediates and derivatives thereof and methods for treating Urotensin-II mediated disorders. Pharmaceutical and veterinary compositions and methods of treating cardiovascular disorders and various other disease states or... Agent: Philip S. Johnson Johnson & Johnson

20070191392 - Dipeptide nitrile cathespin k inhibitors: R1 and R2 are independently H or C1-C7lower alkyl, or R1 and R2 together with the carbon atom to which they are attached form a C3-C8cycloalkyl ring, and Het is an optionally substituted nitrogen-containing heterocyclic substituent, are provided, useful e.g. for therapeutic or prophylactic treatment of a disease or medical... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070191393 - Macrocyclic anilinopyrimidines with substituted sulphoximine as selective inhibitors of cell cycle kinases: The invention relates to macrocyclic anilinopyrimidines with substituted sulphoximine of the general formula I, processes for their preparation, and their use as medicaments.... Agent: Millen, White, Zelano & Branigan, P.C.

20070191394 - Antibacterial agents: Compounds of formula I and methods for their preparation are disclosed. Further disclosed are methods of making biologically active compounds of formula I as well as pharmaceutically acceptable compositions comprising compounds of formula I. Compounds of formula I as disclosed herein can be used in a variety of applications including... Agent: Warner-lambert Company

20070191396 - Fungicidal mixtures: The invention relates to fungicidal mixtures, containing the following in a synergistically effective quantity as active components: 1) the triazolopyrimidine derivative of formula (I); and 2) a phenylamidine derivative of formula (II), in which the variables are defined as follows: R1, R4, R5 represent alkyl, alkenyl or alkynyl; R2, R3... Agent: Birch Stewart Kolasch & Birch

20070191398 - Fungicidal mixtures: e

20070191397 - Fungicidal mixtures based on oxime ether derivatives: The invention relates to fungicidal mixtures containing: A) triazolopyrimidine of formula (I) and B) oxime derivatives of formula (II), wherein the index and substitutents have the following meaning: X=C1-halogen alkyl or C1-halogen alkoxy; R=halogen, alkyl, halogen alkyl, alkoxy or halogen alkoxy; n=0, 1, 2 or 3 in a synergistically effective... Agent: Birch Stewart Kolasch & Birch

20070191395 - Heterocyclic compounds having antifungal activity: A compound which can specifically or selectively expresses an antifungal activity with a broad spectrum, based on the functional mechanism of 1,6-β-glucan synthesis inhibition, is provided, and an antifungal agent which comprises such a compound, a salt thereof or a solvate thereof is provided. A compound represented by the following... Agent: Sughrue Mion, PLLC

20070191399 - Zaleplon synthesis: A process for making zaleplon comprising alkylating 3-[3-(dimethylamino)-1-oxo-2-propenyl]-phenyl]-acetamide with ethyl iodide in the presence of an alkali metal hydroxide or alkoxide selected from sodium hydroxide, potassium hydroxide, sodium methoxide, sodium tert-butoxide or potassium tert-butoxide in an aprotic solvent to give N-ethyl-[3-[3-(dimethylamino)-1-oxo-2-propenyl]-phenyl]-acetamide, condensing N-ethyl-[3-[3-(dimethylamino)-1-oxo-2-propenyl]-phenyl]-acetamide and 3-amino-4-cyanopyrazole, and isolating zaleplon from the... Agent: Conley Rose, P.C.

20070191401 - Indolylmaleimide derivatives: Indolylmaleimide derivatives comprising either a substituted phenyl, naphthyl, tetrahydronaphthyl, quinazolinyl, quinolyl, isoquinolyl or pyrimidinyl residue have interesting pharmaceutical properties, e.g. in the treatment and/or prevention of T-cell mediated acute or chronic inflammatory diseases or disorders, autoimmune diseases, graft rejection or cancer.... Agent: Novartis Corporate Intellectual Property

20070191400 - Pharmaceutical compositions comprising anti-inflammatory quinazolinecarboxamide derivatives: The present invention provides pharmaceutical compositions comprising quinazolinecarboxamide derivative, and certain novel quinazolinecarboxamide derivatives capable of inhibiting heparan sulfate-glycosaminoglycan (HS-GAGs) interactions with L-selectin, and useful in the prevention or treatment of various diseases, disorders and conditions mediated by HS-GAGs, particularly inflammatory and autoimmune diseases, viral diseases, cancer, and amyloid disorders.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070191402 - Method of searching substrate having antidiabetic activity: The present invention provides a screening method of a substance which inhibits binding of a condensed purine derivative to a pancreatic β cell or a treated product of the cell, a substance which inhibits binding of a condensed purine derivative to a protein capable of the condensed purine derivative, and... Agent: Fitzpatrick Cella Harper & Scinto

20070191403 - Gonadotropin-releasing hormone receptor antagonists and methods relating thereto: wherein R1a, R1b, R1c, R2a, R2b, R3, R4, R5, R6 and X are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof... Agent: Seed Intellectual Property Law Group PLLC

20070191404 - Pharmaceutical compositions of pyrimidine-2,4,6-triones: It was surprisingly found that a-trioxopyrimidine-cyclodextrin-complex formed of a trioxopyrimidine derivative represented by the below-described formula (I) and a water-soluble cyclodextrin (further abbreviated as CD) exhibits enhanced water solubility, excellent stability, and low topical stimulation and is useful as a therapeutic agent. Accordingly, the present invention provides a trioxopyrimidine-cyclodextrin complex... Agent: Hoffmann-la Roche Inc. Patent Law Department

20070191405 - Bi-aryl meta-pyrimidine inhibitors of kinases: The invention provides biaryl meta-pyrimidine compounds having the general structure (A). The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the Jak kinase family, and various other specific receptor and non-receptor kinases.... Agent: Dla Piper US LLP

20070191406 - Heterocyclic antiviral compounds: Chemokine receptor antagonists, in particular, 3,7-diazabicyclo[3.3.0]octane compounds according to formula (I) wherein R1-R3 R6c and X1 are as defined herein are antagonists of chemokine CCR5 receptors which are useful for treating or preventing an human immunodeficiency virus (HIV) infection, or treating AIDS or ARC. The invention further provides methods for... Agent: Roche Palo Alto LLC Patent Law Dept. M/s A2-250

20070191407 - Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-2-pyrimidinyl]amino]benzonitrile: e

20070191408 - Compositions useful especially for treatment or prevention of metabolic syndrome: The present invention relates to a method for treatment or prevention of metabolic syndrome and diseases or conditions resulting therefrom in an individual in which an effective amount of an amine oxidase enzyme inhibitor is administered to the individual. The invention also relates to a method for inhibiting an amine... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070191409 - Compounds for inhibiting beta-amyloid production and methods of identifying the compounds: Provided are compounds useful for treating diseases associated with a cerebral accumulation of Alzheimer's amyloid, such as Alzheimer's disease. Also provided are methods for screening for such compounds, by measuring capacitative calcium entry in cells which optionally overexpress APP or a fragment thereof. Also provided are methods of treating or... Agent: King & Spalding LLP

20070191410 - Cyclopamine analogues and methods of use thereof: The present invention provides compositions and methods for modulating smoothened-dependent pathway activation. The present invention provides analogs of cyclopamine that can be used to counteract the phenotypic effects of unwanted activation of a hedgehog pathway, such as resulting from hedgehog gain-of-function, Ptc loss-of-function or smoothened gain-of-function mutations. The compounds of... Agent: Morrison & Foerster LLP

20070191411 - Enhancement of impaired motor and mental functions, using dextromethorphan and oxidase enzyme inhibitor: During clinical trials on patients suffering from neurological disorders, it has been observed that some patients obtain dramatic improvements in motor control and/or higher mental functioning, when they receive a combination of dextromethorphan and quinidine, at suitable dosages. Improved motor control has been exemplified to date by improved ability to... Agent: Patrick D. Kelly Attorney For Applicant

20070191412 - Synergistic analgesic combination of opioid analgesic and cyclooxygenase-2 inhibitor: Disclosed is a pharmaceutical composition, comprising two analgesic compounds and/or pharmaceutically acceptable salts thereof consisting of celecoxib and/or at least one pharmaceutically acceptable salt thereof and oxycodone and/or at least one pharmaceutically acceptable salt thereof, said two analgesic compounds in an amount sufficient to provide an analgesic effect in a... Agent: Davidson, Davidson & Kappel, LLC

20070191413 - Novel heterocycle-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors: s

20070191414 - Novel isoamido-substituted hydroxy-6-phenylphenanthridines:

20070191415 - Production of tacrolimus (fk-506) using new streptomyces species: The invention relates to a new microorganism Streptomyces glaucescens MTCC 5115 and a process for producing the immunosuppressant agent, tacrolimus (FK-506) utilizing the new microorganism Streptomyces glaucescens MTCC 5115. The invention also relates to pharmaceutical compositions that include the tacrolimus (FK-506) and use of said compositions for treatment or prevention... Agent: Ranbaxy Inc.

20070191417 - Quinoline 3-amino chroman derivatives: Quinoline 3-amino chroman derivatives and compositions containing such compounds are disclosed. Methods for using the quinoline 3-amino chroman derivatives and compositions containing such compounds in the treatment of serotonin disorders are disclosed. Also disclosed are processes for preparing quinoline 3-amino chroman derivatives.... Agent: Woodcock Washburn LLP

20070191416 - Tetrahydropyridoindole derivatives: The invention relates to tetrahydropyridoindole derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions comprising one or more of those compounds and methods of treatment comprising administration of said compounds.... Agent: Dickstein Shapiro LLP

20070191418 - Compositions and methods for modulating gated ion channels: The present invention relates to compositions and methods to modulate the activity of gated ion channels.... Agent: Lahive & Cockfield, LLP

20070191419 - Cycloalkanopyridine derivative: [wherein the symbols are the same as those stated in the description]. The compounds act as a nociceptin receptor antagonist, and are useful as medicines for diseases associated with a nociceptin receptor, for example, as a reliever against tolerance to a narcotic analgesic; a reliever against dependence on or addiction... Agent: Merck And Co., Inc

20070191420 - Kinase inhibitors: The invention provides the use of a compound or a composition comprising said compound for inhibiting the activity of at least one kinase, other than ROCK kinase, in vitro or in vivo, pharmaceutical and/or veterinary compositions comprising such compounds, medical and veterinary uses of such compounds and the compounds themselves.... Agent: Foley And Lardner LLP Suite 500

20070191421 - Aryl-isoxazol-4-yl-imidazo[1,5-a]pyridine derivatives: e

20070191422 - Nicotinic acetylcholine receptor ligands: Compounds of formula (I), wherein D, Ar1, E and Ar2 are as defined in the specification, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, especially in the treatment or prophylaxis of psychotic and intellectual impairment disorders.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20070191423 - Isoquinoline derivatives: The present invention relates to isoquinoline derivatives of formula (I), the use of the compounds of formula (I), as inhibitors of one or more kinases, the use of the compounds of formula (I), for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition... Agent: Heller Ehrman LLP

20070191424 - Substituted 1,2,3,4-tetrahydroisoquinoline derivatives: The invention relates to novel 1,2,3,4-tetrahydroisoquinoline derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, phannaceutical compositions containing one or more of those compounds and methods of treatment comprising administration of said... Agent: Dickstein Shapiro LLP

20070191425 - Solifenacin-containing composition: To provide a novel method for producing a composition comprising solifenacin or a salt thereof, and a composition comprising solifenacin or a salt thereof as produced by the method, wherein an optionally substituted lower alkyl is added to the 2-position of the quinuclidine of solifenacin. The composition of the present... Agent: Sughrue Mion, PLLC

20070191426 - Derivatives of 3-aminocarbonylquinoline, pharmaceutical compositions containing them and processes and intermediates for their preparation:

20070191427 - Use of n-piperidine derivatives for the treatment of neurodegenerative pathologies: The present invention relates to chemical compounds, to pharmaceutical and veterinary compositions, and to the use of such compositions for the treatment or prevention of neurodegenerative pathologies and syndromes such as Parkinson's disease, Alzheimer's disease, lesions due to ischaemia and reperfusion, traumatic brain lesions, neuropathy due to HIV, Down's syndrome,... Agent: Roylance, Abrams, Berdo & Goodman, L.L.P.

20070191428 - Fexofenadine polymorphs and processes of preparing the same: Anhydrous crystalline fexofenadine hydrochloride Form C, crystalline fexofenadine acetate monohydrate Form D, crystalline fexofenadine acetate dihydrate Form E and crystalline fexofenadine free base monohydrate Form F, processes of preparing the same, pharmaceutical compositions thereof, therapeutic uses thereof and methods of treatment therewith.... Agent: Conley Rose, P.C.

20070191430 - Method of providing anesthesia: A theory has been presented that provides a simplified explanation of a cohesive mechanism of embryological development, hemostasis, coagulation, wound repair and tissue maintenance that operates continuously in the animal body to oppose the effects of stress. The theory endeavors to fit all known facts, and is based on the... Agent: Cislo & Thomas, LLP

20070191429 - Ppar activators: PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL... Agent: Warner-lambert Company

20070191431 - 2-amino-5-piperidinylimidazolone compounds and use thereof for beta-secretase modulation: A

20070191432 - Novel benzo[d][1,3]-dioxol derivatives: The present invention relates to an isotopologue of Compound 1 substituted with deuterium at the methylene carbon of the benzodioxol ring. The isotopologues of this invention selective serotonin reuptake inhibitors (SSRIs) and possess unique biopharmaceutical and metabolic properties compared to Compound 1. They may also be used to accurately determine... Agent: Edwards Angell Palmer & Dodge LLP

20070191433 - Acylated piperidine derivatives as melanocortin 4-receptor agonists: Certain novel N-acylated piperidine derivatives are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction,... Agent: Merck And Co., Inc

20070191434 - Inhibitors of bacterial impdh: r

20070191435 - Hydrochloride salt of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione: A novel pharmaceutical compound 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione hydrochloride, a process for preparing such a compound, a pharmaceutical composition comprising such a compound and the use of such a compound in medicine... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20070191436 - Diastereomeric purification of rosuvastatin: The invention relates to diastereomerically pure rosuvastatin and processes for preparing diastereomerically pure rosuvastatin and its intermediates.... Agent: Kenyon & Kenyon LLP

20070191437 - Continuous dosing regimen: The invention relates to pharmaceutical compositions comprising combinations of ABT-751 and anti-cancer drugs. These combinations have additive antitumorigenesis activity. This invention also relates to methods of treatment using the combinations.... Agent: Robert Deberardine Abbott Laboratories

20070191438 - Methods for the treatment of hypertension: This invention relates to the treatment of hypertension, cardiac dysfunction or stroke by the administration of an estrogen receptor beta (ER&bgr;) selective agonist either as a single agent, or in combination with other agents.... Agent: Merck And Co., Inc

20070191439 - Intermediates for the preparation of pramipexole: Intermediates useful for the preparation of pramipexole and the use thereof in such synthesis.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070191440 - Methods of treating autism and fragile x syndrome: Subjects having at least one condition selected from the group consisting of mental retardation, Down's syndrome, fragile X syndrome and autism are treated with a composition that includes Formula I.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070191441 - Diphenylamine-substituted salicylthiazole derivatives and related compounds as phosphotyrosine phosphatase 1b (ptb1b) inhibitors for using as blood-sugar decreasing active ingredients for treating diabetes: b

20070191442 - Aqueous pharmaceutical formulations of er-beta selective ligands: The present invention relates to aqueous formulations of ERβ selective ligands. In some embodiments, the formulations include an ERβ selective ligand, a solubilizer/complexant component, and a pH adjusting component. The invention further provides preparations of the formulations, and uses thereof.... Agent: Pepper Hamilton LLP/wyeth

20070191443 - Methods and materials for assessing prostate cancer therapies and compounds: A modest (2-5 fold) increase in androgen receptor (AR) mRNA is the only expression change consistently associated with developing resistance to antiandrogen therapy. Increased levels of AR confer resistance to anti-androgens by amplifying signal output from low levels of residual ligand and altering the normal response to antagonists. This invention... Agent: Venable LLP

20070191444 - Benzimidazolyl derivatives: The present invention relates to benzimidazolyl derivatives of formula (I), with the definition of R8, p, Ar1, E, D, R9, q and R10 according to claim 1, the use of the compounds of formula (I) as inhibitors of one or more kinases, the use of the compounds of formula (I)... Agent: Heller Ehrman LLP

20070191445 - Pyrazole compounds that modulate hsp90 activity: Variable R5 is an optionally substituted heteroaryl; an optionally substituted 6 to 14-membered aryl; a bicyclic 9-member heterocycle optionally substituted at any substitutable nitrogen or carbon atoms; or a substituent R18, defined herein. Ring A is an aryl or a heteroaryl optionally further substituted with one or more substituents in... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070191446 - Tubular proteinuria as an indicator for elevated cardiovascular risk: The invention relates to the use of an ACE inhibitor or an angiotensin receptor antagonist for the preparation of a pharmaceutical composition for reducing tubular proteinuria oral/or α1-microglubulin in a non-diabetic human individual for reducing the risk of a cardiovascular event.... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070191447 - Novel heterocyclic compound: e

20070191448 - Ion channel modulators: The invention relates to compounds, compositions comprising the compounds, and methods of using the compounds and compound compositions. The compounds, compositions, and methods described herein can be used for the therapeutic modulation of ion channel function, and treatment of disease and disease symptoms, particularly those mediated by certain calcium channel... Agent: Edwards Angell Palmer & Dodge LLP

20070191451 - Use of benzo-heteroaryl sulfamide derivatives as neuroprotective agents: The present invention is a methods for neuroprotection, for treating an acute neurodegenerative disorder, for treating a chronic neurodegenerative disorder and/or for preventing neuron death or damage following brain, head and/or spinal cord trauma or injury comprising administering to a subject in need thereof a therapeutically effective amount of one... Agent: Philip S. Johnson Johnson & Johnson

20070191449 - Use of benzo-heteroaryl sulfamide derivatives for the treatment of depression: The present invention is a method for the treatment of depression comprising administering to a subject in need thereof a therapeutically effective amount of one or more novel benzo-heteroaryl sulfamide derivatives of formula (I) as herein defined. The present invention is directed to a method for the treatment of depression,... Agent: Philip S. Johnson Johnson & Johnson

20070191450 - Use of benzo-heteroaryl sulfamide derivatives for the treatment of mania and bipolar disorder: The present invention is a method for the treatment of mania and/or bipolar disorder comprising administering to a subject in need thereof a therapeutically effective amount of one or more novel benzo-heteroaryl sulfamide derivatives of formula (I) as herein defined.... Agent: Philip S. Johnson Johnson & Johnson

20070191452 - Use of benzo-heteroaryl sulfamide derivatives for the treatment of pain: The present invention is a method for the treatment of pain comprising administering to a subject in need thereof a therapeutically effective amount of one or more novel benzo-heteroaryl sulfamide derivatives of formula (I) as herein defined. The present invention is further directed to methods for the treatment of pain... Agent: Philip S. Johnson Johnson & Johnson

20070191453 - Use of benzo-heteroaryl sulfamide derivatives for the treatment of substance abuse and addiction: The present invention is a method for the treatment of substance abuse and/or addiction comprising administering to a subject in need thereof a therapeutically effective amount of one or more novel benzo-heteroaryl sulfamide derivatives of formula (I) as herein defined.... Agent: Philip S. Johnson Johnson & Johnson

20070191454 - Silylated carboxamides: e

20070191455 - Substituted sym-triindole:

20070191456 - Novel process for the preparation of 1-(9h-carbazol-4-yloxy)-3-[[2-(-methoxyphenoxy)-ethyl] amino]-propan-2-ol: The present invention discloses a novel process for preparation of carvedilol by using eco friendly solvents to obtain the said carvedilol in high purity. The said process comprises, reacting 4-hydroxy carbazole of formula (IV) with epichlorhydrin in presence of an organic solvent and a base at temperatures between 10° C.-30°... Agent: Pharmaceutical Patent Attorneys, LLC

20070191457 - Compounds having activity at 5ht2c receptor and uses thereof: wherein R1 is halogen, cyano, C1-6alkyl, C3-7cycloalkyl, C3-7cycloalkyloxy, C1-6alkoxy, C1-6alkylthio, hydroxy, amino, mono- or di-C1-6alkylamino, an N-linked 4 to 7 membered heterocyclic group, nitro, haloC1-6alkyl, haloC1-6alkoxy, aryl, —COOR3, —COR4, wherein R3 and R4 are independently hydrogen or C1-6alkyl, or —COR5, wherein R5 is amino, mono- or di-C1-6alkylamino or an N-linked... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070191458 - Crystals including a malic acid salt of a 3-pyrrole substituted 2-indolinone, and compositions thereof: The present invention provides crystals, and compositions thereof, wherein the crystals include a malic acid salt of N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide. Methods of preparing such crystals are also disclosed.... Agent: Pfizer Inc

20070191459 - Use of benzo-heteroaryl sulfamide derivatives for lowering lipids and lowering blood glucose levels: The present invention is a method for the glucose related disorders and lipid related disorders comprising administering to a subject in need thereof a therapeutically effective amount of one or more novel b benzo-heteroaryl sulfamide derivatives of formula (I) as herein defined. The present invention is further directed to methods... Agent: Philip S. Johnson Johnson & Johnson

20070191460 - Use of benzo-heteroaryl sulfamide derivatives for the treatment of disease modification / epileptogenesis: The present invention is a method for treating, preventing, reversing, arresting or inhibiting the occurrence, development and maturation of seizures or seizure-related disorders. More specifically, the present invention is directed to methods for the use of benzo-heteroaryl sulfamide derivatives of formula (I) as described herein to therapeutically or prophylactically treat,... Agent: Philip S. Johnson Johnson & Johnson

20070191461 - Use of benzo-heteroaryl sulfamide derivatives for the treatment of migraine: The present invention is a method for the treatment or prevention of migraine comprising administering to a subject in need thereof a therapeutically effective amount of one or more novel benzo-heteroaryl sulfamide derivatives of formula (I) as herein defined. The present invention is directed to a method for the treatment... Agent: Philip S. Johnson Johnson & Johnson

20070191462 - Combination of a 5-ht(1) receptor agonist and an alpha-2-delta ligand for the treatment of migraine: The present invention relates to a combination of a 5-HT1B, 5-HT1D or 5-HT1F agonist and an alpha-2-delta ligand. Such a combination is useful in the treatment of pain, particularly the pain arising from migraine.... Agent: Pharmacia Corporation Global Patent Department

20070191463 - Substituted melatonin derivatives, process for their preparation, and methods of use: The invention provides 2 aryl substituted derivatives of melatonin. The invention further provides pharmaceutical compositions comprising such derivatives, methods for preparing such derivatives, and methods of using such derivatives to induce general anesthesia, sedation, and/or hypnotic or sleep effects in a patient, and to treat conditions affected by melatonin activity... Agent: Leydig Voit & Mayer, Ltd

20070191464 - Process for producing monatin or salt thereof: [Problems] To provide a process for producing monatin where steric configuration of 2-position is in an R configuration or a salt thereof by isomerization of 2-position of monatin where steric configuration of 2-position is in an S configuration. [Means for Resolution] A process for producing monatin where steric configuration of... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070191465 - Channel blocking compounds: The invention relates to compositions and associated methods and uses that contain lolitrem compounds containing the moiety shown in structure (I) or derivatives thereof for ion channel antagonist applications, particularly BK channel antagonist applications. Preferred compounds include lolitrem B, 31-epilolitrem B, lolitriol and lolitrem E. For lolitrem B, a particularly... Agent: Knobbe Martens Olson & Bear LLP

20070191466 - Metabolites of wortmannin analogs and methods of using the same: Novel metabolites of wortmannin and wortmannin analogs and their use in inhibiting PI-3 kinase activity in mammals and the treatment and prevention of cancer or tumor formation in a subject are described herein.... Agent: Pepper Hamilton LLP 500 Grant Street

20070191467 - Statin and omega-3 fatty acids for lipid therapy: A method of lipid therapy, comprising providing a subject group having a baseline triglyceride level of 200 to 499 mg/dl and being at or near its low-density lipoprotein cholesterol (LDL-C) level goal, and reducing the triglyceride level and the non-high-density lipoprotein cholesterol (non-HDL-C) level of the subject group as compared... Agent: Arent Fox PLLC

20070191468 - Amino alcohol compound: (wherein R1 represents a methyl group or an ethyl group, R2 represents a methyl group or an ethyl group, and R3 represents a phenyl group substituted with 1 to 3 substituents selected from the group consisting of a halogen atom, a lower alkyl group, a cycloalkyl group, a lower alkoxy... Agent: Frishauf, Holtz, Goodman & Chick, PC

20070191469 - Novel tetracyclic tetrahydrofuran derivatives: h

20070191472 - 2-(n-methyl-propanamine)-3-(2-naphthol)thiophene, an impurity of duloxetine hydrochloride: The invention encompasses 2-N-methyl-propanamine)-3-(2-naphthol) thiophene, a duloxetine hydrochloride impurity, as well as its use as a reference marker and reference standard.... Agent: Kenyon & Kenyon LLP

20070191471 - Dnt-fumarate and methods of preparation thereof: (S)-N,N-Dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine fumarate (DNT-fumarate) and polymorphs of DNT-fumarate, compositions of DNT-fumarate and its polymorphs, processes for the preparation of DNT-fumarate and its polymorphs, and processes for the preparation of duloxetine hydrochloride from DNT-fumarate are provided.... Agent: Kenyon & Kenyon LLP

20070191470 - Use of rotigotine for treating and preventing parkinson's plus syndrome: The invention relates to the use of rotigotine, its salts and prodrugs, as a medicament for preventing and/or treating Parkinson's plus syndrome... Agent: Harness, Dickey, & Pierce, P.l.c

20070191473 - Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof: In accordance with the present invention, there are provided compositions and methods useful for the in vivo delivery of substantially water insoluble pharmacologically active agents (such as the anticancer drug paclitaxel) in which the pharmacologically active agent is delivered in the form of suspended particles coated with protein (which acts... Agent: Morrison & Foerster LLP

20070191474 - Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine: The present invention is a method for the treatment or prevention of migraine comprising administering to a subject in need thereof a therapeutically effective amount of one or more novel benzo-fused heterocycle sulfamide derivatives of formula (I) and formula (II) as herein defined. The present invention is directed to a... Agent: Philip S. Johnson Johnson & Johnson

20070191475 - Novel spiro-1,2,4-trioxanes: Wherein, Ar represents aryl groups such as phenyl, 4-biphenyl, 4-chlorophenyl, 4-methoxyphenyl, 4-methylphenyl, 4-cyclohexylphenyl, 1-naphthyl, 2-naphthyl and the like and R represents hydrogen or the alkyl group such as methyl, ethyl and the like. Several of these compounds show high order of antimalarial activity against multidrug-resistant malaria in mice and thus... Agent: Kenyon & Kenyon LLP

20070191476 - Antioxidant components for reduction of nucleic acid damage in companion animals: The present invention is directed to method of using vitamin E, vitamin C and a carotenoid in the manufacture of a foodstuff for reducing nucleic acid damage in a companion animal. The inventions is also directed to a process and a foodstuff for reducing nucleic acid damage in a companion... Agent: Fulbright & Jaworski, LLP

20070191477 - Schisandrin b preparation: The present invention provides a composition (e.g., a pharmaceutical composition) for reducing aging-related mitochondrial antioxidant status changes in a subject, wherein the composition comprises Schisandrin B. The present invention further provides a composition (e.g., a pharmaceutical composition) for reducing ischemia-reperfusion injury in an aging subject, wherein the composition comprises Schisandrin... Agent: Troutman Sanders LLP

20070191478 - Methods of treating cardio pulmonary diseases with no group compounds: Treatment of pulmonary disorders associated with hypoxemia and/or smooth muscle constriction and/or inflammation comprises administering into the lungs as a gas a compound with an NO group which does not form NO2/NOx in the presence of oxygen or reactive oxygen species at body temperature. Treatment of cardiac and blood disorders,... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070191479 - Aniline derivatives as selective androgen receptor modulators: This invention relates to non-steroidal compounds that are modulators of androgen, glucocorticoid, mineralocorticoid, and progesterone receptors, and also to the methods for the making and use of such compounds.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070191480 - Gycol ether miticides and anti-allergen treatments: The present invention encompasses a cleaning composition and method for controlling dust mites and allergens using glycol ether, glycol ether ester or a combination thereof. The cleaning composition preferably contains a hydrophobic glycol ether and/or glycol ether ester solution present at a level of about 0.01% to 20% by weight... Agent: The Clorox Company

20070191481 - Sulphonic acid salt of sibutramine: Disclosed is a novel sulphonic acid salt of sibutramine, which has good physicochemical properties. Also disclosed are a method of preparing the compound and a pharmaceutical composition comprising the compound.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070191482 - Dicarboxylic acid salt of sibutramine: Disclosed is a novel dicarboxylic acid salt of sibutramine, which has good physicochemical properties. Also disclosed are a method of preparing the compound and a pharmaceutical composition comprising the compound.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070191483 - Method of enhancing reproductive function of mammals by feeding of conjugated linoleic acids: This invention provides methods for improving reproductive performance of lactating dairy cows and other mammals. The method in the case of cows comprises feeding to the cows, a composition comprising conjugated linoleic acids (CLAs), cis-9, trans-11 and trans-10, cis-12. When these CLAs are fed daily to dairy cows starting at... Agent: Hodgson Russ LLP The Guaranty Building

20070191484 - Medicaments containing pantothenic acid: This invention relates to medicaments and their use in the alleviation of inflammation and pain in joints.... Agent: Occhiuti Rohlicek & Tsao, LLP

20070191485 - Active oxygen scavenging composition including citrulline: According to this invention, a novel anti-oxidative substance of naturally originated, with excellent ability to scavenge active oxygen species and high safety was provided. According to the present invention, citrulline was firstly exhibited to have excellent ability to scavenge active oxygen species. A novel active oxygen scavenging composition including citrulline... Agent: Buchanan, Ingersoll & Rooney PC

20070191486 - N-deacetylthiocolchicine derivatives, their use and pharmaceutical formulations containing them: Disclosed is a series of N-deacetylthiocolchicine derivatives of formula (I) in which:—the linker is a bivalent straight or branched C1-C8 alkyl residue, C3-C8 cycloalkyl, a phenylene or heterocyclic C4-C6 ring;—the G1 and G2 junctions, which can be the same or different, are —CO—, —COHN—, —CR2— groups in which R2 is... Agent: Young & Thompson

20070191487 - Galenic formulations of organic compounds: The present invention relates to a solid oral dosage form comprising a therapeutically effective amount of aliskiren or a pharmaceutically acceptable salt thereof, and wherein the active ingredient is present in an amount of more than 46% by weight based on the total weight of the oral dosage form.... Agent: Novartis Corporate Intellectual Property

20070191488 - Method for the treatment of a ubiquitin conjugating disorder: The present invention provides methods for identifying compounds that selectively bind one or more active sites within an ubiquitin conjugating enzyme. The compounds identified by the methods are useful in the treatment of disorders attributed to dysregulated ubiquitin conjugating enzyme function, specifically in hyperproliferative disorders.... Agent: Edwards Angell Palmer & Dodge LLP

20070191489 - Inorganic acid salts of sibutramine: Disclosed are novel inorganic acid salts of sibutramine, which have good physicochemical properties, and crystalline forms thereof. Also disclosed are pharmaceutical compositions comprising the compounds as effective ingredients, methods of preparing the compounds, and the use of the compounds.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070191490 - Withacnistin compounds for treatment of cancer: The subject invention pertains to the treatment of tumors and cancerous tissues and the prevention of tumorigenesis and malignant transformation through the modulation of STAT3 intracellular signaling. The subject invention concerns pharmaceutical compositions containing one or more withacnistin compounds, or a pharmaceutically acceptable salt or derivative thereof. In one embodiment,... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070191491 - Pesticidal treatment of stored goods, enclosures, structures and works of art, with sulphur compounds: in which R represents an alkyl or alkenyl radical containing from 1 to 4 carbon atoms, n is equal to 0, 1 or 2, x is a number ranging from 0 to 4, and R′ represents an alkyl or alkenyl radical containing from 1 to 4 carbon atoms or, only... Agent: Arkema Inc. Patent Department - 26th Floor

20070191492 - Method for suppressing lung tumorigenesis: The invention provides a method of treatment for suppressing or inhibiting lung tumorigenesis, comprising administering to a subject who requires the treatment an effective amount of a compound represented by the following formula (I).... Agent: Sughrue Mion, PLLC

20070191493 - Use of n-alkanols as activators of the cftr channel: The invention relates to a novel use of n-alkanols as activators of the CFTR (systic fibrosis transmembrane conductance regulator) channel, and to the application of said use to treatments of pathologies in which a dysfunction of said channel can be observed, such as mucoviscidosis.... Agent: Alston & Bird LLP

20070191494 - Phenolate-containing formulation with low freezing point: The present invention discloses an aqueous phenolates-containing liquid formulation having a solidification point of less than or equal to −10° C. which is characterized by comprising the following components: a) 50-80% by wt. of one or more phenolates; b) 0.1-10% by wt. of at least one crystallization inhibitor; and water... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070191495 - Lipase inhibitor: An object of the present invention is to provide a fat-soluble lipase inhibitor which can contribute to prevention or treatment of obesity due to excessive fat intake or diseases caused by obesity, can be added to fats and oils of all types, and can mildly inhibit hydrolysis by lipase. The... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070191496 - Therapeutically useful molecules: A T cell receptor molecule (TCR) containing an alpha chain portion and a beta chain portion wherein the alpha chain portion contains three complementarity determining regions (CDRs): CDR1α: SSYSPS CDR2α: YTSAATL CDR3α: VVSPF-SGGGADGLT or comprising or consisting of SPFSGGGADGLT and the beta chain portion contains three complementarity determining regions (CDRs):... Agent: Marshall, Gerstein & Borun LLP

20070185058 - Heteroaryl and benzyl amide compounds: P

20070185055 - Method for treating cachexia with retinoid ligands: The present invention relates to a method of treatment of cachexia in a subject in need of treatment. More specifically, the present invention relates to the use of retinoid compounds that act on retinoid X receptors (RXRs) for the treatment of cachexia in a subject in need of treatment. The... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070185007 - Aza-quinolinol phosphonate integrase inhibitor compounds: Aza-quinolinol phosphonate compounds and methods for inhibition of HIV-integrase are disclosed. Formula (I). Ar is aryl or heteroaryl connecting R6 to L. L is a bond or a linker connecting a ring atom of Ar to N. The ring atoms, X1-X5 may be N, substituted nitrogen, or substituted carbon, and... Agent: Gilead Sciences Inc

20070185009 - Coated catheters: Provided herein are coated medical devices. More specifically, at least a portion of the device (e.g., catheter) is coated with an active component, wherein the active component prevents or treats occlusions and the formation(s) thereof.... Agent: Dla Piper US LLP

20070185008 - Stereocomplex hydrogels with tunable degradation times: The present invention relates to stereocomplex hydrogels for drug delivery and tissue engineering. The hydrogels comprise block or graft polymers with at least one hydrophilic region and at least two enantiomerically enriched degradable regions, which may represent grafts or terminal blocks. In the hydrogels, degradable regions of opposite chirality form... Agent: Morrison & Foerster LLP

20070185010 - Novel polypeptide hormone phosphatonin: The present invention relates to a novel human protein called phosphatonin, and isolated polynucleotides encoding this protein. Also provided are vectors, host cells, antibodies, and recombinant methods for producing this human protein. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to this... Agent: Bozicevic, Field & Francis LLP

20070185011 - C1 inhibitor with short half-life transient treatment: The present invention relates to the use of a C1 inhibitor (C1INH) with shorter half-life than plasma-derived C1INH for the preparation of a medicament for the transient treatment of an individual. It relates to both therapeutic and prophylactic treatment. The method of the invention allows for the administration of C1INH... Agent: Townsend And Townsend And Crew, LLP

20070185012 - Glycopeptides for the treatment of als and other metabolic and autoimmune disorders: New compositions and methods for treating patients suffering from Amyotrophic Lateral Sclerosis (ALS) and other metabolic and autoimmune disorders, which include glycopeptides such as N-acetyl-D-glucosaminyl(β1-4)-N-Acetyl-muramyl-L-alanyl-D-isoglutamine (GMDP) and peptide analog-L-alanyl-D-glutamic acid (GMDP-A) of at least 98% purity administered either alone, or in combination with a flavone such as luteolin and/or an... Agent: Robert D Buyan Stout Uxa Buyan & Mullins

20070185014 - Methods and compositions for modulating conjunctival goblet cells: The present invention relates to conjunctival goblet cell proliferation and secretions. The present invention also relates to compositions that can modulate conjunctival goblet cell proliferation and secretions. The present invention also relates to galectins, PDGF, bFGF, and the regulation of goblet cells.... Agent: Cozen O'connor, P.C.

20070185015 - Semi-synthetic desmethyl-vancomycin-based glycopeptides with antibiotic activity: Semi-synthetic glycopeptides that have antibacterial activity are based on modifications of the desmethyl-vancomycin scaffold, in particular, acylation of the amino substituent on the amino-substituted sugar moiety on this scaffold with certain acyl groups; and/or conversion of the acid moiety on the macrocyclic ring of this scaffolds to certain substituted amides.... Agent: Novartis Vaccines And Diagnostics Inc.

20070185013 - Use of chk1 inhibitors to control cell proliferation: The present invention relates to improved methods for inhibiting aberrant cell proliferation involving the scheduling of administration of Chk1 activators (e.g., chemotherapeutic agents) and Chk1 inhibitors. At least one Chk1 activator is administered at a dose and for a time sufficient to induce substantial synchronization of cell cycle arrest in... Agent: Marshall, Gerstein & Borun LLP

20070185016 - Novel staphylococcus peptides for bacterial interference: wherein X is selected from the group consisting of an amino acid, an amino acid analog, a peptidomimetic and a non-amide isostere, Z is selected from the group consisting of a synthetic amino acid and a biosynthetic amino acid, R is selected from the group consisting of oxygen, nitrogen, sulfur... Agent: Klauber & Jackson

20070185023 - Antiproliferative peptides and antibodies for their detection: The present invention relates to developmental peptides and peptidomimetics thereof, which may be used therapeutically to inhibit abnormal cell proliferation of damaged cells, including cancer cells or virally infected cells. In one embodiment, a seven to eleven amino acid developmental peptide and methods of using the same is provided.... Agent: Pepper Hamilton LLP

20070185027 - Antiviral agents for the treatment, control and prevention of infections by coronaviruses: The invention provides compositions and methods that are useful for preventing and treating a coronavirus infection in a subject. More specifically, the invention provides peptides and conjugates and pharmaceutical compositions containing those peptides and conjugates that block fusion of a coronavirus, such as the SARS virus, to a target cell.... Agent: Proskauer Rose LLP

20070185017 - Compositions and methods for the treatment of immune related diseases: The present invention relates to compositions containing novel proteins and methods of using those compositions for the diagnosis and treatment of immune related diseases.... Agent: Genentech, Inc.

20070185026 - Compositions and methods for treating bacteria: The present invention relates to the field of bacteriology. In particular, the present invention provides compositions (e.g., comprising a lantibiotic and mupirocin or gentamicin) and methods of treating (e.g., killing or inhibiting growth of) bacteria. For example, the present invention provides pharmaceutical compositions (e.g., comprising a lantibiotic and mupirocin or... Agent: Medlen & Carroll, LLP

20070185028 - Compositions and methods for treatment of protein misfolding and protein aggregation diseases: Small molecular weight molecules are provided including, but not limited to, peptides, peptide analogs and peptide mimetics that stabilize and prevent the aggregation of abnormally folded and compromised proteins. Methods for treatment of disease are provided utilizing the peptides, peptide analogs or peptide mimetics, or utilizing nucleic acids encoding the... Agent: Woodcock Washburn LLP

20070185021 - Diabetogenic epitopes: The present invention provides nucleotide and amino acid sequences of diabetogenic epitopes, and proteins comprising diabetogenic epitopes. Also provided are kits comprising diabetogenic epitopes, methods of identifying subjects comprising antibodies to diabetogenic epitopes and foodstuffs modified to remove or reduce diabetogenic epitopes or proteins comprising diabetogenic epitopes. Diabetogenic epitopes and... Agent: Suzannah K. Sundby

20070185025 - Filoviral immunosuppressive peptides and uses thereof: The invention provides a region of strong secondary structure conservation between the C-terminus domain of the envelope glycoprotein of filoviruses and an immunosuppressive domain found in retroviral envelope glycoproteins. The invention provides filoviral peptides and modified derivatives thereof with strong immunosuppressive bioactivity. The invention further provides methods for treatment of... Agent: Wilmerhale/columbia University

20070185020 - Methods and compositions for treating disorders of the extracellular matrix: The present invention provides a method for altering the level of an extracellular matrix (ECM) protein produced by a cell, the method including modulating expression or activity of a cell division auto antigen (CDA). The Applicants have surprisingly found that a CDA is involved in a pathway that controls the... Agent: Nixon Peabody LLP - Patent Group

20070185029 - Methods of tx condition in animal: The invention relates to compositions comprising of SEQ NO: 1-244, 248-249, and any homologs, analogs, and fragments thereof. Such compositions can be used to treat, prevent, and modulate pain, inflammation, and metabolic processes in various organisms including plants and animals. Such compositions can be formulated with an acceptable pharmaceutical excipient... Agent: Wilson Sonsini Goodrich & Rosati

20070185019 - Novel antimicrobial peptides with heparin binding activity: The invention relates to an antimicrobial peptide with heparin binding activity, being derived from endogenous mammalian proteins being substantially free from antimicrobial activity selected from the group consisting of laminin isoforms, complement factor C3, histidin rich glycoprotein and kininogen and having from 10 to 36 amino acid residues, wherein the... Agent: Merchant & Gould PC

20070185024 - Systems and methods for screening for modulators of neural differentiation: The present invention provides in vitro systems for use in identifying modulators of neural differentiation. Also provided are modulators identified by these systems. The present invention further provides methods for identifying a modulator of neural differentiation, a modulator of a Wnt signalling pathway, a modulator of Wnt-dependent neural differentiation, a... Agent: Baker Botts L.L.P.

20070185022 - Therapeutic composiitons comprising bactericidal/permeability-increasing (bpi) protein products: Improved therapeutic compositions having enhanced anti-microbial activity comprising a bactericidal/permeability-increasing (BPI) protein product and an bactericidal-activity enhancing polyoxyethylene block copolymer surfactant (poloxamer) surfactant or a bacterial and fungal growth-inhibiting enhancing poloxamer surfactant, optionally with EDTA, and methods for treating bacterial infection by administering such compositions, alone or concurrently with antibiotics.... Agent: Anne Dollard Xoma (us) LLC

20070185018 - Use of secretin in treatments of disorders associated with the amygdala: In general, the present invention provides methods for treating disorders associated with the amygdala. The methods of treatment are based on the administration of a therapeutically effective amount of secretin to an individual suffering from a disorder associated with the amygdala, e.g., bipolar disorder or a substance use disorder.... Agent: Clark & Elbing LLP

20070185030 - Immune response suppressor and treatment of multiple sclerosis: The present invention provides methods of treating multiple sclerosis, type 1 diabetes mellitus and other autoimmune diseases by administering a soluble immune response suppressor (SIRS) peptide or a variant thereof to an individual having such disease. The SIRS peptide or variant reduces the severity of or frequency of relapse of... Agent: Fulbright & Jaworski L.L.P.

20070185032 - Pharmaceutical formulations for sustained drug delivery: Sustained delivery formulations comprising a water-insoluble complex of a peptidic compound (e.g., a peptide, polypeptide, protein, peptidomimetic or the like) and a carrier macromolecule are disclosed. The formulations of the invention allow for loading of high concentrations of peptidic compound in a small volume and for delivery of a pharmaceutically... Agent: Lahive & Cockfield, LLP

20070185031 - Reducing polyglutamine-based aggregation: The disclosure features, inter alia, methods for treating or preventing neurodegenerative disorders and disorders that caused at least in part by polyglutamine aggregation. The method can include reducing activity of the IGF-1/GH axis in a subject. One exemplary neurodegenerative disorder that is also caused at least in part by polyglutamine... Agent: Fish & Richardson PC

20070185034 - Crystalline form of a drug: Ac-Sar-Gly-Val-D-allo-Ile-Thr-Nva-Ile-Arg-ProNHCH2CH3 Crystalline Form 1, ways to make it, compositions containing it and methods of treatment of diseases and inhibition of adverse physiological events using it are disclosed.... Agent: Robert Deberardine Abbott Laboratories

20070185033 - Pharmaceutical formulations for sustained drug delivery: Sustained delivery formulations comprising a water-insoluble complex of a peptidic compound (e.g., a peptide, polypeptide, protein, peptidomimetic or the like) and a carrier macromolecule are disclosed. The formulations of the invention allow for loading of high concentrations of peptidic compound in a small volume and for delivery of a pharmaceutically... Agent: Lahive & Cockfield, LLP

20070185035 - Enhanced mucosal administration of neuroprotective peptides: A formulation for intranasal delivery of a neuroprotective peptide, comprising an aqueous mixture of a peptide having the sequence NAPVSIPQ or a pharmaceutically acceptable salt thereof, a solubilizing agent, a chelator, and a surface active agent. The formulation can contain a peptide salt or mucosal delivery-enhancing agent which increases the... Agent: Nastech Pharmaceutical Company Inc

20070185036 - Ester derivatives of rhein and their therapeutic use: Compounds that may have anti-inflammatory activity are of general formula (I); wherein X1, is H or COR1, and X2 is H or COR2 but X1, and X2 are not both H; R1 and R2 are the same or different and are each C1-4 alkyl substituted with R3, or a four... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070185039 - Novel galactoside inhibitors of galectins: The present invention relates to novel compounds and the use of said compounds as a medicament, as well as for the manufacture of a medicament for treatment of disorders relating to the binding of galectin to receptors in a mammal. Said galectin is preferably galectin-3.... Agent: Gauthier & Connors, LLP

20070185038 - Regulation of mammalian keratinous tissue using skin care actives: Personal care compositions comprising skin and/or hair care actives. Such compositions are useful for regulating the condition of mammalian keratinous tissue needing such treatments, particularly skin lightening. In accordance with one embodiment, there is provided a personal care composition comprising a safe and effective amount of a first active selected... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070185037 - Sulfated oligosaccharide derivatives: The invention relates to compounds which are polysulfated oligosaccharide derivatives having activity as inhibitors of heparan sulfate-binding proteins and inhibitors of the enzyme heparanase; methods for the preparation of the compounds; compositions comprising the compounds, and use of the compounds and compositions thereof for the antiangiogenic, antimetastatic, anti-inflammatory, antimicrobial, anticoagulant... Agent: Fish & Richardson P.C.

20070185040 - Guanidinium derivatives for improved cellular transport: Reagents and methods useful for the synthesis of conjugates comprising guanidinylated cyclic acetals are provided. Also provided are methods for increasing the cellular uptake of various therapeutic compounds and treatment modalities using these conjugates.... Agent: Dla Piper US LLP

20070185041 - Novel 3-triazolyl-galactoside inhibitors of galectins: The present invention relates to novel compounds, the use of said compounds as a medicament as well as for the manufacture of a medicament for treatment of disorders relating to the binding of galectin to receptors in a mammal. Said galectin is preferably a galectin-3.... Agent: Gauthier & Connors, LLP

20070185046 - Double strand compositions comprising differentially modified strands for use in gene modulation: The present invention provides double stranded compositions wherein each strand is modified to have a motif defined by positioning of β-D-ribonucleosides and sugar modified nucleosides. More particularly, the present compositions comprise one strand having an alternating motif and another strand having a hemimer motif, a blockmer motif, a fully modified... Agent: Woodcock Washburn LLP

20070185047 - Double strand compositions comprising differentially modified strands for use in gene modulation: The present invention provides double stranded compositions wherein each strand is modified to have a motif defined by positioning of β-D-ribonucleosides and sugar modified nucleosides. More particularly, the present compositions comprise one strand having an alternating motif and another strand having a hemimer motif, a blockmer motif, a fully modified... Agent: Woodcock Washburn LLP

20070185050 - Double-stranded rna (dsrna) and method of use for inhibiting expression of a fusion gene: The present invention relates to the specific inhibition of expression of a fusion gene in mammals using a short double stranded RNA. The dsRNA is approximately 19-24 nucleotides in length, and has a nucleotide sequence which is complementary to at least a part of the target gene. The dsRNAs of... Agent: Fish & Richardson PC

20070185045 - Inhibitors of 2-oxoglutarate dioxygenase as gamma globin inducers: The present invention provides methods for increasing endogenous globin expression in a subject, specifically γ-globin expression. The invention also provides compounds and medicaments for use in the methods. The methods are particularly useful for increasing fetal hemoglobin production in a subject, and can be used to treat various disorders, e.g.,... Agent: Wilmer Cutler Pickering Hale And Dorr LLP

20070185044 - Modulation of ace2 expression: Compounds, compositions and methods are provided for modulating the expression of ACE2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding ACE2. Methods of using these compounds for modulation of ACE2 expression and for diagnosis and treatment of diseases and conditions associated with expression of ACE2 are provided.... Agent: Knobbe, Martens, Olson & Bear, LLP

20070185048 - Protein disulfide isomerase and abc transporter homologous proteins involved in the regulation of energy homeostasis: The present invention discloses three novel proteins regulating the energy homeostasis and the metabolism of triglycerides, and polynucleotides, which identify and encode the proteins disclosed in this invention. The invention also relates to vectors, host cells, antibodies, and recombinant methods for producing the polypeptides and polynucleotides of the invention. The... Agent: Sutherland Asbill & Brennan LLP

20070185049 - Rna interference mediated inhibition of histone deacetylase (hdac) gene expression using short interfering nucleic acid (sina): The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, disease and conditions that respond to the modulation of histone deacetylase (HDAC) gene expression and/or activity. The present invention is also directed to compounds, compositions, and methods relating to traits, diseases and conditions... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070185043 - Rna interference mediated inhibition of nogo and nogo receptor gene expression using short interfering nucleic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating NOGO and/or NOGO receptor gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of NOGO and/or NOGO... Agent: Mcdonnell, Boehnen, Hulbert And Berghoff, LLP

20070185042 - Sirna based methods for treating alzheimer's disease: The present invention relates to siRNA molecules derived from BACE1 and BACE2 genes. Accordingly, provided herein are siRNA molecules comprising a nucleotide sequence consisting essentially of a BACE1 or BACE2 gene. Also provided are methods for reducing the level of BACE1 protein in a cell. Further provided are methods for... Agent: Foley Hoag, LLP Patent Group (w/huv Hmv)

20070185051 - Partial and full agonists of a1 adenosine receptors: e

20070185052 - Use of lipid conjugates in cystic fibrosis and applications thereof: wherein L is a lipid or a phospholipid, Z is either nothing, ethanolamine, serine, inositol, choline, or glycerol, Y is either nothing or a spacer group ranging in length from 2 to 30 atoms, X is a physiologically acceptable monomer, dimer, oligomer, or polymer, wherein X is a glycosaminoglycan; and... Agent: Pearl Cohen Zedek Latzer, LLP

20070185053 - Single-dose needle-free administration of antithrombotic medications: An antithrombotic drug is administered by a needle-free injection device for prevention or treatment of venous thromboembolism. In an embodiment, the needle-free injection device is a pre-filled, single-use, disposable device with antithrombotic medication and labeled regarding drug, dose and time of delivery.... Agent: Bozicevic, Field & Francis LLP

20070185054 - Novel parenteral carbamazepine formulation: The present invention is directed to a carbamazepine-cyclodextrin inclusion complex useful for the parenteral administration of carbamazepine. The carbamazepine-cyclodextrin inclusion complex is prepared by the admixture of a modified cyclodextrin and carbamazepine in a physiologically acceptable fluid. Modified cyclodextrins include 2-hydroxypropyl-beta-cyclodextrin and sulfoalkyl cyclodextrins. More particularly, the sulfoalkyl cyclodextrins are... Agent: Patent Administrator Katten Muchin Rosenman LLP

20070185059 - Antiallergic agents: wherein X represents a connecting group whose number of atoms in the main chain is 2 to (said connecting group may be substituted), A represents hydrogen atom or acetyl group, E represents an aryl group which may be substituted or a hetero aryl group which may be substituted, ring Z... Agent: Greenblum & Bernstein, P.L.C

20070185056 - Indane modulators of glucocorticoid receptor, ap-1, and/or nf/kb activity and use thereof: or enantiomers, diastereomers, or a pharmaceutically-acceptable salt, or hydrate, thereof, where X is -A1QA2-; Q is a bond, —C(═O)—, —OC(O)—, —C(═O)NR5—, —SOp—, —SOpNR5—, —C(O)O—, —NR5C(O)—, —OC(O)NR5—, —NR5C(O)O—, —S(O)pNR5C(O)—, —C(O)NR5S(O)p— —NR5S(O)p—, or —NR5C(═O)NR6—. Y is selected from hydrogen, C1-4alkyl, OR16, substituted C1-6alkyl, cycloalkyl, aryl, heterocyclo and heteroaryl. A1 and A2 are... Agent: Louis J. Wille Bristol-myers Squibb Company

20070185057 - Novel indanone compounds: Novel indanylidene compounds can be used as UV-A filters in cosmetic compositions for protecting skin and hair and for technical applications.... Agent: Akerman Senterfitt

20070185060 - Boronic acid thrombin inhibitors: A thrombin inhibitor selected from boronic acids of formula (I), and salts, prodrugs and prodrug salts thereof: wherein X is H (to form NH2) or an amino-protecting group; aa1 is an amino acid residue having a side chain selected from formula (A) and (B)—(CO)a—(CH2)b-Dc-(CH2)d-E (A), —(CO)a—(CH2)b-Dc-Ce(E1)(E2)(E3) wherein E1, E2 and... Agent: Klarquist Sparkman, LLP

20070185061 - Heterocyclic boronic acid compounds: wherein n is 1 to 3; X is CH2; S; O; CF2 or C(CH3)2; Z is H; halogen; hydroxyl; (C1-6)alkoxy; (C1-12)alkyl; (C3-12)cycloalkyl; phenyl; or heteroaryl; where the phenyl and heteroaryl groups are optionally mono- or independently plurisubstituted with R7; optionally, X together with an adjacent ring carbon and Z form... Agent: Schwegman, Lundberg, Woessner & Kluth, P.A.

20070185064 - 2-aminopurine analogs having hsp90-inhibiting activity: 2-Aminopurine analogs are described and demonstrated or predicted to have utility as Heat Shock Protein 90 (HSP90) inhibiting agents in the treatment and prevention of various HSP90 mediated disorders, e.g., proliferative disorders. Method of synthesis and use of such compounds are also described and claimed.... Agent: Wilson Sonsini Goodrich & Rosati

20070185062 - Phosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production: The present invention relates to novel phosponate nucleosides, more specifically to novel phosponalkoxy substituted nucleosides. The invention further relates to compounds having HIV (Human Immunodeficiency Virus) replication inhibiting properties and to compounds having antiviral activities with respect to other viruses. The invention also relates to methods for preparation of all... Agent: Clark & Elbing LLP

20070185063 - Seven-membered ring nucleosides: The present invention provides nucleoside analogue compounds that treat a host infected with a Flaviviridae virus infection, or other viruses that exhibit RNA-dependent RNA viral replication, compositions comprising these compounds and methods of using the compounds for the treatment and/or prophylaxis of viral infection, especially hepatitis C, in an infected... Agent: Jones Day

20070185065 - Combination therapy for coronary artery disease: A combination therapy and methods for administering the combination therapy is provided that reduces mortality or morbidity of coronary artery disease (CAD) or coronary artery disease equivalents in individuals. The combination therapy can be administered to an individual in various forms, and the therapy is a medicament combining an anti-platelet... Agent: Boyle Fredrickson Newholm Stein & Gratz, S.c.

20070185066 - Systems and methods for the delivery of corticosteroids: The present invention relates to methods and systems for the delivery of a corticosteroid comprising (1) an inhalable aqueous mixture comprising a corticosteroid and a solubility enhancer and (2) an inhalable nebulizer, wherein the delivery of the aqueous mixture comprising the corticosteroid by the nebulizer results in an enhanced pharmacokinetic... Agent: Wilson Sonsini Goodrich & Rosati

20070185067 - Ciclesonide and glycopyrronium combination: The invention relates to pharmaceutical formulations containing combinations of ciclesonide and a pharmaceutically acceptable salt of glycopyrronium and the use of such pharmaceutical compositions in medicine, in particular in the prophylaxis and treatment of respiratory disease.... Agent: Nath & Associates PLLC

20070185068 - Use of sex steroid function modulators to treat wounds and fibrotic disorders: The present application relates to the use of compounds that influence the sex hormone system for the treatment of wounds and/or fibrotic disorders. Preferred compounds for use in such treatments are steroid hormones and especially the oestrogens.... Agent: Nixon & Vanderhye, PC

20070185069 - Anti-angiogenic activity of 2-methoxyestradiol in combination with anti-cancer agents: The present invention relates generally to methods and compositions of treating disease characterized by abnormal cell proliferation and/or abnormal or undesirable angiogenesis by administering antiangiogenic agents in combination with chemotherapeutic agents. More specifically, the present invention relates to a methods and compositions of treating diseases characterized by abnormal cell proliferation... Agent: King & Spalding LLP

20070185070 - Novel ppar ligands that do not cause fluid retention, edema or congestive heart failure: Methods are provided for treating or prophylactically preventing metabolic disorders in humans without causing, promoting, or aggravating fluid retention, peripheral edema, pulmonary edema, or congestive heart failure, by administration of a therapeutically effective amount of a compound sufficient to partially or fully activate peroxisome proliferator activated receptors (PPARs) and partially... Agent: Morrison & Foerster LLP

20070185071 - Histone deacetylase inhibitor and process for producing the same: HDAC inhibitors represented by formula (1) show strong inhibitory activity against various subtypes of HDACs. The compounds of the present invention find utility as pharmaceutical agents for treating or preventing diseases associated with HDAC 1, 4, and 6. The methods for producing the compounds of the present invention enable easy... Agent: Fish & Richardson P.C.

20070185072 - Nitrogeneous polycyclic derivatives useful as chelators of metal ions and their applications: The invention relates to the use of nitrogeneous polycyclic derivatives for preparing drugs for treating neurodegenerative diseases,... Agent: Nixon & Vanderhye, PC

20070185073 - Pyrrolobenzodiazepines: A compound of formula (I) and salts and solvates thereof, wherein: R10 is a nitrogen protecting group and R11 is either OH or O—R12, wherein R12 is an oxygen protecting group, or R10 and R11 together form a double bond between N10 and C11; and R10′ and R11′ are selected... Agent: Michael Best & Friedrich, LLP

20070185074 - Synthetic molecules that specifically react with target sequences: The present invention features biarsenical molecules. Target sequences that specifically react with the biarsenical molecules are also included. The present invention also features kits that include biarsenical molecules and target sequences. Tetraarsenical molecules are also featured in the invention.... Agent: Townsend And Townsend And Crew, LLP

20070185076 - Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial inections: A method and a composition for treatment of pulmonary bacterial infections caused by gram-negative bacteria suitable for treatment of infection caused by Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, Serratia marcescens as well as those caused by Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans,... Agent: Peters Verny , L.L.P.

20070185077 - Methods of treating, preventing and inhibiting cancer metastasis and tumor formation: Disclosed are methods for treating, preventing or inhibiting tumor cell metastasis, tumor cell formation, and destroying tumors in a subject comprising administering to the subject in need of such therapy a therapeutically effective amount of an activated aIIbβ3 receptor antagonist and by transplanting affected bone marrow with β3−/−marrow or controlling... Agent: Sonnenschein Nath & Rosenthal LLP

20070185075 - Pyrimidine derivatives: s

20070185078 - Substituted triazole derivatives as oxytocin antagonists: This invention relates to compounds of formula (I)... Agent: Pfizer Inc.

20070185080 - Pharmaceutical compositions: The present invention provides methods of treatment with a pharmaceutical composition, more particularly a sustained release pharmaceutical composition, comprising 11-[4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl]dibenzo-[b,f][1,4]thiazepine or a pharmaceutically acceptable salt thereof, as well as new and improved methods for treating a variety of psychological disorders and conditions including, but not limited to, Mood Disorders and... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20070185079 - Therapeutic agents i: Compounds of formula(I), processes for preparing such compounds, their use in the treatment of obesity, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy, and related conditions, and neurological disorders such as dementia, multiple sclerosis, Parkinson's disease, Huntington's chorea and Alzheimer's disease and pain related disorders, and pharmaceutical compositions containing them.... Agent: Pepper Hamilton LLP

20070185081 - Bicyclic heterocylces, pharmaceutical compositions containing these compounds, their use and processes for preparing them: Ra, Rb, Rc, Rd, Re and X are defined as in claim 1, the tautomers, the stereoisomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids, which have valuable pharmacological properties, particularly an inhibitory effect on signal transduction mediated by tyrosine... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070185082 - Treating rhinitis by topically administering an epinastine solution to the nasal mucous membrane: A method for treating allergic rhinitis, comprising topically administering to the nasal mucus membrane of a host in need of such treatment a solution comprising: epinastine, optionally in the form of its racemate, its enantiomers, or its pharmacologically acceptable acid addition salts, in a pharmacologically acceptable carrier.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070185083 - Hcv ns5b inhibitors: The invention encompasses compounds of Formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.... Agent: Louis J. Wille Bristol-myers Squibb Company

20070185084 - Compositions of an anticonvulsant and methods of using the same for reversing weight gain: Disclosed are compositions for reversing weight gain comprising a first compound and a second compound, where the first compound is an anticonvulsant and the second compound is a psychotherapeutic agent.... Agent: Knobbe Martens Olson & Bear LLP

20070185085 - Noribogaine in the treatment of pain and drug addiction: The present invention is directed to methods of treating patients for pain by administering noribogaine. Noribogaine may also be used to treat patients for the symptoms associated with withdrawal from drug dependency. In the latter case, the noribogaine treatment should be supplemented with the administration of an opioid antagonist such... Agent: Henry D. Coleman

20070185086 - Pharmaceutical compositions and methods for effecting dopamine release: Patients susceptible to or suffering from disorders, such as central nervous system disorders, which are characterized by an alteration in normal neurotransmitter release, such as dopamine release (e.g., Parkinsonism, Parkinson's Disease, Tourette's Syndrome, attention deficient disorder, or schizophrenia), are treated by administering a 1-aza-2-(3-pyridyl)bicyclo[2.2.1]heptane, a 1-aza-2-(3-pyridyl)bicyclo[2.2.2]octane, a 1-aza-2-(3-pyridyl)bicyclo[3.2.1]octane, a 1-aza-2-(3-pyridyl)bicyclo[3.2.2]nonane,... Agent: Womble Carlyle Sandridge & Rice, PLLC

20070185087 - Compounds and methods for inhibiting mitotic progression: This invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer.... Agent: Millennium Pharmaceuticals, Inc.

20070185088 - M3 muscarinic acetylchoine receptor antagonists: Muscarinic Acetylcholine receptor antagonists and methods of using them are provided.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070185089 - Benzazepine derivatives for the treatment of neurological and psychiatric disorders: The present invention relates to novel benzazepine derivatives of formula (I); wherein: R1 represents —C3-7 cycloalkyl optionally substituted by C1-3 alkyl; R2 represents -aryl, -heterocyclyl, heteroaryl, -aryl-X—C3-8 cycloalkyl, cycloalkyl, -aryl-X-aryl, -aryl-X-heteroaryl, -aryl-X-heterocyclyl, -heteroaryl-X—C3-8 cycloalkyl, -heteroaryl-X-aryl, -heteroaryl-X-heteroaryl, -heteroaryl-X-heterocyclyl, -heterocyclyl-X—C3-8 cyclooalkyl, -heterocyclyl-X-aryl, -heterocyclyl-X-heteroaryl or -heterocyclyl-X-heterocyclyl; X represents a bond, O, CO, —CH2O—,... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070185090 - Muscarinic acetylchoine receptor antagonists: Muscarinic Acetylcholine receptor antagonists and methods of using them are provided.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070185091 - Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them: Ra to Rc, A to E and X are defined as in claim 1, the tautomers, stereoisomers and salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable pharmacological properties, in particular an inhibitory effect on signal transduction mediated by tyrosine kinases,... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070185092 - Factor xa inhibitors: The present invention is directed to compounds represented by Formula (I) or a pharmaceutically acceptable salt, ester, or prodrug thereof which are inhibitors of Factor Xa. The present invention is also directed to and intermediates used in making such compounds, pharmaceutical compositions containing such compounds, methods to prevent or treat... Agent: Foley & Lardner LLP

20070185093 - Benzotriazepine derivatives and their use as gastrin and cholecystokinin receptor ligands: This invention relates to a compound of formula (I). The compound is useful for the treatment of gastrin related disorders.... Agent: Proskauer Rose LLP

20070185095 - Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists: The present invention is directed to compounds of formula: (I); wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, R1, R2, R3, R4, and n are as defined for formula I in the description. The invention also relates to processes for the preparation of the compounds and to... Agent: Birch, Stewart, Kolasch & Birch, LLP

20070185097 - Melanin concentrating hormone receptor-1 antagonists: wherein R1a, R1b, R1c, Q, A, R3, W, D and R2 are defined herein. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from... Agent: Louis J. Wille Bristol-myers Squibb Company

20070185094 - Novel 3-substitued-1,4-benzodiazepines: The present invention relates to compounds of formula (I). The invention also relates to methods for preparing the compounds and their uses as CCK receptor ligands and CCK antagonists.... Agent: Synnestvedt Lechner & Woodbridge LLP

20070185096 - Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the rsv fusion protein: A pharmaceutical composition which comprises a pharmaceutically acceptable carrier or diluent and: (a) an inhibitor of the RSV fusion protein; and (b) a benzodiazepine derivative capable of inhibiting RSV replication is found to be highly active against RSV.... Agent: Lahive & Cockfield, LLP

20070185098 - Inhibitors of protein kinases: wherein R1, R2, R3, R4, G, and Q are defined herein. The compounds of the present invention are useful as inhibitors of protein kinases. The present invention is also directed to compositions comprising a compound according to the above formula. The present invention is also directed to compounds that stabilize... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070185099 - Triazolopyrimidine compounds and their use for controlling pathogenic fungi: The present invention furthermore provides the use of the triazolopyrimidine compounds of the formula I, their tautomers and their agriculturally acceptable salts for controlling phytopathogenic fungi (=harmful fungi) and a method for controlling phytopathogenic harmful fungi, which method comprises treating the fungi or the materials, plants, the soil or seed... Agent: Birch Stewart Kolasch & Birch

20070185100 - Poly-heterocyclic compounds and their use as metabotropic glutamate receptor antagonists: The present invention relates to new compounds of formula (I), wherein P, Q, X1, X2, X3, X4, X5, X6, R1, R2, R3, m, n, and p are as defined as in formula (I), or salts, or hydrates thereof, processes for their preparation and new intermediates used in the preparation thereof,... Agent: Birch, Stewart, Kolasch & Birch, LLP

20070185101 - Antiparasitic terpene alkaloids: The present invention relates to novel terpene alkaloids and their use as antiparasitic agents. The present invention also relates to an antiparasitic agent which comprises a terpene alkaloid compound of this invention as an effective ingredient in an, antiparasitic formulation. More particularly, the present invention relates to derivatives of the... Agent: Pharmacia & Upjohn

20070185102 - Mineralocorticoid receptor modulator compounds and methods, and pharmaceutical compositions containing these compounds: This invention relates to compounds that bind to mineralocorticoid receptors and/or modulate activity of mineralocorticoid receptors, and to methods for making and using such compounds.... Agent: Knobbe Martens Olson & Bear LLP

20070185103 - Beta-secretase modulators and methods of use: wherein A, B, R3, R4, R5, i and j are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, methods of use for these compounds, including treatment of AD and related diseases, by administering the compound(s) of Formula I, or compositions including them,... Agent: Amgen Inc.

20070185104 - Benzoxazole acetonitriles: The present invention is related to benzoxazole acetonitriles as well as to pharmaceutical formulations containing such benzoxazole acetonitriles pof formula (I). Said benzoxazole acetonitriles are useful in the treatment of metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type II, inadequate glucose tolerance, insulin resistance, obesity, polycystic ovary... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070185105 - Calcium channel blockers: with the proviso that Y is not a tropolone, a coumarin, or an antioxidant containing an aromatic group and with the further proviso that if 13 is 0, and either 11 and 12 is 0 or 1 and if R1 and/or R2 represent F in the para position, Z cannot... Agent: Morrison & Foerster LLP

20070185107 - Chroman compounds: t

20070185106 - Pyrrole derivatives as gonadotropin releasing hormone (gnrh) antagonists: The invention relates to a group of novel thieno-pyrrole compounds of formula (I) wherein: R1, R2, R3, R4 M, and R5 are as defined in the specification, as inter alia, gonadotrophin releasing hormone antagonists. Novel compounds of formula (I) are also claimed. The invention also relates to pharmaceutical formulations of... Agent: Astrazeneca R&d Boston

20070185110 - Antiallergic agents: wherein X represents a connecting group whose number of atoms in the main chain is 2 to 5 (said connecting group may be substituted), A represents hydrogen atom or acetyl group, E represents an aryl group which may be substituted or a hetero aryl group which may be substituted, ring... Agent: Greenblum & Bernstein, P.L.C

20070185109 - Idene derivatives and process for the preparation thereof: The inventive indene derivatives of formula (I) are capable of selectively modulating the activities of peroxisome proliferator activated receptors (PPARs), causing no adverse side effects, and thus, they are useful for the treatment and prevention of disorders modulated by PPARs, i.e., metabolic syndromes such as diabetes, obesity, arteriosclerosis, hyperlipidemia, hyperinsulinism... Agent: Anderson, Kill & Olick, P.C.

20070185108 - Process of obtaining taxosteroids and precursors thereof: The present invention relates to a process of obtaining taxosteroids and precursors thereof from the hydrindane bicyclic ring system. The compounds have a tetracyclic system which combines the structural characteristics of taxanes, such as the bicyclo[5.3.1]undecane system (cycles A and B), fused to a six-membered ring (C), and of steroids,... Agent: Merchant & Gould PC

20070185111 - Aurora kinase modulators and method of use: wherein A1, A2, C1, C2, D, L1, L2, Z and R1- are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating... Agent: Amgen Inc.

20070185112 - Piperidine/piperazine-type inhibitors of p38 kinase: Piperazine compounds and methods for treating conditions mediated by p38-α kinase are disclosed.... Agent: Morrison & Foerster LLP

20070185113 - Heteroaryl and benzyl amide compounds: p

20070185114 - Novel use for pde5 inhibitors: The present invention is concerned with the use of PDE5 inhibitors in medicine.... Agent: Nath & Associates PLLC

20070185116 - Bicyclic compounds: R5 and R6 may be the same or different from each other, and each is hydrogen, an optionally substituted alkyl, etc., or a pharmaceutically acceptable salt thereof, which is a large conductance calcium-activated K channel opener useful for treatment of pollakiuria, urinary incontinence, etc.... Agent: Birch Stewart Kolasch & Birch

20070185115 - Novel ureido-and amido-pyrazolone derivatives: The present invention provides compounds of formula (I); wherein each of R1 to R4 is independently selected from hydrogen, a halogen, a substituted or unsubstituted cyclic and heterocyclic moiety, substituted or unsubstituted, linear or branched alkyl, alkyloxy, alkylcarbonyl, alkyloxycarbonyl, alkenyl, alkenyloxy, alkenylcarbonyl, alkenyloxycarbonyl, alkynyl, alkynyloxy, alkynylcarbonyl, alkynyloxycarbonyl, aryl, benzyl, arlyoxy,... Agent: Synnestvedt Lechner & Woodbridge LLP

20070185120 - Heterocyclic compounds: Certain thienopyrrolyl and furanopyrrolyl compounds are disclosed as useful to treat or prevent disorders and conditions mediated by the histamine H4 receptor, including allergic rhinitis.... Agent: Philip S. Johnson Johnson & Johnson

20070185117 - Novel 14 and 15 membrered ring compounds: r

20070185119 - Therapeutic agents ii: Compounds of Formula (I) as well as optical isomers and racemates thereof as well as pharmaceutically acceptable salts, thereof, processes for preparing such compounds, their use in the treatment of obesity, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy, and related conditions, and neurological disorders such as dementia, multiple sclerosis,... Agent: Pepper Hamilton LLP

20070185118 - Use of methylene amide derivatives in cardiovascular disorders: The present invention is related to the use of substituted methylene amide derivatives of Formula (I) for the treatment and/or prevention of cardiovascular disorders such as coronary obstruction and heart failure. In particular, the present invention is related to the use of substituted methylene amide derivatives of Formula (I) in... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070185121 - Heterocyclyl-substituted dihydroquinazolines and their use as antiviral agents: e

20070185123 - Novel compounds useful for modulating abnormal cell proliferation: wherein: R1, R2 and R3 are each independently selected from OH, C1-6alkyl, OC1-6alkyl, OC(O)C1-6alkyl, C(O)OC1-6alkyl, NH2, NH—C1-6alkyl, N(C1-6alkyl)(C1-6alkyl), C(O)NHC1-6alkyl, C(O)N(C1-6alkyl)(C1-6alkyl), SH, SC1-6alkyl, NO2, CF3, OCF3 and halogen; and Ar is an aromatic or heteroaromatic group chosen from benzene, naphthalene, quinoline, isoquinoline, indole, pyridine, pyrasine, pyrimidine, imidazole, furan and thiophene, unsubstituted... Agent: Gowling Lafleur Henderson LLP

20070185122 - Use of efletirizine for treating persistent allergic rhinitis: The present invention relates to a pharmaceutical use of efletirizine for the treatment of persistent allergic rhinitis.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070185124 - Cancer treatment with topoisomerase-ii inhibitor, a bis-dioxypiperazine and radiation: The present invention relates to a method of treatment of a tumour cell which comprises administering to a subject in need of treatment an effective amount of a topoisomerase-II poison, e.g. etoposide, in combination with a bis-dioxypiperazine, e.g. dexrazoxane wherein said subject is further treated with radiation.... Agent: Nixon & Vanderhye, PC

20070185125 - Pyridones useful as inhibitors of kinases: The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.... Agent: Vertex Pharmaceuticals Inc.

20070185127 - 2-(arylalkoxy)-1-phenylethylamine derivatives as nk1 antagonist and serotonin reuptake inhibitors: Compounds of the following formula (I) wherein R1 R2, n, A1 and A2 are as defined in the specification, in vivo-hydrolysable precursors thereof, pharmaceutically acceptable salts thereof, the use in therapy and pharmaceutical compositions and methods of treatment using the same. The example compounds are 1-(2-(naphthylmethoxy)-1-phenylethyl)piperazine derivatives. The compounds are... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20070185126 - Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them: The present invention relates to novel 1,3-dihydroindol-2-one (oxindole) derivatives of the formula (I) in which A, R3, R4, R5 R6 and R7 are defined according to claim 1, and to medicaments containing them for the treatment of diseases. In particular, the novel oxindole derivatives can be used for the control... Agent: Wood, Phillips, Katz, Clark & Mortimer

20070185129 - Acid addition salts of thienopyrancarboxamide derivatives: The invention relates to novel addition salts of N-{3-[4-(2-Methoxyphenyl)-1-piperazinyl]propyl}-7-oxo-5-trifluoromethyl-7H-thieno[3,2-b]pyran-3-carboxamide, comprising N-{3-[4-(2-Methoxyphenyl)-1-piperazinyl]propyl}-7-oxo-5-trifluoromethyl-7H-thieno[3,2-b]pyran-3-carboxamide and an acid counterion wherein the acid counterion is selected from the group consisting of: (i) inorganic acids and (ii) sulfonic acids.... Agent: Darby & Darby P.C.

20070185128 - Compounds and compositions for treating obesity: Compounds of this invention can advantageously exhibit melanocortin receptor agonist activity. New and useful compounds comprising such a chemical structure and methods of modulating melanocortin receptor activity in a subject (and promoting, inducing, and/or enhancing the treatment or prevention of related diseases) by administering such a compound or composition also... Agent: Novo Nordisk, Inc. Patent Department

20070185130 - Compounds for inhibiting beta-amyloid production and methods of identifying the compounds: Provided are compounds useful for treating diseases associated with a cerebral accumulation of Alzheimer's amyloid, such as Alzheimer's disease. Also provided are methods for screening for such compounds, by measuring capacitative calcium entry in cells which optionally overexpress APP or a fragment thereof. Also provided are methods of treating or... Agent: King & Spalding LLP

20070185131 - Heterocyclic compounds: Certain thienopyrrolyl and furanopyrrolyl compounds are disclosed as useful to treat or prevent disorders and conditions mediated by the histamine H4 receptor, including allergic rhinitis.... Agent: Philip S. Johnson Johnson & Johnson

20070185133 - Aminopyrimidine compounds and methods of use: The invention relates to aminopyrimidine compounds useful for treating diseases mediated by polo-like kinase 1 (Plk1). The invention also relates to the therapeutic use of such aminopyrimidine compounds and compositions thereof in treating disease states associated with abnormal cell growth and unwanted cell proliferation.... Agent: Amgen Inc.

20070185132 - Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereo: e

20070185137 - Derivatives of 5-(pyridin-3-yl)-1-azabicyclo[3.2.1]octane, their preparation and their therapeutic application:

20070185135 - Drug-polymer conjugates: This invention relates to a polypeptide-polymer conjugate that includes a polypeptide moiety, a polyalkylene oxide moiety, a linker connecting the polypeptide moiety with the polyalkylene oxide moiety, a first linkage between the polypeptide moiety and the linker, and a second linkage between the polyalkylene oxide moiety and the linker.... Agent: Occhiuti Rohlicek & Tsao, LLP

20070185134 - Inhibitors of cyclin dependent kinases as anti-cancer agent: The present invention relates to 2-substituted 4-heteroaryl-pyrimidines, their preparation, pharmaceutical compositions containing them and their use as inhibitors of cyclin-dependent kinases (CDKs) and hence their use in the treatment of proliferative disorders such as cancer, leukaemia, psoriasis and the like.... Agent: Lahive & Cockfield, LLP

20070185136 - Sulphonamide derivatives, their preparation and their therapeutic application: as defined herein, the preparation thereof, and the use thereof for the prophylaxis or treatment of any disease involving a dysfunction associated with the orexin 2 receptor such as obesity, appetite or taste disorders including cachexia, anorexia and bulimia, diabetes, metabolic syndromes, vomiting and nausea, depression and anxiety, addictions, mood... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070185138 - Imidazolopyrimidines used as fungicidal active ingredients:

20070185139 - Thiazolopyrimidine kinase inhibitors:

20070185140 - Novel purine derivatives, method for preparing them, their application as medicinal products, pharmaceutical compositions and novel use: R3 represents H, Hal, alkyl, cyano, NO2, NR4R5, trifluoromethyl or aryl, R2 represents R4, OR4, SR4 or NR4R5, R4 represents H, alkyl, cycloalkyl or aryl, either R4 and R5 are chosen from the values for R4, or R4 and R5 form, with N, a heterocyclic radical which may contain N,... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070185141 - Thiamine composition for enhancement of physical and mental energy, and related method: A composition that includes thiamine disulfide diisobutyrate and caffeine. Related methods also are provided.... Agent: Stephen T. Sullivan

20070185142 - Process for producing substituted aminoquinazolinone derivative, intermediate therefor, and pest control agent: A process for producing a substituted aminoquinazolinone derivative represented by the formula (I), characterized by reducing a substituted iminoquinazolinone derivative represented by the formula (II) with hydrogen in the presence of a catalyst and either of a halogen compound and a sulfur compound; a substituted iminoquinazolinone derivative represented by the... Agent: Manelli Denison & Selter

20070185143 - Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors: Pyrazolo-quinazoline derivatives of formula (Ia) or (Ib) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention maybe useful in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like... Agent: Scully, Scott, Murphy & Presser, P.C.

20070185144 - Beta-secretase modulators and methods of use: wherein A, B, W, R3, R4, R5, i and j are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, methods of use for these compounds, including treatment of AD and related diseases, by administering the compound(s) of Formula I, or compositions including... Agent: Amgen Inc.

20070185146 - Opioids for the treatment of the chronic obstructive pulmonary disease (copd): The present invention relates to an opioid controlled release oral dosage form comprising at least one opioid for the manufacture of a medicament to treat patients with Chronic Obstructive Pulmonary Disease (COPD).... Agent: Darby & Darby P.C.

20070185147 - Opioids for the treatment of the restless leg syndrome: The present invention relates to an opioid controlled release oral dosage form comprising at least one opioid for the manufacture of a medicament to treat patients with restless leg syndrome (RLS).... Agent: Darby & Darby P.C.

20070185145 - Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same: A pharmaceutical composition for treating or preventing a disease, condition or symptoms thereof in a warm-blooded animal including a human, includes a therapeutically effective amount of an opioid agonist exhibiting potential pharmacologically addictive properties in warm blooded animals including humans; a side-effect reducing agent present in amounts sufficient to at... Agent: Watov & Kipnes, P.C.

20070185148 - M3 muscarinic acetylchoine receptor antagonists: Muscarinic Acetylcholine receptor antagonists and methods of using them are provided.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070185149 - Novel amido-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibtors: s

20070185151 - Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane nmda, 5ht3 and neuronal nicotinic receptor antagonists: Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexanes which are systemically-active as NMDA, 5HT3, and nicotinic receptor antagonists, pharmaceutical compostions comprising the same, method of preparation thereof, and method of treating CNS disorders which involve disturbances of glutamatergic, serotoninergic, and nicotinic transmission, treating immunomodulatory disorders, and antimalaria, antitrypanosomal, anti-Borna virus, anti-HSV... Agent: The Firm Of Hueschen And Sage

20070185150 - Therapeutic methods: Disclosed are methods for treating a patient with an mTOR inhibitor such as AP23573, sirolimus, temsirolimus, everolimus, etc.... Agent: David L. Berstein Ariad Gene Therapeutics, Inc.

20070185152 - Inhibitors of akt activity: Invented are novel pyridine compounds, the use of such compounds as inhibitors of PKB/AKT kinase activity and in the treatment of cancer and arthritis.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070185153 - Compounds: Tricyclic nitrogen containing compounds and their use as antibacterials... Agent: Glaxosmithkline Corporate Intellectual Property-uw2220

20070185154 - Heterobicyclic amide compounds: i

20070185156 - 8-azabicyclo[3.2.1]octane derivatives: wherein each of the substituents is given the definition as set forth in the specification and claims, or a pharmaceutically acceptable salt thereof or solvate thereof. The present invention also relates to a pharmaceutical composition comprising an 8-azabicyclo[3.2.1]octane derivative in admixture with one or more pharmaceutically acceptable auxiliaries and to... Agent: Organon Usa, Inc. Patent Department

20070185155 - Muscarinic acetylcholine receptor antagonists: Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070185157 - Tropane derivatives useful in therapy: s

20070185158 - Indol-4 sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators: The present invention refers to new sulfonamide derivatives, of general formula (1a, 1b, 1c), optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemate, or in form of a mixture of at least two of their stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070185159 - Novel nitrogen-containing heteroaryl compounds and methods of use thereof: The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.... Agent: Foley & Lardner LLP

20070185160 - 1-(2h)-isoquinolone derivative: [wherein Y1 and Y4 represent a hydrogen atom or a halogen atom; either one of Y2 and Y3 represents —NR1R2, and the other represents a hydrogen atom or a halogen atom; X represents an aryl group or a heteroaryl group that may be substituted; R1 represents a hydrogen atom, or... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070185161 - Bicyclic substituted indole-derivative steroid hormone nuclear receptor modulators: The present invention provides a compound of the formula: Formula (I); or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising an effective amount of a compound of Formula I in combination with a suitable carrier, diluent, or excipient, and methods for treating physiological disorders, particularly congestive heart disease, hypertension, and... Agent: Eli Lilly & Company

20070185162 - Substituted diketopiperazines as oxytocin receptor antagonists: wherein R1 is 2-indanyl, R2 is 1-ethylpropyl, R3 is a heterocyclic group optionally substituted by one or more C1-6 alkyl groups, R4 represents methyl and R5 represents hydrogen or methyl and pharmaceutically acceptable derivatives thereof are described, as are processes for their preparation, pharmaceutical compositions containing them and their use... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070185163 - Imidazol derivatives of piperidine as histamine antagonists: e

20070185165 - N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase: The present invention is directed to N-hydroxyamidino compounds which are modulators of indoleamine 2,3-dioxygenase (IDO), as well as pharmaceutical compositions thereof and methods of use thereof relating to the treatment of cancer and other diseases.... Agent: Fish & Richardson PC

20070185164 - Process for producing an aromatic carbonate: A process for producing an aromatic carbonate, which comprises the steps of: (I) transesterifying a starting material selected from the group consisting of a dialkyl carbonate, an alkyl aryl carbonate and a mixture thereof with a reactant selected from the group consisting of an aromatic monohydroxy compound, an alkyl aryl... Agent: Birch Stewart Kolasch & Birch

20070185166 - Indolin-2-one pyridine derivatives, preparation and therapeutic use thereof: p

20070185167 - Sodium salts of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione: A compound 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione sodium salt, or a pharmaceutically acceptable solvate thereof, characterised in that the sodium salt is non-hygroscopic or slightly hygroscopic; a pharmaceutical composition containing such a compound and the use of such a compound in medicine.... Agent: Galaxosmithkline Corporate Intellectual Property - Uw2220

20070185168 - Piperidine derivatives: For example, a piperidine derivative represented by following formula (I) (wherein, —C(═O)-Z- represents —C(═O)—CH2—, —C(═O)—C(CH3)2—, —C(═O)—NH—, —C(═O)—O—, —C(═O)—S—, —C(═O)—CH2CH2—, —C(═O)—CH═CH—, —C(═O)—CH2O—, —C(═O)—CH2S—, —C(═O)—CH2CH2CH2— or —C(═O)—NR8CH2—; R1 represents a hydrogen atom, substituted or unsubstituted lower alkyl, or the like; R2 represents a hydrogen atom or hydroxy; R3 represents a hydrogen atom,... Agent: Antonelli, Terry, Stout & Kraus, LLP

20070185169 - 2-mercapto-4,5-diarylimidazole derivatives and the use thereof as cyclooxygenase inhibitors: The invention relates to the 2-mercapto-4,5-diarylimidazole derivatives of formula (I), wherein R1, R2, R3 and R4 are defined as in the description. The inventive compounds have an immunomodulatory and cyclooxygenase-inhibiting activity and are therefore suitable for the treatment of disease that are associated with a disturbed immune system.... Agent: Alston & Bird LLP

20070185170 - Derivatives of pyridine and quinoline: The invention provides compounds of formula I blocking phosphorylcholine biosynthesis by means of the selective blocking of the choline kinase enzyme in tumor cells or in cells affected by parasitic infection and therefore being applicable in the treatment of tumors and parasitic diseases or diseases produced by viruses and fungi... Agent: Moore & Van Allen PLLC

20070185171 - Compounds and methods of use: Selected compounds are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention... Agent: Amgen Inc.

20070185172 - Organic compounds: l

20070185173 - Process for the preparation of the salts of 4-(benzimidazolylmethylamino)-benzamides: The invention relates to a process for preparing a salt of an optionally substituted 4-benzimidazol-2-ylmethylamino)-benzamidine, characterised in that (a) an optionally correspondingly substituted diaminobenzene is condensed with 2-[4-(1,2,4-oxadiazol-5-on-3-yl)-phenylamino]-acetic acid, b) i) the product thus obtained is hydrogenated, ii) optionally the amidino group is carbonylated, without isolating the intermediate product of... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070185174 - Use of thiazole derivatives for preparing a medicament intended to protect the mitochondria: e

20070185175 - Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors:

20070185176 - Heparanase inhibitors and uses thereof: The invention provides heparanase inhibitors suitable for treatment of diseases and disorders caused by or associated with heparanase catalytic activity such as cancer, inflammatory disorders and autoimmune diseases.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070185177 - Metaxalone polymorphs: The invention provides two crystalline forms A and B of the skeletal muscle relaxant and anxiolytic agent, Metaxalone of formula (I), and a process for preparation thereof. The two crystalline forms A and B are bioavailable. The invention further provides pharmaceutical compositions comprising the two bioavailable crystalline forms, useful for... Agent: Merchant & Gould PC

20070185178 - Triazole compounds and their use as metabotropic glutamate receptor antagonists: The present invention relates to new compounds of formula (I), wherein P, Q, X1, X2, X3, X4, X7, X8, R1, R2, R3, m, n, and p are as defined as in formula (I), or salts, or hydrates thereof, processes for their preparation and new intermediates used in the preparation thereof,... Agent: Birch, Stewart, Kolasch & Birch, LLP

20070185179 - New compounds: e

20070185180 - Pharmaceutical formulation containing phenytoin sodium and magnesium stearate: The present invention relates to a novel pharmaceutical formulation comprising phenytoin sodium, a high amount of magnesium stearate, and a low level of a hydrophilic polymer such as a methocel, and a method of preparing the same by blending.... Agent: Taro Pharmaceuticals U.s.a., Inc. C/o Venable LLP

20070185181 - Treatment or prevention of hypotension and shock: A method for the prevention and treatment of hypotension and shock due to low peripheral resistance, comprising administering to a mammal in need thereof an effective amount of a certain imidazole derivative or pharmaceutically acceptable ester or salt thereof, and a method for the treatment of cardiopulmonary resuscitation, comprising administering... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070185182 - Heteroaryl carboxamide compounds: m

20070185183 - Indolinesulphanilic acid amides as ppar-delta modulators: The invention relates to novel indolin-sulfanilic acid amides of general formula (I), methods for the production thereof, and the use thereof in medicaments, especially as potent PPAR delta agonists for preventing and/or treating cardiovascular diseases, particularly dyslipidemia, arteriosclerosis, and coronary heart diseases.... Agent: Jeffrey M. Greenman

20070185184 - Carbazole derivatives: wherein n, R1, R2, R3, X, R4, R5, R6, R8, R9, and Y are as defined herein. Compounds of Formula I are useful in the treatment of diseases and/or conditions related to cell proliferation and/or abnormal cell mitosis, such as cancer, inflammation and inflammation-associated disorders, and conditions associated with angiogenesis.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070185186 - Compositions for the delivery of substituted napthyl indole derivatives and methods of their use: This invention relates to compositions for the delivery of substituted naphthyl indole derivatives as well as to the use of these compositions and methods for treating disease.... Agent: Woodcock Washburn LLP/wyeth

20070185185 - Derivatives of thienopyrrole as gnrh antagonists: The invention relates to a group of novel thieno-pyrrole compounds of Formula (I) wherein: R1, R2, R3, R4 are as defined in the specification, which compounds are useful as gonadotrophin releasing hormone antagonists. The invention also relates to pharmaceutical formulations of said compounds, methods of treatment using said compounds and... Agent: Astrazeneca R&d Boston

20070185188 - Bladder cancer treatment and methods: Disclosed herein are various bladder cancer treatments and methods. The present disclosure can take advantage of propylene glycol concentrations and/or NAD(P)H:quinone oxidoreductase-1 (NQO1), Cytochrome P450 Oxidoreductase (P450R) and Glucose transporter 1 (Glut-1) protein expression in human transitional cell carcinoma of the bladder to offer individually targeted bladder cancer treatments.... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP

20070185187 - Indazolecarboxamide derivatives for the treatment and prevention of malaria: The invention relates to methods of treating or preventing malaria which comprises administering to a patient in need thereof, an effective amount of a 1H-indazole-3-carboxamide derivative of general formula (I), in the form of a base or of an addition salt with an acid, or in the form of a... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070185190 - Agent or method for treating severe aphasia in cerebrovascular accident chronic stage: This relates to an agent or method for treating severe aphasia in cerebrovascular accident chronic stage, which comprises 2-oxo-1-pyrrolidineacetamide as an active ingredient.... Agent: Sughrue Mion, PLLC

20070185189 - Prolinylarylacetamides: Novel compounds of the formula (I), in which R, R1, R2, R3, X, X′ and Y have the meaning indicated in Patent Claim 1, are inhibitors of coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic diseases and for the treatment of tumours.... Agent: Millen, White, Zelano & Branigan, P.C.

20070185192 - Dnt-maleate and methods of preparation thereof: (S)-N,N-Dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine maleate (DNT-maleate) and polymorphs of DNT-maleate, compositions of DNT-maleate and its polymorphs, processes for the preparation of DNT-maleate and its polymorphs, and processes for the preparation of duloxetine hydrochloride from DNT-maleate are provided.... Agent: Kenyon & Kenyon LLP

20070185191 - Hydrazide derivatives as prostaglandin receptors modulators: The present invention relates to hydrazide derivatives of Formula I notably for use as pharmaceutically active compounds, as well as to pharmaceutical formulations containing such hydrazide derivatives. Said hydrazide derivatives are useful in the treatment of preterm labor, dysmenorrhea, fertility disorders, asthma, hypertension, undesired blood clotting, preelampsia, eclampsia, an eosinophil... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070185193 - Huvastatin and its preparation and formulation comprising the huvastatin: The invention relates to statin compounds, and it discloses novel small molecule compounds, i.e., huvastatins, which are classified into I, II, and III. The invention also provides the preparation methods thereof and the formulations comprising the huvastatin as active ingredient. The present compounds can be used at lower dosage compared... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20070185194 - Stable oral compositions of azithromycin monohydrate: The present invention relates to stable oral compositions of azithromycin monohydrate with reduced bitterness, processes for making these compositions, and methods of using these compositions for the treatment of microbial infections. The stable oral compositions of azithromycin include an azithromycin premix, at least one pharmaceutically accepted excipient, and, optionally, at... Agent: Ranbaxy Inc.

20070185195 - Medicinal compositions containing 6-hydroxybenzbromarone or salts thereof: [PROBLEMS] To provide highly safe therapeutic or preventive agents for hyperuricemia, more specifically uricosuric agents, which have potent uricosuric effect and do not cause grave hepatic disorder. [MEANS FOR SOLVING PROBLEMS] Medicinal compositions for the treatment or prevention of hyperuricemia or diseases caused by hyperuricemia, which contain 6-hydroxybenzbromarone or salts... Agent: Edwards Angell Palmer & Dodge LLP

20070185196 - Inhibitionof bid-induced cell-death using small organic moleculeus: Various phenylamine derivatives are described as well as the use of compounds to inhibit BID protein for controlling apoptotic cascade.... Agent: Dla Piper US LLP

20070185197 - Phenol derivative, medicinal composition containing the same, and medicinal use thereof: The present invention provides phenol derivatives represented by the following general formula or pharmaceutically acceptable salts thereof, or prodrugs thereof, which exhibit an inhibitory activity in human SGLT and are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, postprandial hyperglycemia, impaired... Agent: Sughrue Mion, PLLC

20070185198 - Composition and method for preventing recurrence of stroke: By using a composition for preventing onset and/or recurrence of stroke which contains ethyl icosapentate as its effective component, onset and/or recurrence of stroke is prevented, or in particular, the onset and/or recurrence of stroke in a hyperlipidemia patient who has been treated with HMG-CoA RI, or in particular the... Agent: Birch Stewart Kolasch & Birch

20070185199 - Pharmaceutical formulations: The present invention relates to oral formulations comprising an active agent comprising at least one of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid, salts of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid or buffered 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid.... Agent: Robert Deberardine Abbott Laboratories

20070185200 - Screen for pre-eclampsia: It has been demonstrated that the level of asymmetric dimethylarginine (ADMA) increases in women that subsequently develop pre-eclampsia or whose fetus subsequently develops intrauterine growth restriction (IUGR) and that ADMA plays a key role in the development of maternal hypertension. Accordingly, the level of ADMA in a pregnant woman can... Agent: Fulbright & Jaworski L.l.p

20070185201 - Compositions and methods for preventing or treating inflammatory bowel disease: Compositions comprising docosahexaenoic acid (DHA) and optionally one or more fatty acids selected from the group consisting of eicosapentaenoic acid (EPA), arachidonic acid (ARA), linoleic acid (LA), and α-linoleic acid (ALA) are administered to felines for preventing or treating feline inflammatory bowel disease (IBD).... Agent: Colgate-palmolive Company

20070185203 - Compositions and methods for treating diseases: This invention relates to compositions and methods for treatment of vascular conditions. The invention provides arginine polymers and arginine homopolymers for the treatment and/or prevention of glaucoma, pulmonary hypertension, asthma, chronic obstructive pulmonary disease, erectile dysfunction, Raynaud's syndrome, heparin overdose, vulvodynia, and wound healing. The invention also provides arginine polymers... Agent: Wilson Sonsini Goodrich & Rosati

20070185202 - Methods and compositions for ophthalmic treatment of fungal and bacterial infections: The present invention provides methods and compositions for use in the methods for contacting an eye of a patient with an effective amount of a therapeutic composition comprising a pharmaceutically acceptable chelating agent, a pharmaceutically acceptable pH buffering agent and an antimicrobial agent.... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20070185204 - Crystalline forms of 3-biphenyl-4-yl-(2s)-[(4'-trifluoromethyl-biphenyl-4-carbonyl)-amino]-propionic acid, and methods of use: The present invention relates to crystalline Forms of 3-biphenyl-4-yl-(2S)-[(4′-trifluoromethyl-biphenyl-4-carbonyl)-amino]-propionic acid. In one embodiment, the present invention provides polymorphic Forms I, II, and III of 3-biphenyl-4-yl-(2S)-[(4′trifluoromethyl-biphenyl-4-carbonyl)-amino]-propionic acid.... Agent: Kilpatrick Stockton LLP - 41305 Charles Calkins

20070185205 - Airway alkalinization as therapy for airway diseases: The present invention relates to a method of treating asthma by raising the pH of the airways of an individual. The effect can be mediated directly by administering a pharmaceutically acceptable basic solution or alternatively, the effect can be mediated by enhancing the activity of glutaminase.... Agent: Woods, Rogers, P.L.C

20070185206 - Method for preparing 15-keto-prostaglandin e derivative: Disclosed is an improved method for preparing 15-keto-prostaglandin E derivative. According to the invention, the deprotection of protected hydroxy group required in manufacturing a 15-keto-prostaglandin derivative is conducted under the presence of a phosphoric acid compound.... Agent: Sughrue Mion, PLLC

20070185207 - Indol-7 sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators: The present invention refers to new sulfonamide derivatives, of general formula (1a, 1b, ic), optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemate, or in form of a mixture of at least two of their stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070185208 - Amide compound: is used. In formula 1, R1, R2 and R3 are each independently a hydrogen atom or an alkyl group having a carbon number of from 1 to 3 with the proviso that at least one of R1, R2 and R3 is a hydrogen atom. R4, R5 and R6 are each... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070185209 - Treatment methods using triaryl methane compounds: The use of novel inhibitors of potassium flux is disclosed for the treatment of inflammatory processes, such as multiple sclerosis, insulin-dependent (type I) diabetes mellitus, rheumatoid arthritis, peripheral neuritis and pulmonary hypertension. The compounds are also of use in treating and preventing stroke. These inhibitors have a high specificity for... Agent: Morgan, Lewis & Bockius LLP (sf)

20070185210 - Compositions and methods for promoting fat loss: This invention provides diets useful for promoting fat loss in animals having a total lysine to metabolizable energy ratio of from about 6 to about 10 g/Mcal. This invention also provides compositions for promoting fat loss in animals, methods for preparing the compositions, methods for using the diets and compositions,... Agent: Colgate-palmolive Company

20070185211 - Crystal forms of cinacalcet hci and processes for their preparation: Provided are crystalline forms of cinacalcet HCl and processes for their preparation.... Agent: Kenyon & Kenyon LLP

20070185212 - Substituted amino compounds as 5-ht/na uptake inhibitors: The invention relates to substituted amino compounds, to processes for their preparation, to pharmaceutical formulations containing these compounds and to the use of these substances in the preparation of pharmaceutical formulations, especially for the treatment or inhibition of depression, anxiety, pain and urinary incontinence, and to related methods of treating... Agent: Crowell & Moring LLP Intellectual Property Group

20070185213 - Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines: The invention provides compositions containing a fraction isolated or derived from hops and a methylxanthine. The invention additionally provides compositions containing a fraction derived from hops and a curcuminoid. The invention also provides methods of using such compositions to reduce inflammation.... Agent: Mcdermott Will & Emery LLP

20070185214 - Process of obtaining type ii dehydroquinase enzyme inhibitors and precursors thereof: The present invention relates to a process of obtaining type II dehydroquinase enzyme inhibitors and the precursors thereof from (−)-quinic acid. The described compounds have a carboxycyclohexene structure. The process of preparing the compounds and their application as compositions with pharmacological properties and herbicides of interest are described.... Agent: Merchant & Gould PC

20070185215 - Pharmaceutical composition containing obovatol as an active ingredient for the prevention and treatment of neurodegenerative diseases: Disclosed herein a pharmaceutical composition, comprising obovatol as an active ingredient, for the prevention and treatment of neurodegenerative diseases. Having superior inhibitory activity against the production of neurotoxic nitric oxides, the obovatol isolated and purified from Magnoliaceae can be used as active ingredient for a pharmaceutical composition or a neuroprotective... Agent: Lucas & Mercanti, LLP

20070185216 - Antiviral method: This invention provides a method of inactivating non-enveloped virus particles. The method includes the step of contacting the virus with a virucidally-enhanced alcoholic composition that includes an alcohol, and an enhancer selected from the group consisting of cationic oligomers and polymers, proton donors, chaotropic agents, and mixtures thereof.... Agent: Renner, Kenner, Greive, Bobak, Taylor & Weber

20070185217 - Propofol analogs, process for their preparation, and methods of use: The invention provides para substituted dialkylphenol derivatives of propofol. The invention further provides pharmaceutical compositions comprising such analogs, methods for preparing such analogs, and methods of using such analogs to induce general anesthesia, sedation, and/or hypnotic or sleep effects in a patient.... Agent: Leydig Voit & Mayer, Ltd

20070185218 - Controlled release formulation for oral administration of metformin: A controlled release formulation for oral administration of metformin or a pharmaceutically acceptable salt thereof comprising metformin or a pharmaceutically acceptable salt thereof as an active ingredient; a combination of a polyethylene oxide and a natural gum as a carrier for controlled release; and a pharmaceutically acceptable additive.... Agent: Sughrue Mion, PLLC

20070179083 - Covalent attachment of ligands to nucleophilic proteins guided by non-covalent binding: A covalently reactive ligand analogue (CAL) of formula (1): wherein, L1 . . . Lx . . . Lm are components defining a ligand determinant, Lx is a component unit of the ligand determinant selected from the group consisting of an amino acid residue, sugar residue, a fatty acid residue... Agent: Bingham Mccutchen LLP

20070179084 - Process for reducing the concentration of blood glucose in a diabetic patient: A complex for serving diabetics to reduce the concentration of blood glucose is provided, including a transferrin and a metal ion (or an oxidized metal ion). The transferrin can carry the metal ion (or the oxidized metal ion) into cells of a patient, thereby encouraging glucose uptake by the cells... Agent: Rabin & Berdo, PC

20070179085 - Modulation of rhamm-caveolin/lipid raft interactions to affect development, responses to tissue injury, angiogenesis, tumorigenesis, metastasis and growth factor/cytokine responses: Compositions and methods for identifying agents which modulate RHAMM-mediated biological activities are provided. Also disclosed are methods for inhibiting exacerbation of certain injuries via regulation of RHAMM-mediated cellular signaling.... Agent: Dann, Dorfman, Herrell & Skillman

20070179096 - pharmaceutical formulation: The invention relates to aqueous pharmaceutical formulations comprising human growth hormone, histidine, poloxamer, phenol, and mannitol.... Agent: Novo Nordisk, Inc. Patent Department

20070179088 - Foggy: The present invention relates to neucleotide and amino acid sequences having homology to the zebrafish transcription elongation factor foggy, and to neuronal formation, to a method of directing the differentiation of neuroprogenitor cells into dopaminergic or serotonergic neurons and to a method of treating disorders characterized by abnormalites in and... Agent: Genentech, Inc.

20070179090 - G protein coupled receptor agonists and antagonists and methods of activating and inhibiting g protein coupled receptors using the same: The invention relates generally to G protein coupled receptors and in particular to agonists and antagonists of G protein receptors and methods of using the same.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c,

20070179093 - Growth factor modified protein matrices for tissue engineering: Proteins are incorporated into protein or polysaccharide matrices for use in tissue repair, regeneration and/or remodeling and/or drug delivery. The proteins can be incorporated so that they are released by degradation of the matrix, by enzymatic action and/or diffusion. As demonstrated by the examples, one method is to bind heparin... Agent: Patrea L. Pabst Pabst Patent Group LLP

20070179091 - Hedgehog kinases and their use in modulating hedgehog signaling: The present invention provides for a method of using CDC2L1, CSNK1A1, GYK, NEK1, PLK1, PRKAR1A, PRKRA, TTBK2 or TTK hedgehog kinase antagonists to inhibit hedgehog signaling, as well as treating and diagnosing disorders relating to hedgehog signaling or overexpression of hedgehog, including cancer, cell proliferative disorders, and angiogenesis, neurological disorders,... Agent: Genentech, Inc.

20070179087 - Method for treating inflammatory diseases using heat shock proteins: This invention relates to a method to protect a mammal from a disease associated with an inflammatory response, and in particular, from an inflammatory disease characterized by eosinophilia, airway hyperresponsiveness and/or a Th2-type immune response. The method includes administration of a heat shock protein to a mammal having such a... Agent: Sheridan Ross PC

20070179092 - Method of enhancing neural stem cell proliferation, differentiation, and survival using pituitary adenylate cyclase activating polypeptide (pacap): The present invention relates to a method of increasing the number and/or differentiation of neural stem cells and/or neural stem cell progeny using pituitary adenylate cyclase-activating polypeptide (PACAP). In a preferred embodiment, additional growth factors are also utilized. The present invention can be practiced in vivo and in vitro, rendering... Agent: Fish & Richardson P.C.

20070179094 - Modulation of mdl-1 activity for treatment of inflammatory disease: The present invention provides compositions and methods that modulate MDL-1 activity in a cell, in vivo or in vitro. In particular, the present invention provides methods for treatment of inflammatory diseases using synthetic or recombinant compositions that modulate MDL-1 activity in a mammalian cell, in vivo or in vitro. More... Agent: Foley And Lardner LLP Suite 500

20070179095 - Oral treatment of hemophilia: Disclosed herein is a simple method for the treatment of antigen-deficiency diseases, by orally administering to a subject a therapeutically effective amount of the deficient antigen, wherein the antigen is not present in a liposome. In one embodiment the method increases hemostasis in a subject having hemophilia A or B,... Agent: Klarquist Sparkman, LLP

20070179086 - Polypeptides and antibodies: Polypeptides are provided. Antibodies or antigen binding domains are provided which bind such polypeptides. Also provided are methods of obtaining an antibody that binds tumor necrosis factor (TNF)-related apoptosis-inducing ligand (“TRAIL”) Receptor-2 (TR-2) comprising administering at least one of such polypeptides to an animal and obtaining an antibody that binds... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070179089 - Structure of socs and uses thereof: The present invention relates to the identification of a PEST motif in Suppressor of Cytokine Signalling (SOCS) proteins, the deletion/inactivation of which has been found to increase the stability of the protein whilst maintaining at least one biological activity of the protein. Such SOCS proteins with deleted/inactivated PEST motifs can... Agent: Bozicevic, Field & Francis LLP

20070179097 - Gnrh agonist combination drugs: In the field of pharmaceuticals, it is intended to provide drugs whereby the preventive and therapeutic effects of a GnRH agonist on various diseases can be enhanced and QOL can be improved. More specifically, combination of drugs characterized in that the GnRH agonist is combined with a chemical selected from... Agent: Foley And Lardner LLP Suite 500

20070179098 - Treatment of functional dyspepsia using asimadoline: The present invention relates to derivatives of N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide with covalently bonded acids, and to the salts, solvates and prodrugs thereof, to the derivatives as medicaments, to the use of these derivatives for the preparation of a medicament, to the use of these derivatives for the preparation of a pharmaceutical composition,... Agent: Morrison & Foerster LLP

20070179099 - Methods of cholesterol reduction using isoflavones: This invention relates to supplements that can be used to prevent or ameliorate such conditions as breast cancer, benign breast disease, pre-menstrual syndrome, or symptoms associated with menopause in women, or various types of cancer, and especially for high blood cholesterol levels in all humans, for instance.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070179106 - Double strand compositions comprising differentially modified strands for use in gene modulation: The present invention provides double stranded compositions wherein each strand is modified to have a motif defined by positioning of β-D-ribonucleosides and sugar modified nucleosides. More particularly, the present compositions comprise one strand having a gapped motif and another strand having a gapped motif, a hemimer motif, a blockmer motif,... Agent: Woodcock Washburn LLP

20070179107 - Double strand compositions comprising differentially modified strands for use in gene modulation: The present invention provides double stranded compositions wherein each strand is modified to have a motif defined by positioning of β-D-ribonucleosides and sugar modified nucleosides. More particularly, the present compositions comprise one strand having a gapped motif and another strand having a gapped motif, a hemimer motif, a blockmer motif,... Agent: Woodcock Washburn LLP

20070179108 - Double strand compositions comprising differentially modified strands for use in gene modulation: The present invention provides double stranded compositions wherein each strand is modified to have a motif defined by positioning of β-D-ribonucleosides and sugar modified nucleosides. More particularly, the present compositions comprise one strand having a gapped motif and another strand having a gapped motif, a hemimer motif, a blockmer motif,... Agent: Woodcock Washburn LLP

20070179109 - Double strand compositions comprising differentially modified strands for use in gene modulation: The present invention provides double stranded compositions wherein each strand is modified to have a motif defined by positioning of β-D-ribonucleosides and sugar modified nucleosides. More particularly, the present compositions comprise one strand having a gapped motif and another strand having a gapped motif, a hemimer motif, a blockmer motif,... Agent: Woodcock Washburn LLP

20070179110 - Expression of immunogenic substances: Disclosed is a method of regulating the expression in a human or animal subject of a nucleic acid sequence encoding a polypeptide which is immunogenic in the subject; the method comprising introducing into a mammal a cell comprising the nucleic acid sequence encoding the immunogenic polypeptide, said sequence being operably... Agent: Fish & Richardson P.C.

20070179113 - Gm-csf gene therapy for crohn's disease using an improved regulated expression system: The present invention provides an improved, expression system for the regulated expression of an encoded protein or nucleic acid therapeutic molecule in the cells of a subject, for use in the treatment of disease. In particular, the present invention provides an improved, regulated gene expression system, and pharmaceutical compositions and... Agent: Foley And Lardner LLP Suite 500

20070179103 - Immunostimulatory oligonucleotide multimers: The invention provides an immunostimulatory nucleic acid. In certain embodiments according to this aspect of the invention, the sequence of the immunostimulatory oligonucleotide and/or immunomer is at least partially self-complementary.... Agent: Joseph C. Zucchero Keown & Associates

20070179101 - Immunostimulatory oligonucleotide that induces interferon alpha: e

20070179105 - Method and means for treating solid tumors: The present invention relates to method and means for treating a vascularized solid tumor using a number of, in vitro prepared, anticellular agent(s)-carrying blood platelets to induce a thrombus formation within the tumor vasculature, and at the same time to deliver a high concentration of an anticellular agent within the... Agent: Essam T. Awdalla

20070179102 - Methods and compositions for the treatment and diagnosis of pain disorders using 9805, 2047, 46566, 57749, 577, 20739, 57145, 1465, 1587, 2146, 2207, 32838, 336 or 52908: The present invention relates to methods and compositions for the treatment and diagnosis of pain disorders. The invention further provides methods for identifying a compound capable of treating a pain disorder. In addition, the invention provides a method for treating a subject having a pain disorder, e.g., a pain disorder... Agent: Millennium Pharmaceuticals, Inc.

20070179111 - Methods of treating proteinuria by reducing double-stranded dna antibodies: The invention provides methods of treating proteinuria in an individual such as human by administering an effective amount of an agent that reduces the level of anti-dsDNA antibodies (such as a dsDNA epitope as in the form of an epitope-presenting carrier or an epitope-presenting valency platform molecule like LJP 394)... Agent: Morrison & Foerster LLP

20070179112 - Polymeric nucleoside prodrugs: Disclosed are polymeric compounds which are useful as prodrugs, comprising a chain of monomeric nucleosides, nucleoside analogs or abasic nucleosides, wherein at least one of the nucleosides or nucleoside analogs or a heterocyclic derivative thereof is pharmaceutically active and the nucleosides, nucleoside analogs or abasic nucleosides are linked by a... Agent: Darby & Darby P.C.

20070179100 - Protected monomers: This invention relates to protected monomers for the synthesis of iRNA agents.... Agent: Fish & Richardson PC

20070179104 - Rna interference mediated inhibition of winged helix nude (whn) gene expression using short interfering nucleic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating Winged Helix Nude (WHN) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of Winged Helix Nude... Agent: Mcdonnell, Boehnen, Hulbert And Berghoff, LLP

20070179114 - Novel 2'-c methyl nucleoside derivatives: Compounds of Formula I, stereoisomers, and pharmaceutically acceptable salts or prodrugs thereof, their preparation, and their uses for the treatment of hepatitis C viral infection are described:... Agent: Wolf Greenfield & Sacks, P.C.

20070179115 - Purinenucleoside derivative modified in 8-position and medical use thereof: In the formula, n is 1 or 2; RA is a hydrogen atom or a hydroxyl group; R1 is a hydrogen atom, a hydroxyl group, a thiol group, an amino group or a chlorine atom; ring J represents an optionally substituted 2-naphthyl group, or a group represented by the following... Agent: Stuart D. Frenkel Frenkel & Associates, P.C.

20070179116 - Fused pentacyclic polyethers:

20070179117 - Injectable crosslinked and uncrosslinked alginates and the use thereof in medicine and in cosmetic surgery: The invention relates to the use of implantable microcapsules, or microparticles or gels produced from alginates that are crosslinked with bivalent or multivalent cations or that are uncrosslinked, for the treatment of skin defects such as e.g. wrinkles, for the treatment of gastro-oesophageal reflux, urinary incontinence and vesico-ureteral reflux.... Agent: Sughrue Mion, PLLC

20070179118 - 2-(pyridin-2-ylamino)-pyrido [2,3 d]pyrimidin-7-ones: The present invention provides substituted 2-aminopyridines useful in treating cell proliferative disorders. The novel compounds of the present invention are potent inhibitors of cyclin-dependent kinases 4 (cdk4).... Agent: Pfizer Inc

20070179120 - Hydroxyl compounds and compositions for cholesterol management and related uses: The present invention relates to novel hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence,... Agent: Warner-lambert Company

20070179119 - Solid and crystalline ibandronate sodium and processes for preparation thereof: The present invention relates to solid amorphous and crystalline forms of ibandronate sodium.... Agent: Kenyon & Kenyon LLP

20070179121 - Method of treating pediatric patients with corticosteroids: The present invention comprises a method of treating pediatric patients suffering from an inflammatory or pruritic skin disorder comprising topically applying fluocinonide to an affected area. Treatment according to this method does not result in clinically significant suppression of the HPA-axis.... Agent: William J. Mcnichol, Jr., Esquire Reed Smith LLP

20070179122 - Beta-aminoacid-derivatives as factor xa inhibitors: in which R0; R1; R2; R3; R4; R5, R, Q; V, G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070179123 - Methods and compositions for treating diseases associated with pathogenic proteins: wherein R1-4, W, X, Y and Z are as defined in the specification, for inhibiting and treating diseases and disorders associated with pathogenic proteins causing neurodegenerative diseases and amyloid diseases, such as protease resistant prion proteins (PrPSc) and those associated with transmissible spongiform encephalopathies (TSEs), Alzheimer's Disease, amyloidosis, and the... Agent: Cynthia Ruth Moore

20070179124 - Substituted porphyrins: The present invention relates, in general, to a method of modulating physiological and pathological processes and, in particular, to a method of modulating cellular levels of oxidants and thereby processes in which such oxidants are a participant. The invention also relates to compounds and compositions suitable for use in such... Agent: Sheridan Ross PC

20070179126 - 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof: The disclosure concerns 2-carbamide-4-phenylthiazole derivatives of general formula (I). The disclosure also concerns pharmaceutical compositions containing a compound of general formula (I) and to processes for preparing and methods of using compounds of general formula (I).... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070179125 - Aminopyrimidines useful as kinase inhibitors: The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, and disorders. The invention also provides processes for preparing compounds of the inventions.... Agent: Vertex Pharmaceuticals Inc.

20070179127 - Sulfonamide compound: A compound represented by the formula (1) [A represents a nitrogen-containing saturated ring; m represents an integer of 0 to 2; n represents an integer of 1 to 4; G1 represents hydrogen atom, chlorine atom, hydroxyl group, an alkoxy group, or amino group; G2 represents a halogen atom, hydroxyl group,... Agent: Birch Stewart Kolasch & Birch

20070179128 - Substituted spirobenzazepines: The invention is directed to nonpeptide substituted benzazepines of Formula I, which are useful as vasopressin receptor antagonists for treating conditions associated with vasopressin receptor activity such as those involving increased vascular resistance and cardiac insufficiency, including congestive heart failure, hyponatremia, and hypertension, among others disclosed. Pharmaceutical compositions comprising a... Agent: Philip S. Johnson Johnson & Johnson

20070179129 - Opioid receptor antagonists: A compound of the formula (I) (I) wherein the variables X1 to X6, Ra, Rb, R1 to R7 including R3′, E, p, j, y, z, A, B and C are as described or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or... Agent: Eli Lilly & Company

20070179130 - C-met modulators and method of use: The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides appropriately functionalized 5,6-fused bicyclics which inhibit, regulate and/or modulate kinase receptor, particularly c-Met, KDR, and flt-3, signal transduction pathways related... Agent: Leydig Voit & Mayer, Ltd

20070179132 - Inhibitors of macrophage migration inhibitory factor and methods for identifying the same: e

20070179131 - Novel m3 muscarinic acetylcholine receptor antagonists: Muscarinic Acetylcholine receptor antagonists and methods of using them are provided.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070179133 - Compositions useful as inhibitors of protein kinases: The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.... Agent: Vertex Pharmaceuticals Inc.

20070179134 - Urea derivatives, processes for their preparation, their use as medicaments, and pharmaceutical compositions containing them: e

20070179136 - 1h-benzimidazole-4-carboxamides substituted with phenyl at the 2-position are potent parp inhibitors:

20070179135 - Cannabinoid derivatives: This invention discloses cannabinoid derivatives and pharmaceutical uses thereof.... Agent: Ashok Tankha Of Counsel, Lipton Weinberger & Husick

20070179138 - 6-phenyl-1h-imidazo[4,5-c]pyridine-4-carbonitrile derivatives: wherein each of the substituents is given the definition as set forth in the specification and claims, pharmaceutical compositions comprising the same as well as to the use of these derivatives for the preparation of a medicament for the treatment of cathepsin S and/or cathepsin K related diseases such as... Agent: Akzo Nobel Inc.

20070179137 - Screening of anti-viral drugs and pharmaceuticals composition containing thiazolidinone derivatives: The present invention relates to a method of screening for small organic molecules that directly inhibit the interaction of glycosaminoglycans (GAGs) with GAG-binding viral proteins (GBVPs), which comprises contacting a GAG with an GBVP in the presence of at least one candidate compound; and measuring the amount of the GAG... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070179139 - Substituted aminodicarboxylic acid derivatives having pharmaceutical properties: e

20070179140 - Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses: The present invention provides stereoisomers and stereoisomeric mixtures of 3-aminocarbonyl-bicycloheptene-2,4-pyrimidinediamine compounds having antiproliferative activity, compositions comprising the compounds and methods of using the compounds to inhibit cellular proliferation and to treat proliferate diseases such as tumorigenic cancers.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070179141 - Therapeutic agents useful for treating pain: 4-Tetrazolyl-4-phenylpiperidine Compounds, compositions comprising an effective amount of a 4-Tetrazolyl-4-phenylpiperidine Compound, methods for treating or preventing pain or diarrhea in an animal comprising administering to an animal in need thereof an effective amount of a 4-Tetrazolyl-4-phenylpiperidine Compound and methods for stimulating opioid-receptor function in a cell comprising contacting a cell... Agent: Jones Day

20070179142 - Amido compounds and their use as pharmaceuticals: The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or... Agent: Fish & Richardson PC

20070179143 - Tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them: The present invention relates to tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them. More precisely, the present invention relates to tricyclic derivatives as colchicine derivatives, pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them. Tricyclic derivatives of the present invention show very... Agent: Medlen & Carroll, LLP

20070179144 - 5(z)-5-(6-quinoxalinylmethylidene)-2-[(2,6-dichlorophenyl)amino]-1,3-thiazol-4(5h)-one: Invented is the compound (5Z)-5-(6-quinoxalinylmethylidene)-2-[(2,6-dichlorophenyl)amino]-1,3-thiazol-4(5H)-one, and/or pharmaceutically acceptable salts, hydrates, solvates and pro-drugs thereof. Also invented are pharmaceutical compositions containing this compound, methods of preparing this compound and pharmaceutically acceptable salts, hydrates, solvates and pro-drugs thereof. Also invented are methods of using this compound as an inhibitor of hYAK3 proteins.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20070179145 - Compositions and methods of reducing side effects and toxicity of methotrexate when given as orotate derivatives: This invention is in the field of chemical restructuring of antimetabolite agents known to have poor oral bioavailability and to cause tissue toxicity as a side effect, by producing their orotate derivatives. More particularly, it concerns orotate derivatives of the methotrexate and trimetrexate, that are found to improve the oral... Agent: Rashida A. Karmali

20070179146 - 2-(piperidin-4-yl)-4,5-dihydro-2h-pyridazin-3-one derivatives as pde4 inhibitors: The compounds of a certain formula 1, in which R1, R2, R3 and R9 have the meanings as given in the description, are novel effective PDE4 inhibitors.... Agent: Nath & Associates PLLC

20070179147 - Methods of treating and preventing alzheimer's disease: The present invention relates to methods of treating or preventing the progression of Alzheimer's disease, by administering to a patient in need thereof certain thiosemicarbazone compounds. More particularly, the present invention relates to methods of preventing or treating neuronal damage and neuronal cell death occurring as a result of cellular... Agent: Panacea Pharmaceuticals, Inc.

20070179148 - Piperazinyl derivatives as modulators of chemokine receptor activity: or stereoisomers or pharmaceutically acceptable salts thereof, wherein m, T, W, R1, R4, R5, R5a and R5b are as defined herein. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis using said modulators... Agent: Louis J. Wille Bristol-myers Squibb Company

20070179150 - Nitrosated proton pump inhibitors, compositions and methods of use: The invention describes novel nitrosated proton pump inhibitor compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated proton pump inhibitor compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived... Agent: Wilmer Cutler Pickering Hale And Dorr LLP

20070179149 - Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors: including forms such as stereoisomers, free forms, pharmaceutically acceptable salts or esters thereof, solvates, or combinations of such forms, wherein n, R1, R2, R3, X, and Y are as defined herein. Compositions comprising an inhibitor of macrophage migration inhibitory factor in combination with a pharmaceutically acceptable carrier are also provided,... Agent: Knobbe Martens Olson & Bear LLP

20070179151 - Isoquinoline aminopyrazole derivatives: c

20070179152 - Combination therapy for the treatment of neoplasms: The invention features compositions, methods, and kits for the treatment of neoplasms... Agent: Clark & Elbing LLP

20070179153 - Derivatives of heterocycles with 5 members, their preparation and their use as medicaments: e

20070179154 - Coumarin derivatives, process for their production and use thereof: wherein R1 and R2 are each hydrogen, halogen, an optionally substituted linear hydrocarbon group, or hydroxyl which may be substituted with an optionally substituted liner hydrocarbon group, or R1 and R2 together with the carbon atoms adjacent thereto may form an optionally substituted cyclic hydrocarbon or a dihydrofuran ring which... Agent: Edwards Angell Palmer & Dodge LLP

20070179155 - N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases: The present invention relates to certain substituted N-phenyl-piperazine derivatives of Formula: (I) that are modulators of the 5HT2c receptor. Accordingly, compounds of the present invention are useful for the prophylaxis or treatment of 5HT2c receptor associated diseases or disorders, such as, obesity, Alzheimer Disease, erectile dysfunction and related disorders.... Agent: Arena Pharmaceuticals, Inc.

20070179157 - Nonnucleoside reverse transcriptase inhibitors: This invention relates to methods of treating an HIV infection with novel heterocyclic compounds of formula I wherein R1—R4, X1 and X2 are as defined in the summary and pharmaceutically acceptable salts, and methods to inhibit or modulate Human Immunodeficiency Virus (HIV) reverse transcriptase with compounds of formula I.... Agent: Roche Palo Alto LLC Patent Law Dept. M/s A2-250

20070179156 - Pyridones useful as inhibitors of kinases: The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.... Agent: Vertex Pharmaceuticals Inc.

20070179158 - 2,6-disubstituted piperiddines as modulators: The present invention is further directed to compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R16, R17, R18, R19, R20, R21 and R22 are as defined herein) which are modulators of chemokine receptor activity and are useful in the prevention or treatment of... Agent: Merck And Co., Inc

20070179159 - Compounds for the treatment of proliferative disorders: e

20070179160 - Use of rnai inhibiting parp activity for the manufacture of a medicament for the treatment of cancer: The present invention relates to the use of an agent that inhibits the activity of an enzyme that mediates repair of a DNA strand break in the manufacture of a medicament for the treatment of diseases caused by a defect in a gene that mediates homologous recombination.... Agent: Bozicevic, Field & Francis LLP

20070179161 - Pyrazolopyrimidine compounds and their use in medicine: Compounds of formula (I) or salts, N-oxides, hydrates or solvates thereof are inhibitors of kinase activity, and useful for the treatment of, for example, cancer, psoriasis or restenosis: wherein ring A is an optionally substituted carbocyclic or heterocyclic radical. Alk represents an optionally substituted divalent C1-C6 alkylene radical. n is... Agent: Banner & Witcoff, Ltd.

20070179162 - Triazolopyrimdines: The invention relates to novel triazolopyrimidines of formula (I), in which R1, R2, R3 and X are defined as cited in the description, to a method for producing said substances and to their use for controlling undesirable micro-organisms. The invention also relates to novel intermediate products of the formulae (II),... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070179163 - Process for the preparation of risperidone: A process is provided for the preparation of risperidone of Formula (1); which process comprises reacting, in a condensation reaction, 6-fluoro-3-(4-piperidinyl)-1,2-benzisoxazole monohydrochloride of Formula (2) with 3-(2-chloroethyl)-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2,a]pyrimidin-4-one monohydrochloride of Formula (3).... Agent: Welsh & Katz, Ltd

20070179164 - Compounds for modulating trpv3 function: The present application relates to compounds and methods for treating pain and other conditions related to TRPV3.... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070179165 - Cyclic compounds: (wherein, ring Aa is a 5- or 6-membered ring which may be further substituted; ring Ab is a 5- or 6-membered ring which may be further substituted; ring Ac is a 5- or 6-membered ring which may be substituted; R1 is optionally substituted alkyl, substituted amino, substituted hydroxy, etc.; X... Agent: Mark Chao Intellectual Property Department

20070179166 - Process for preparation of statins with high syn to anti ratio: Provided is a process for reduction of statin ketoesters and purification of diol esters of the statins through selective crystallization.... Agent: Kenyon & Kenyon LLP

20070179167 - Inhibitors of serine proteases: o

20070179168 - Methods of treating anxiety disorders: Disclosed are methods of treating an anxiety disorder, e.g., obsessive compulsive disorder, in an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to restore normal monoaminergic tone within the synapse.... Agent: Knobbe Martens Olson & Bear LLP

20070179169 - Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone: In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.... Agent: Davidson, Davidson & Kappel, LLC

20070179171 - Vinca derivatives: The present invention relates to derivatives of vinca alkaloids. Pharmaceutical compositions containing these compounds as well as processes of preparation and treatment of various conditions are also disclosed.... Agent: Nixon Peabody LLP - Patent Group

20070179170 - Vinorelbine derivatives: The present invention relates to novel vinorelbine derivatives. Pharmaceutical compositions containing these compounds as well as processes of preparation and processes of use for treatment of various conditions are also disclosed.... Agent: Nixon Peabody LLP - Patent Group

20070179173 - Carbostyril compound: or a salt thereof, wherein A is a direct bond, a lower alkylene group, or a lower alkylidene group; X is an oxygen atom or a sulfur atom; R4 and R5 each represent a hydrogen atom; the bond between the 3 and 4 positions of the carbostyril skeleton is a... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070179172 - Positive modulators of nicotinic acetylcholine receptors:

20070179174 - Methods and compositions for slowing aging: The present invention provides a pharmacological agent based on derivatives of hydrogenated pyrido (4,3-b) indoles and uses thereof. Specifically, the invention provides a geroprotector in the series of hydrogenated pyrido (4,3-b) indoles (several derivatives), which can be used for slowing aging, prolonging lifespan of an individual or cells in an... Agent: Morrison & Foerster LLP

20070179175 - Tetrahydronaphthyridine derivative: The invention relates to 6-[2-(1-Isopropyl-piperidin-4-yloxy)-7,8-dihydro-5H-[1,6]naphthyridin-6-yl]-nicotinamide and to processes for the preparation of, compositions containing and the uses of, the compound. The compound is an H3 ligand and is useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.... Agent: Pharmacia Corporation Global Patent Department

20070179178 - Aryl-isoxazol-4-yl-imidazo[1,2-a]pyridine derivatives: e

20070179177 - Azaindazoles useful as inhibitors of kinases: The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.... Agent: Vertex Pharmaceuticals Inc.

20070179176 - Monohydrated sodium salt of s-tenatoprazole and the use thereof in therapy: e

20070179179 - Beta2-adrenergic receptor agonists: Disclosed are multibinding compounds which are β2 adrenergic receptor agonists and are useful in the treatment and prevention of respiratory diseases such as asthma, bronchitis. They are also useful in the treatment of nervous system injury and premature labor.... Agent: Theravance, Inc.

20070179182 - 7-((1h-imidazol-4-yl)methyl)-5,6,7,8-tetrahydroquinoline: s

20070179180 - Novel m3 muscarinic acetylcholine receptor antagonists: Muscarinic Acetylcholine receptor antagonists and methods of using them are provided.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070179181 - Treatment of inflammatory disorders and pain using beta-aminoalcohols: A compound that has utility in the treatment or prevention of a condition associated with T-cell proliferation or that is mediated by pro- and/or anti-inflammatory cytokines, is of formula (I) wherein R1 is H or Me; R2 is H or alkyl and R3 is H or Me, or R2 and... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070179183 - N-(2-phenylethyl)sulfamide derivatives as integrin alpha4 antagonists: c

20070179185 - New disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission:

20070179184 - Novel m3 muscarinic acetylcholine receptor antagonists: Muscarinic Acetylcholine receptor antagonists and methods of using them are provided.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070179186 - Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme: The present invention relates to compounds that are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme, The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other... Agent: Robert Deberardine Abbott Laboratories

20070179187 - Thrombin receptor antagonists: R13 and R14 together form a spirocyclic or a heterospirocyclic ring of 3-6 atoms, Het is a mono- or bi-cyclic optionally substituted heteroaryl group; and B is a bond, alkylene, or optionally substituted alkenylene or alkynylene, wherein the remaining substituents are as defined in the specification, are disclosed, as well... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070179188 - Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists: The present invention relates to new compounds of formula (I), to pharmaceutical formulations containing the compounds, and to the use of the compounds in the prevention and/or treatment of mGluR5 receptor-mediated disorders.... Agent: Birch, Stewart, Kolasch & Birch, LLP

20070179189 - Modulators of the glucocorticoid receptor, ap-1, and/or nf-kb activity and use thereof: including a stereoisomer thereof, a tautomer thereof, a prodrug thereof, or a pharmaceutically acceptable salt thereof, where Q is selected from N, O, and S; Y is aryl or heteroaryl; Z is H, C2-6alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, halo, or alkoxy; and A, B, R, Ra, Rb, Rc and Rd... Agent: Louis J. Wille Bristol-myers Squibb Company

20070179190 - Vla-4 antagonists: Compounds of Formula I are antagonists of VLA-4, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of inflammatory bowel disease including ulcerative colitis and Crohn's... Agent: Merck And Co., Inc

20070179191 - Oxadiazolones and derivatives thereof as ppar delta agonists: in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved; neurodegenerative diseases and/or... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070179192 - Thrombopoietin mimetics: Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070179193 - Method for preparing aqueous composition for sterilization: wherein R represents a substituted or unsubstituted C1-C20 alkyl group, or a substituted or unsubstituted C6-C30 aryl group, with an aqueous solution containing a hydrogen peroxide source to produce a corresponding peroxycarboxylic acid. An aqueous composition for sterilization suitable for sterilization of medical apparatuses such as endoscopes, which can be... Agent: Birch Stewart Kolasch & Birch

20070179194 - Method for the treatment of diabetes: The present invention provides a method for treatment of diabetes, comprising administering a pitavastatin, and in combination therewith, enalapril or a salt thereof.... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070179195 - Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use: The invention provides novel nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) selective inhibitors and novel compositions and kits comprising at least one nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) selective inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous... Agent: Wilmerhale/nitromed

20070179196 - Hiv integrase inhibitors: Hydroxy (tetra- or hexa-)hydronaphthyridine dione compounds of Formula I are inhibitors of HIV integrase and inhibitors of HIV replication: (I) wherein a, R,1?, R,2?, R,3?, R,4? and R,5? are defined herein. The compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in... Agent: Merck And Co., Inc

20070179197 - Compositions and methods for improving or preserving brain function: The present invention is related to mammalian nutrition and effects thereof in individuals with age associated cognitive decline such as Age Associated Memory Inpairment (AAMI) or a dementing illness such as Alzheimer's disease or related dementia, or Mild Cognitive Impairment, such as improving performance in, or reversal, prevention, reducing and... Agent: Swanson & Bratschun L.L.C.

20070179198 - Method for evaluating transparency and water holding capacity of stratum corneum using oxidized protein in stratum corneum as an indicator: The present invention provides a method for evaluating the transparency and/or water holding capacity of a stratum corneum by using oxidized protein in the stratum corneum as an indicator.... Agent: Snider & Associates